Anti-TNFRSF9 antibodies and uses thereof

By developing 4-1BB-specific antibodies and antigen binding fragments of high identity amino acid sequences, the problem of inefficiency of existing anti-cancer therapies in 4-1BB targets is solved, and more effective immune response and tumor suppression are achieved, reducing side effects .

CN112739718BActive Publication Date: 2024-11-26EUCURE (BEIJING) BIOPHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980059455.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-09-12
Filing Date
2019-09-11
Publication Date
2024-11-26
Estimated Expiration
2039-09-11

AI Technical Summary

Technical Problem

Existing anti-cancer therapies have problems of inefficiency and major side effects when targeting TNFRSF9 (4-1BB) targets, making it difficult to effectively inhibit tumor growth and treat cancer.

Method used

Develop antibody and antigen-binding fragments that specifically bind 4-1BB, containing heavy and light chain variable regions of high identity amino acid sequences, and promotes its signaling pathways and enhances immune responses to inhibit tumors by specifically binding to 4-1BB. Grow.

Benefits of technology

It improves the anti-tumor immune response, enhances the activation and proliferation of T cells and NK cells, effectively inhibits tumor growth, reduces side effects, and improves the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112739718B_ABST
    Figure CN112739718B_ABST
Patent Text Reader

Abstract

The present disclosure provides an anti-TNFRSF9 (tumor necrosis factor receptor superfamily member 9) antibody, an antigen-binding fragment, and uses thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Priority claim

[0002] This application claims the benefit of PCT application No. PCT / CN2018 / 105162, filed September 12, 2018, which is incorporated herein by reference in its entirety. Technical Field

[0003] The present disclosure relates to anti-TNFRSF9 (tumor necrosis factor receptor superfamily member 9) antibodies, antigen-binding fragments, and uses thereof. Background Art

[0004] Cancer is one of the diseases with the highest mortality rates among human beings. According to statistics from the World Health Organization, in 2012, global cancer cases and deaths reached 14 million and 8.2 million, respectively. In China, there were 3.07 million newly diagnosed cancer cases and 2.2 million deaths.

[0005] The recent clinical and commercial success of anti-cancer antibodies has generated significant interest in antibody-based therapeutics. There is a need to develop anti-cancer antibodies for use in various antibody-based therapies to treat cancer. Summary of the Invention

[0006] The present disclosure relates to anti-TNFRSF9 (tumor necrosis factor receptor superfamily member 9; also known as "4-1BB" or "CD137") antibodies, antigen-binding fragments thereof, and uses thereof.

[0007] In one aspect, the present disclosure relates to an antibody or antigen-binding fragment thereof that binds 4-1BB (TNF receptor superfamily member 9), the antibody or antigen-binding fragment thereof comprising: a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3, wherein the VH CDR1 region comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to a selected VH CDR1 amino acid sequence, the VH CDR2 region comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to a selected VH CDR2 amino acid sequence, and the VH CDR3 region comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to a selected VH CDR3 amino acid sequence; and a light chain variable region (VL) comprising CDRs 1, 2, and 3, wherein the VL CDR1 region comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to a selected VL the VH CDR 1, 2 and 3 amino acid sequences and the selected VL CDR 1, 2 and 3 amino acid sequences are one of the following:

[0008] (1) the selected VH CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 1, 2, and 3, respectively, and the selected VL CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 4, 5, and 6, respectively;

[0009] (2) the selected VH CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 7, 8, and 9, respectively, and the selected VL CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 10, 11, and 12, respectively;

[0010] (3) the selected VH CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 13, 14, and 15, respectively, and the selected VL CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 16, 17, and 18, respectively;

[0011] (4) the selected VH CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 19, 20, and 21, respectively, and the selected VL CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 22, 23, and 24, respectively;

[0012] (5) the selected VH CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 25, 26, and 27, respectively, and the selected VL CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 28, 29, and 30, respectively;

[0013] (6) the selected VH CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 31, 32, and 33, respectively, and the selected VL CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 34, 35, and 36, respectively;

[0014] (7) the selected VH CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 37, 38, and 39, respectively, and the selected VL CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 40, 41, and 42, respectively;

[0015] (8) the selected VH CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 43, 44, and 45, respectively, and the selected VL CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 46, 47, and 48, respectively;

[0016] (9) the selected VH CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 49, 50, and 51, respectively, and the selected VL CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 52, 53, and 54, respectively;

[0017] (10) the selected VH CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 55, 56, and 57, respectively, and the selected VL CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 58, 59, and 60, respectively;

[0018] (11) the selected VH CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 61, 62, and 63, respectively, and the selected VL CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 64, 65, and 66, respectively;

[0019] (12) the selected VH CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 67, 68, and 69, respectively, and the selected VL CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 70, 71, and 72, respectively;

[0020] (13) the selected VH CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 73, 74, and 75, respectively, and the selected VL CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 76, 77, and 78, respectively;

[0021] (14) the selected VH CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 79, 80, and 81, respectively, and the selected VL CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 82, 83, and 84, respectively;

[0022] (15) the selected VH CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 85, 86, and 87, respectively, and the selected VL CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 88, 89, and 90, respectively;

[0023] (16) the selected VH CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 91, 92, and 93, respectively, and the selected VL CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 94, 95, and 96, respectively;

[0024] (17) the selected VH CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 97, 98, and 99, respectively, and the selected VL CDR 1, 2, and 3 amino acid sequences are represented by SEQ ID NOs: 100, 101, and 102, respectively;

[0025] (18) The selected VH CDR 1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 103, 104, and 105, respectively, and the selected VL CDR 1, 2, and 3 amino acid sequences are shown in SEQ ID NOs: 106, 107, and 108, respectively.

[0026] In some embodiments, the VH comprises CDRs 1, 2, 3 having the amino acid sequences shown in SEQ ID NOs: 1, 2, and 3, respectively, and the VL comprises CDRs 1, 2, 3 having the amino acid sequences shown in SEQ ID NOs: 4, 5, and 6, respectively.

[0027] In some embodiments, the VH comprises CDRs 1, 2, 3 having the amino acid sequences shown in SEQ ID NOs: 7, 8, and 9, respectively, and the VL comprises CDRs 1, 2, 3 having the amino acid sequences shown in SEQ ID NOs: 10, 11, and 12, respectively.

[0028] In some embodiments, the VH comprises CDRs 1, 2, 3 having the amino acid sequences shown in SEQ ID NOs: 13, 14, and 15, respectively, and the VL comprises CDRs 1, 2, 3 having the amino acid sequences shown in SEQ ID NOs: 16, 17, and 18, respectively.

[0029] In some embodiments, the antibody or antigen binding fragment specifically binds to human 4-1BB. In some embodiments, the antibody or antigen binding fragment is a humanized antibody or its antigen binding fragment. In some embodiments, the antibody or antigen binding fragment is a single-chain variable fragment (scFv).

[0030] In one aspect, the present disclosure also relates to a nucleic acid comprising a polynucleotide encoding a polypeptide comprising:

[0031] (1) an immunoglobulin heavy chain or fragment thereof comprising a heavy chain variable region (VH), wherein the heavy chain variable region (VH) comprises complementarity determining regions (CDRs) 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 1, 2, and 3, respectively, and wherein the VH binds to 4-1BB when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NOs: 225, 226, 227, 228, or 244;

[0032] (2) an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 4, 5, and 6, respectively, and wherein the VL binds to 4-1BB when paired with a VH comprising the amino acid sequence set forth in SEQ ID NOs: 221, 222, 223, 224, or 243;

[0033] (3) an immunoglobulin heavy chain or fragment thereof comprising a heavy chain variable region (VH) comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 7, 8, and 9, respectively, and wherein the VH binds to 4-1BB when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NOs: 232, 233, 234, 235, or 246;

[0034] (4) an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 10, 11, and 12, respectively, and wherein the VL binds to 4-1BB when paired with a VH comprising the amino acid sequence set forth in SEQ ID NOs: 229, 230, 231, or 245;

[0035] (5) an immunoglobulin heavy chain or fragment thereof comprising a heavy chain variable region (VH) comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 13, 14, and 15, respectively, and wherein the VH binds to 4-1BB when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NOs: 239, 240, 241, 242, or 248;

[0036] (6) an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 16, 17, and 18, respectively, and wherein the VL binds to 4-1BB when paired with a VH comprising the amino acid sequence set forth in SEQ ID NOs: 236, 237, 238, or 247;

[0037] (7) an immunoglobulin heavy chain or fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 19, 20, and 21, respectively, and wherein the VH binds to 4-1BB when paired with a VL comprising the amino acid sequence shown in SEQ ID NO: 250;

[0038] (8) an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 22, 23, and 24, respectively, and wherein the VL binds to 4-1BB when paired with a VH comprising the amino acid sequence shown in SEQ ID NO: 249;

[0039] (9) an immunoglobulin heavy chain or fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 25, 26, and 27, respectively, and wherein the VH binds to 4-1BB when paired with a VL comprising the amino acid sequence shown in SEQ ID NO: 252;

[0040] (10) an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 28, 29, and 30, respectively, and wherein the VL binds to 4-1BB when paired with a VH comprising the amino acid sequence shown in SEQ ID NO: 251;

[0041] (11) an immunoglobulin heavy chain or fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 31, 32, and 33, respectively, and wherein the VH binds to 4-1BB when paired with a VL comprising the amino acid sequence shown in SEQ ID NO: 254;

[0042] (12) an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 34, 35, and 36, respectively, and wherein the VL binds to 4-1BB when paired with a VH comprising the amino acid sequence shown in SEQ ID NO: 253;

[0043] (13) an immunoglobulin heavy chain or fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 37, 38, and 39, respectively, and wherein the VH binds to 4-1BB when paired with a VL comprising the amino acid sequence shown in SEQ ID NO: 256;

[0044] (14) an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 40, 41, and 42, respectively, and wherein the VL binds to 4-1BB when paired with a VH comprising the amino acid sequence shown in SEQ ID NO: 255;

[0045] (15) an immunoglobulin heavy chain or fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 43, 44, and 45, respectively, and wherein the VH binds to 4-1BB when paired with a VL comprising the amino acid sequence shown in SEQ ID NO: 258;

[0046] (16) an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 46, 47, and 48, respectively, and wherein the VL binds to 4-1BB when paired with a VH comprising the amino acid sequence shown in SEQ ID NO: 257;

[0047] (17) an immunoglobulin heavy chain or fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 49, 50, and 51, respectively, and wherein the VH binds to 4-1BB when paired with a VL comprising the amino acid sequence shown in SEQ ID NO: 260;

[0048] (18) an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 52, 53, and 54, respectively, and wherein the VL binds to 4-1BB when paired with a VH comprising the amino acid sequence shown in SEQ ID NO: 259;

[0049] (19) an immunoglobulin heavy chain or fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 55, 56, and 57, respectively, and wherein the VH binds to 4-1BB when paired with a VL comprising the amino acid sequence shown in SEQ ID NO: 262;

[0050] (20) an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 58, 59, and 60, respectively, and wherein the VL binds to 4-1BB when paired with a VH comprising the amino acid sequence shown in SEQ ID NO: 261;

[0051] (21) an immunoglobulin heavy chain or fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 61, 62, and 63, respectively, and wherein the VH binds to 4-1BB when paired with a VL comprising the amino acid sequence shown in SEQ ID NO: 264;

[0052] (22) an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 64, 65, and 66, respectively, and wherein the VL binds to 4-1BB when paired with a VH comprising the amino acid sequence shown in SEQ ID NO: 263;

[0053] (23) an immunoglobulin heavy chain or fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 67, 68, and 69, respectively, and wherein the VH binds to 4-1BB when paired with a VL comprising the amino acid sequence shown in SEQ ID NO: 266;

[0054] (24) an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 70, 71, and 72, respectively, and wherein the VL binds to 4-1BB when paired with a VH comprising the amino acid sequence shown in SEQ ID NO: 265;

[0055] (25) an immunoglobulin heavy chain or fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 73, 74, and 75, respectively, and wherein the VH binds to 4-1BB when paired with a VL comprising the amino acid sequence shown in SEQ ID NO: 268;

[0056] (26) an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 76, 77, and 78, respectively, and wherein the VL binds to 4-1BB when paired with a VH comprising the amino acid sequence shown in SEQ ID NO: 267;

[0057] (27) an immunoglobulin heavy chain or fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 79, 80, and 81, respectively, and wherein the VH binds to 4-1BB when paired with a VL comprising the amino acid sequence shown in SEQ ID NO: 270;

[0058] (28) an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 82, 83, and 84, respectively, and wherein the VL binds to 4-1BB when paired with a VH comprising the amino acid sequence shown in SEQ ID NO: 269;

[0059] (29) an immunoglobulin heavy chain or fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 85, 86, and 87, respectively, and wherein the VH binds to 4-1BB when paired with a VL comprising the amino acid sequence shown in SEQ ID NO: 272;

[0060] (30) an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 88, 89, and 90, respectively, and wherein the VL binds to 4-1BB when paired with a VH comprising the amino acid sequence shown in SEQ ID NO: 271;

[0061] (31) an immunoglobulin heavy chain or fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 91, 92, and 93, respectively, and wherein the VH binds to 4-1BB when paired with a VL comprising the amino acid sequence shown in SEQ ID NO: 274;

[0062] (32) an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 94, 95, and 96, respectively, and wherein the VL binds to 4-1BB when paired with a VH comprising the amino acid sequence shown in SEQ ID NO: 273;

[0063] (33) an immunoglobulin heavy chain or fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 97, 98, and 99, respectively, and wherein the VH binds to 4-1BB when paired with a VL comprising the amino acid sequence shown in SEQ ID NO: 276;

[0064] (34) an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 100, 101, and 102, respectively, and wherein the VL binds to 4-1BB when paired with a VH comprising the amino acid sequence shown in SEQ ID NO: 275;

[0065] (35) an immunoglobulin heavy chain or fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 103, 104, and 105, respectively, and wherein the VH binds to 4-1BB when paired with a VL comprising the amino acid sequence shown in SEQ ID NO: 278;

[0066] (36) An immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences shown in SEQ ID NOs: 106, 107, and 108, respectively, and wherein the VL binds to 4-1BB when paired with a VH comprising the amino acid sequence shown in SEQ ID NO: 277.

[0067] In some embodiments, the nucleic acid comprises a polynucleotide encoding a polypeptide comprising an immunoglobulin heavy chain or fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 1, 2, and 3, respectively.

[0068] In some embodiments, the nucleic acid comprises a polynucleotide encoding a polypeptide comprising an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 4, 5, and 6, respectively.

[0069] In some embodiments, the nucleic acid comprises a polynucleotide encoding a polypeptide comprising an immunoglobulin heavy chain or fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 7, 8, and 9, respectively.

[0070] In some embodiments, the nucleic acid comprises a polynucleotide encoding a polypeptide comprising an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 10, 11, and 12, respectively.

[0071] In some embodiments, the nucleic acid comprises a polynucleotide encoding a polypeptide comprising an immunoglobulin heavy chain or fragment thereof comprising a VH comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 13, 14, and 15, respectively.

[0072] In some embodiments, the nucleic acid comprises a polynucleotide encoding a polypeptide comprising an immunoglobulin light chain or fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs: 16, 17, and 18, respectively.

[0073] In some embodiments, the VH specifically binds human 4-1BB when paired with the VL, or the VL specifically binds human 4-1BB when paired with the VH.

[0074] In some embodiments, the immunoglobulin heavy chain or fragment thereof is a humanized immunoglobulin heavy chain or fragment thereof, and the immunoglobulin light chain or fragment thereof is a humanized immunoglobulin light chain or fragment thereof.

[0075] In some embodiments, the nucleic acid encodes a single-chain variable fragment (scFv). In some embodiments, the nucleic acid is a cDNA.

[0076] In one aspect, the present disclosure relates to a vector comprising one or more of the nucleic acids described herein. In one aspect, the present disclosure also relates to a vector comprising two of the nucleic acids described herein. In some embodiments, the vector encodes a VL region and a VH region that together bind to 4-1BB.

[0077] In one aspect, the disclosure relates to a vector pair, wherein each vector comprises one of the nucleic acids described herein, wherein the vector pair collectively encodes a VL region and a VH region that together bind 4-1BB.

[0078] In one aspect, the disclosure relates to a cell comprising a vector or vector pair as described herein. In some embodiments, the cell is a CHO cell.

[0079] In one aspect, the present disclosure relates to a cell comprising one or more of the nucleic acids described herein. In one aspect, the present disclosure relates to a cell comprising two of the nucleic acids described herein. In some embodiments, the two nucleic acids jointly encode a VL region and a VH region that together bind to 4-1BB.

[0080] In one aspect, the present disclosure relates to a method of producing an antibody or an antigen-binding fragment thereof, the method comprising

[0081] (a) culturing the cell as described herein under conditions sufficient for the cell to produce an antibody or antigen-binding fragment; and

[0082] (b) collecting the antibodies or antigen-binding fragments produced by the cells.

[0083] In one aspect, the present disclosure relates to an antibody or antigen-binding fragment thereof that binds to 4-1BB, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region (VH) comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to a selected VH sequence, and the light chain variable region (VL) comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to a selected VL sequence, wherein the selected VH sequence and the selected VL sequence are one of the following:

[0084] (1) the selected VH sequence is SEQ ID NO: 221, 222, 223, 224 or 243, and the selected VL sequence is SEQ ID NO: 225, 226, 227, 228 or 244;

[0085] (2) the selected VH sequence is SEQ ID NO: 229, 230, 231 or 245, and the selected VL sequence is SEQ ID NO: 232, 233, 234, 235 or 246;

[0086] (3) the selected VH sequence is SEQ ID NO: 236, 237, 238 or 247, and the selected VL sequence is SEQ ID NO: 239, 240, 241, 242 or 248;

[0087] (4) the selected VH sequence is SEQ ID NO: 249, and the selected VL sequence is SEQ ID NO: 250;

[0088] (5) the selected VH sequence is SEQ ID NO: 251, and the selected VL sequence is SEQ ID NO: 252;

[0089] (6) the selected VH sequence is SEQ ID NO: 253, and the selected VL sequence is SEQ ID NO: 254;

[0090] (7) the selected VH sequence is SEQ ID NO: 255, and the selected VL sequence is SEQ ID NO: 256;

[0091] (8) the selected VH sequence is SEQ ID NO: 257, and the selected VL sequence is SEQ ID NO: 258;

[0092] (9) the selected VH sequence is SEQ ID NO: 259, and the selected VL sequence is SEQ ID NO: 260;

[0093] (10) the selected VH sequence is SEQ ID NO: 261, and the selected VL sequence is SEQ ID NO: 262;

[0094] (11) the selected VH sequence is SEQ ID NO: 263, and the selected VL sequence is SEQ ID NO: 264;

[0095] (12) the selected VH sequence is SEQ ID NO: 265, and the selected VL sequence is SEQ ID NO: 266;

[0096] (13) the selected VH sequence is SEQ ID NO: 267, and the selected VL sequence is SEQ ID NO: 268;

[0097] (14) the selected VH sequence is SEQ ID NO: 269, and the selected VL sequence is SEQ ID NO: 270;

[0098] (15) the selected VH sequence is SEQ ID NO: 271, and the selected VL sequence is SEQ ID NO: 272;

[0099] (16) the selected VH sequence is SEQ ID NO: 273, and the selected VL sequence is SEQ ID NO: 274;

[0100] (17) the selected VH sequence is SEQ ID NO: 275, and the selected VL sequence is SEQ ID NO: 276;

[0101] (18) The selected VH sequence is SEQ ID NO: 277, and the selected VL sequence is SEQ ID NO: 278.

[0102] In some embodiments, the antibody or antigen-binding fragment specifically binds human 4-1BB.

[0103] In some embodiments, the antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof.

[0104] In some embodiments, the antibody or antigen-binding fragment is a single-chain variable fragment (scFv).

[0105] In one aspect, the present disclosure relates to an antibody-drug conjugate comprising an antibody or antigen-binding fragment thereof as described herein covalently bound to a therapeutic agent. In some embodiments, the therapeutic agent is a cytotoxic agent or a cytostatic agent.

[0106] In one aspect, the disclosure relates to a method of treating a subject having cancer, comprising administering to the subject a therapeutically effective dose of a composition comprising an antibody or antigen-binding fragment thereof as described herein, or an antibody-drug conjugate as described herein.

[0107] In some embodiments, the subject has a solid tumor. In some embodiments, the cancer is breast cancer, oropharyngeal cancer, ovarian cancer, B-cell lymphoma, or non-Hodgkin's lymphoma. In some embodiments, the cancer is non-small cell lung cancer (NSCLC), melanoma, B-cell non-Hodgkin's lymphoma, colorectal cancer, or multiple myeloma.

[0108] In one aspect, the disclosure relates to a method of reducing tumor growth rate, comprising administering to a subject in need thereof an effective dose of a composition comprising an antibody or antigen-binding fragment thereof as described herein, or an antibody-drug conjugate as described herein.

[0109] In one aspect, the disclosure relates to a method of killing tumor cells, comprising administering to a subject in need thereof an effective dose of a composition comprising an antibody or antigen-binding fragment thereof as described herein, or an antibody-drug conjugate as described herein.

[0110] In one aspect, the present disclosure relates to a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof as described herein, and a pharmaceutically acceptable carrier.

[0111] In one aspect, the present disclosure relates to a pharmaceutical composition comprising an antibody drug conjugate as described herein, and a pharmaceutically acceptable carrier.

[0112] In some embodiments, the antibody is an IgG1 antibody. In some embodiments, the antibody is a human IgG1 antibody.

[0113] In one aspect, the present disclosure relates to an IgG1 antibody or antigen-binding fragment thereof that binds to 4-1BB, the antibody or antigen-binding fragment thereof comprising: a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3, wherein the VH CDR1 region comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to a selected VH CDR1 amino acid sequence, the VH CDR2 region comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to a selected VH CDR2 amino acid sequence, and the VH CDR3 region comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to a selected VH CDR3 amino acid sequence; and a light chain variable region (VL) comprising CDRs 1, 2, and 3, wherein the VL CDR1 region comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to a selected VL The VH CDR1, 2, and 3 amino acid sequences and the selected VL CDR1, 2, and 3 amino acid sequences are selected from one of the antibodies shown in Table 3. In some embodiments, the antibody is a human IgG1 antibody.

[0114] In one aspect, the present disclosure relates to an IgG1 antibody or antigen-binding fragment thereof that binds to 4-1BB, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region (VH) comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to a selected VH sequence, and the light chain variable region (VL) comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to a selected VL sequence, wherein the selected VH sequence and the selected VL sequence are selected from one of the antibodies shown in Table 3. In some embodiments, the antibody is a human IgG1 antibody.

[0115] In one aspect, the present disclosure relates to a method of treating a subject having cancer, comprising administering to the subject a therapeutically effective dose of an anti-4-1BB IgG1 antibody or an antigen-binding fragment thereof, and a therapeutically effective dose of an anti-PD-1 antibody or an antigen-binding fragment thereof.

[0116] In some embodiments, the anti-PD-1 antibody is an anti-PD-1 IgG4 antibody. In some embodiments, the anti-PD-1 antibody is pembrolizumab.

[0117] In one aspect, the present disclosure relates to a method of treating a subject having cancer, comprising administering to the subject a therapeutically effective dose of an anti-4-1BB IgG1 antibody or an antigen-binding fragment thereof, and a therapeutically effective dose of an anti-CTLA4 antibody or an antigen-binding fragment thereof.

[0118] In some embodiments, the anti-CTLA4 antibody is an anti-CTLA IgG1 antibody or an anti-CTLA IgG2 antibody. In some embodiments, the anti-CTLA4 antibody is ipilimumab or tremelimumab.

[0119] As used herein, the term "cancer" refers to a cell with the ability to grow autonomously. Examples of such cells include cells with an abnormal state or condition characterized by rapidly proliferating cell growth. The term is intended to include cancerous growths, for example, tumors; carcinogenic processes, metastatic tissues, and malignantly transformed cells, tissues, or organs, regardless of the tissue pathology type or degree of infiltration. Also included are malignancies of various organ systems, such as those of the respiratory, cardiovascular, renal, reproductive, hematological, nervous, hepatic, gastrointestinal, and endocrine systems; and adenocarcinomas, which include malignancies such as most colon cancers, renal cell carcinomas, prostate cancers, and / or testicular tumors, non-small cell lung cancer, and small intestinal cancer. "Naturally occurring" cancers include any cancer other than cancers experimentally induced by implanting cancer cells into a subject, and include, for example, spontaneously occurring cancers, cancers caused by exposure of a patient to one or more carcinogens, cancers caused by insertion of a transgenic oncogene or knockout of a tumor suppressor gene, and cancers caused by infection (e.g., viral infection). The term "cancer" is recognized in the art and refers to a malignancy of epithelial or endocrine tissue. The term also includes carcinosarcoma, which includes malignancies composed of cancerous and sarcomatous tissue. "Adenocarcinoma" refers to a cancer that originates from glandular tissue or a cancer in which the tumor cells form a recognizable glandular structure. The term "sarcoma" is recognized in the art and refers to a malignancy that is mesenchymal derived. The term "hematopoietic neoplastic disorder" includes diseases involving proliferative cells / tumor cells of hematopoietic origin. Hematopoietic neoplastic disorders can arise from myeloid, lymphoid, or erythroid lineages or their precursor cells.

[0120] As used herein, the term "antibody" refers to any antigen binding molecule containing at least one (e.g., one, two, three, four, five or six) complementary determining region (CDR) (e.g., any one of the three CDRs from an immunoglobulin light chain or any one of the three CDRs from an immunoglobulin heavy chain) and capable of specific binding to an epitope. Non-limiting examples of antibodies include: monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), single-chain antibodies, chimeric antibodies, human antibodies and humanized antibodies. In some embodiments, the antibody may contain the Fc region of a human antibody. The term antibody also includes derivatives such as bispecific antibodies, single-chain antibodies, double antibodies, linear antibodies and multispecific antibodies formed by antibody fragments.

[0121] As used herein, the term "antigen-binding fragment" refers to a portion of a full-length antibody, wherein the portion of the antibody is capable of specifically binding to an antigen. In some embodiments, an antigen-binding fragment contains at least one variable domain (e.g., a heavy chain variable domain or a light chain variable domain). Non-limiting examples of antibody fragments include, for example, Fab, Fab', F(ab')2, and Fv fragments.

[0122] As used herein, the term "human antibody" refers to an antibody encoded by endogenous nucleic acids present in the human body (e.g., human immunoglobulin heavy chain or light chain loci of rearrangement). In some embodiments, human antibodies are collected from people or produced in human cell cultures (e.g., human hybridoma cells). In some embodiments, human antibodies are produced in non-human cells (e.g., mouse or hamster cell lines). In some embodiments, human antibodies are produced in bacteria or yeast cells. In some embodiments, human antibodies are produced in transgenic non-human animals (e.g., bovines) containing unrearranged or rearranged human immunoglobulin loci (e.g., heavy chain or light chain human immunoglobulin loci).

[0123] As used herein, the term "chimeric antibody" refers to an antibody containing a sequence present in at least two different antibodies (e.g., antibodies from two different mammalian species, such as human antibodies and mouse antibodies). A non-limiting example of a chimeric antibody is an antibody containing a variable domain sequence (e.g., all or part of a light chain and / or heavy chain variable domain sequence) of a non-human (e.g., mouse) antibody and the constant domains of a human antibody. Additional embodiments of chimeric antibodies are described herein and are known in the art.

[0124] As used herein, the term "humanized antibody" refers to a non-human antibody containing the minimum sequence derived from non-human (e.g., mouse) immunoglobulin and containing a sequence derived from human immunoglobulin. In non-limiting embodiments, a humanized antibody is a human antibody (receptor antibody), wherein the hypervariable region (e.g., CDR) residues of the receptor antibody are replaced by hypervariable region (e.g., CDR) residues of a non-human antibody (e.g., donor antibody) such as mouse, rat or rabbit antibody with desired specificity, affinity and ability. In some embodiments, the Fv framework residues of human immunoglobulin are replaced by corresponding non-human (e.g., mouse) immunoglobulin residues. In some embodiments, humanized antibodies can contain residues not found in receptor antibody or donor antibody. These modifications can further improve antibody performance. In some embodiments, humanized antibodies contain at least one and generally substantially all of two variable domains, wherein all or substantially all of the hypervariable loops (CDRs) correspond to the hypervariable loops of non-human (e.g., mouse) immunoglobulin, and all or substantially all of the framework regions are the framework regions of human immunoglobulin. Humanized antibodies can also contain at least a portion of an immunoglobulin constant region (Fc), typically a human immunoglobulin constant region. Humanized antibodies can be produced using molecular biology methods known in the art. Non-limiting examples of methods for producing humanized antibodies are described herein.

[0125] As used herein, the term "single-chain antibody" refers to a single polypeptide containing at least two immunoglobulin variable domains (e.g., variable domains of mammalian immunoglobulin heavy or light chains) capable of specific binding to an antigen. Non-limiting examples of single-chain antibodies are described herein.

[0126] As used herein, the term "multimeric antibody" refers to an antibody containing four or more (e.g., six, eight, or ten) immunoglobulin variable domains. In some embodiments, the multimeric antibody is capable of cross-linking a target molecule (e.g., 4-1BB) to at least one second target molecule (e.g., HER2) on the surface of a mammalian cell (e.g., human T cell, human tumor cell).

[0127] As used herein, the terms "subject" and "patient" are used interchangeably throughout the specification and describe a human or non-human animal for which treatment is provided according to the methods of the present invention. Veterinary and non-veterinary applications are encompassed by the present invention. Human patients can be adults or minors (e.g., people under 18 years of age). In addition to humans, patients include, but are not limited to, mice, rats, hamsters, guinea pigs, rabbits, ferrets, cats, dogs, and primates. Including, for example, non-human primates (e.g., monkeys, chimpanzees, gorillas, etc.), rodents (e.g., rats, mice, gerbils, hamsters, ferrets, rabbits), lagomorphs, pigs (e.g., piglets, miniature pigs), horses, dogs, felines, bovines, and other domesticated animals, farm animals, and zoo animals.

[0128] As used herein, when referring to an antibody, the phrases “specifically bind to…” and “specifically bind…” refer to an antibody interacting with its target molecule (e.g., 4-1BB), preferably interacting with other molecules, because the interaction depends on the presence of a specific structure (i.e., antigenic determinant or epitope) on the target molecule; in other words, the reagent typically recognizes and binds to molecules comprising a specific structure, rather than all molecules. An antibody that specifically binds to a target molecule may be referred to as a target-specific antibody. For example, an antibody that specifically binds to a 4-1BB molecule may be referred to as a 4-1BB-specific antibody or an anti-4-1BB antibody.

[0129] As used herein, the terms "polypeptide," "peptide," and "protein" are used interchangeably to refer to amino acid polymers of any length of at least two amino acids.

[0130] As used herein, the terms "polynucleotide," "nucleic acid molecule," and "nucleic acid sequence" are used interchangeably herein to refer to a nucleotide polymer of any length of at least two nucleotides, and include, but are not limited to, DNA, RNA, DNA / RNA hybrids, and modifications thereof.

[0131] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Methods and materials for use in the present invention are described herein; other suitable methods and materials known in the art may also be used. The materials, methods, and examples are illustrative only and are not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated herein by reference in their entirety. In the event of a conflict, the present specification (including definitions) shall prevail.

[0132] Other features and advantages of the invention will become apparent from the following detailed description and from the accompanying drawings and claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0133] Figure 1 is a flow chart showing the first part of an exemplary protocol for preparing anti-h4-1BB antibodies.

[0134] Figure 2 is a flow chart showing the second part of an exemplary scheme for preparing anti-h4-1BB antibodies.

[0135] Figure 3 This is a set of flow cytometry results showing the binding activity of anti-h4-1BB antibodies to human 4-1BB.

[0136] Figure 4 Figure 1 is a set of graphs showing flow cytometry results analyzing cross-reactivity of anti-h4-1BB antibodies with monkey 4-1BB (CHO-r4-1BB), mouse 4-1BB (CHO-m4-1BB), and human-mouse chimeric 4-1BB (CHO-c4-1BB). NC represents a negative control.

[0137] Figure 5 Graphs showing surface plasmon resonance (SPR) results using the chimeric anti-h4-1BB antibody 16-1C4-mHvKv-IgG4 and human 4-1BB.

[0138] Figure 6 Graphs showing surface plasmon resonance (SPR) results using the chimeric anti-h4-1BB antibody 29-6A5-mHvKv-IgG2 and human 4-1BB.

[0139] Figure 7 is a graph showing changes in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with mouse anti-h4-1BB antibodies 1C4 and 5F9 and urelumab.

[0140] Figure 8 is a graph showing the change in percentage of body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with mouse anti-h4-1BB antibodies 1C4 and 5F9 and Urelumab.

[0141] Figure 9 Graph showing changes in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with mouse anti-h4-1BB antibodies 1C4 and 5F9 and Urelumab.

[0142] Figure 10Graph showing changes in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with mouse anti-h4-1BB antibodies 29-6A5, 29-4A10, 29-5F10, 45-8F1, 45-4B9, and Urelumab.

[0143] Figure 11 Graph showing the change in percentage of body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with mouse anti-h4-1BB antibodies 29-6A5, 29-4A10, 29-5F10, 45-8F1, 45-4B9, and Urelumab.

[0144] Figure 12 Graph showing changes in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with mouse anti-h4-1BB antibodies 29-6A5, 29-4A10, 29-5F10, 45-8F1, 45-4B9, and Urelumab.

[0145] Figure 13 is a graph showing the change in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with urelumab and mouse anti-h4-1BB antibodies 45-8E2, 45-7E9, 45-7G9, 45-2B3, and 45-2C11.

[0146] Figure 14 is a graph showing the change in percentage of body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with urelumab and mouse anti-h4-1BB antibodies 45-8E2, 45-7E9, 45-7G9, 45-2B3, and 45-2C11.

[0147] Figure 15 Graph showing the change in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with urelumab and mouse anti-h4-1BB antibodies 45-8E2, 45-7E9, 45-7G9, 45-2B3, and 45-2C11.

[0148] Figure 16 is a graph showing the changes in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with urelumab and mouse anti-h4-1BB antibodies 16-1C4, 55-8F6, and 54-8B11.

[0149] Figure 17is a graph showing the change in percentage of body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with urelumab and mouse anti-h4-1BB antibodies 16-1C4, 55-8F6, and 54-8B11.

[0150] Figure 18 Graph showing the change in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with urelumab and mouse anti-h4-1BB antibodies 16-1C4, 55-8F6, and 54-8B11.

[0151] Figure 19 is a graph showing the changes in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with urelumab and mouse anti-h4-1BB antibodies 54-1A11, 55-1E3, 55-8H5, and 56-2A6.

[0152] Figure 20 is a graph showing the change in percentage of body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with urelumab and mouse anti-h4-1BB antibodies 54-1A11, 55-1E3, 55-8H5, and 56-2A6.

[0153] Figure 21 Graph showing the change in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with urelumab and mouse anti-h4-1BB antibodies 54-1A11, 55-1E3, 55-8H5, and 56-2A6.

[0154] Figure 22 is a graph showing the changes in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with urelumab and mouse anti-h4-1BB antibodies 58-4B8, 69-3C2, and 69-4B11.

[0155] Figure 23 is a graph showing the change in percentage of body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with urelumab and mouse anti-h4-1BB antibodies 58-4B8, 69-3C2, and 69-4B11.

[0156] Figure 24Graph showing the change in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with urelumab and mouse anti-h4-1BB antibodies 58-4B8, 69-3C2, and 69-4B11.

[0157] Figure 25 Graph showing changes in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 30-5F9-mHvKv-IgG2, 30-5F9-mHvKv-IgG4, 16-1C4-mHvKv-IgG2, 16-1C4-mHvKv-IgG4, 16-1C4-mHvKv-IgG1, 30-5F9, 16-1C4, utomilumab, and urelumab.

[0158] Figure 26 Graph showing the change in percentage of body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 30-5F9-mHvKv-IgG2, 30-5F9-mHvKv-IgG4, 16-1C4-mHvKv-IgG2, 16-1C4-mHvKv-IgG4, 16-1C4-mHvKv-IgG1, 30-5F9, 16-1C4, utolutumab, and urelumab.

[0159] Figure 27 Graph showing changes in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 30-5F9-mHvKv-IgG2, 30-5F9-mHvKv-IgG4, 16-1C4-mHvKv-IgG2, 16-1C4-mHvKv-IgG4, 16-1C4-mHvKv-IgG1, 30-5F9, 16-1C4, utolutumab, and urelumab.

[0160] Figure 28 Graph showing changes in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 16-1C4-mHvKv-IgG2, 29-6A5-mHvKv-IgG2, 30-5F9-mHvKv-IgG2, 45-2B3-mHvKv-IgG2, 45-7E9-mHvKv-IgG2, 45-7G9-mHvKv-IgG2, 45-8E2-mHvKv-IgG2, 45-8F1-mHvKv-IgG2, and Urelumab.

[0161] Figure 29 Graph showing the change in percentage of body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 16-1C4-mHvKv-IgG2, 29-6A5-mHvKv-IgG2, 30-5F9-mHvKv-IgG2, 45-2B3-mHvKv-IgG2, 45-7E9-mHvKv-IgG2, 45-7G9-mHvKv-IgG2, 45-8E2-mHvKv-IgG2, 45-8F1-mHvKv-IgG2, and Urelumab.

[0162] Figure 30 Graph showing changes in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 16-1C4-mHvKv-IgG2, 29-6A5-mHvKv-IgG2, 30-5F9-mHvKv-IgG2, 45-2B3-mHvKv-IgG2, 45-7E9-mHvKv-IgG2, 45-7G9-mHvKv-IgG2, 45-8E2-mHvKv-IgG2, 45-8F1-mHvKv-IgG2, and Urelumab.

[0163] Figure 31 Graph showing changes in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 6A5-H1K2-IgG2, 6A5-H1K3-IgG2, 6A5-H2K2-IgG2, 6A5, and Urelumab.

[0164] Figure 32 is a graph showing the change in percentage of body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 6A5-H1K2-IgG2, 6A5-H1K3-IgG2, 6A5-H2K2-IgG2, 6A5, and Urelumab.

[0165] Figure 33 Graph showing changes in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 6A5-H1K2-IgG2, 6A5-H1K3-IgG2, 6A5-H2K2-IgG2, 6A5, and Urelumab.

[0166] Figure 34Graph showing changes in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 1C4-H1K1-IgG4, 1C4-H1K2-IgG4, 5F9-H1K1-IgG4, 5F9-H1K2-IgG4, 16-1C4, 30-5F9, and Urelumab.

[0167] Figure 35 Graph showing the change in percentage of body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 1C4-H1K1-IgG4, 1C4-H1K2-IgG4, 5F9-H1K1-IgG4, 5F9-H1K2-IgG4, 16-1C4, 30-5F9, and Urelumab.

[0168] Figure 36 Graph showing changes in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 1C4-H1K1-IgG4, 1C4-H1K2-IgG4, 5F9-H1K1-IgG4, -5F9-H1K2-IgG4, 16-1C4, 30-5F9, and Urelumab.

[0169] Figure 37 Graph showing changes in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 16-1C4-mHvKv-IgG1 (G2), 16-1C4-mHvKv-IgG2 (G3), 16-1C4-mHvKv-IgG4 (G4), 16-1C4 (G5), and Urelumab (G6).

[0170] Figure 38 Graph showing the change in percentage of body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 16-1C4-mHvKv-IgG1 (G2), 16-1C4-mHvKv-IgG2 (G3), 16-1C4-mHvKv-IgG4 (G4), 16-1C4 (G5), and Urelumab (G6).

[0171] Figure 39Graph showing changes in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 16-1C4-mHvKv-IgG1 (G2), 16-1C4-mHvKv-IgG2 (G3), 16-1C4-mHvKv-IgG4 (G4), 16-1C4 (G5), and Urelumab (G6).

[0172] Figure 40 Figure 2 is a graph showing the change in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells, treated with anti-h4-1BB antibodies 54-8B11-mHvKv-IgG2 (G2), 55-8F6-mHvKv-IgG2 (G3), 56-2A6-mHvKv-IgG2 (G4), 69-3C2-mHvKv-IgG2 (G5), 61-6A7-mHvKv-IgG2 (G6), 70-6F10-mHvKv-IgG2 (G7), 70-3F9-mHvKv-IgG2 (G8), 45-4B9-mHvkv-IgG2 (G9), and also urelumab (G10).

[0173] Figure 41 Figure 2 is a graph showing the percentage of body weight change over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells, treated with anti-h4-1BB antibodies 54-8B11-mHvKv-IgG2 (G2), 55-8F6-mHvKv-IgG2 (G3), 56-2A6-mHvKv-IgG2 (G4), 69-3C2-mHvKv-IgG2 (G5), 61-6A7-mHvKv-IgG2 (G6), 70-6F10-mHvKv-IgG2 (G7), 70-3F9-mHvKv-IgG2 (G8), 45-4B9-mHvkv-IgG2 (G9), and also urelumab (G10).

[0174] Figure 42Figure 2 is a graph showing the change in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 54-8B11-mHvKv-IgG2 (G2), 55-8F6-mHvKv-IgG2 (G3), 56-2A6-mHvKv-IgG2 (G4), 69-3C2-mHvKv-IgG2 (G5), 61-6A7-mHvKv-IgG2 (G6), 70-6F10-mHvKv-IgG2 (G7), 70-3F9-mHvKv-IgG2 (G8), 45-4B9-mHvkv-IgG2 (G9), and also urelumab (G10).

[0175] Figure 43 Graph showing changes in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 6A5-H1K2-IgG2, 6A5-H1K3-IgG2, 1C4-H1K1-IgG2, 1C4-H1K2-IgG2, 5F9-H1K1-IgG2, 5F9-H1K2-IgG2, 16-1C4-mHvKv-IgG2, 29-6A5-mHvKv-IgG2, 30-5F9-mHvKv-IgG2, and Urelumab.

[0176] Figure 44 Graph showing the change in percentage of body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 6A5-H1K2-IgG2, 6A5-H1K3-IgG2, 1C4-H1K1-IgG2, 1C4-H1K2-IgG2, 5F9-H1K1-IgG2, 5F9-H1K2-IgG2, 16-1C4-mHvKv-IgG2, 29-6A5-mHvKv-IgG2, 30-5F9-mHvKv-IgG2, and Urelumab.

[0177] Figure 45 Graph showing changes in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 6A5-H1K2-IgG2, 6A5-H1K3-IgG2, 1C4-H1K1-IgG2, 1C4-H1K2-IgG2, 5F9-H1K1-IgG2, 5F9-H1K2-IgG2, 16-1C4-mHvKv-IgG2, 29-6A5-mHvKv-IgG2, 30-5F9-mHvKv-IgG2, and Urelumab.

[0178] Figure 46 Graph showing changes in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies Urelumab-IgG1, Urelumab-IgG2, Urelumab-IgG4, Urelumab-IgG1-N297A, Urelumab-IgG1-FC-SI, and Urelumab-IgG1-FC-V11.

[0179] Figure 47 Graph showing the change in percentage of body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with the anti-h4-1BB antibodies Urelumab-IgG1, Urelumab-IgG2, Urelumab-IgG4, Urelumab-IgG1-N297A, Urelumab-IgG1-FC-SI, and Urelumab-IgG1-FC-V11.

[0180] Figure 48 Graph showing changes in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies Urelumab-IgG1, Urelumab-IgG2, Urelumab-IgG4, Urelumab-IgG1-N297A, Urelumab-IgG1-FC-SI, and Urelumab-IgG1-FC-V11.

[0181] Figure 49 Graph showing changes in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 16-1C4-mHvKv-IgG1, 16-1C4-mHvKv-IgG2, 16-1C4-mHvKv-IgG4, 16-1C4-mHvKv-IgG1-FC-V11, 16-1C4-mHvKv-IgG1-FC-SI, 16-1C4, and Urelumab.

[0182] Figure 50 Graph showing the change in percentage of body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 16-1C4-mHvKv-IgG1, 16-1C4-mHvKv-IgG2, 16-1C4-mHvKv-IgG4, 16-1C4-mHvKv-IgG1-FC-V11, 16-1C4-mHvKv-IgG1-FC-SI, 16-1C4, and Urelumab.

[0183] Figure 51 Graph showing changes in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 16-1C4-mHvKv-IgG1, 16-1C4-mHvKv-IgG2, 16-1C4-mHvKv-IgG4, 16-1C4-mHvKv-IgG1-FC-V11, 16-1C4-mHvKv-IgG1-FC-SI, 16-1C4, and Urelumab.

[0184] Figure 52 The CDR sequences of several anti-h4-1BB antibodies as defined by Kabat numbering and the CDR sequences of their humanized anti-h4-1BB antibodies are listed.

[0185] Figure 53 The CDR sequences of several anti-h4-1BB antibodies as defined by Chothia numbering are listed, as well as the CDR sequences of their humanized anti-h4-1BB antibodies.

[0186] Figure 54 The amino acid sequences of human 4-1BB ("h4-1BB"), mouse 4-1BB ("m4-1BB"), monkey 4-1BB ("rm4-1BB" or "r4-1BB"), and chimeric 4-1BB ("chi4-1BB" or "c4-1BB") are listed.

[0187] Figure 55 The amino acid sequences of the heavy and light chain variable regions of the humanized antibody based on 1C4 are listed.

[0188] Figure 56 The amino acid sequences of the heavy chain variable region and the light chain variable region of the humanized antibody based on 6A5 are listed.

[0189] Figure 57 The amino acid sequences of the heavy chain variable region and the light chain variable region of the humanized antibody based on 5F9 are listed.

[0190] Figure 58 The amino acid sequences of the heavy chain variable regions and light chain variable regions of several mouse anti-h4-1BB antibodies are listed.

[0191] Figure 59Graph showing changes in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies ushelumab-mIgG1 (G2), ushelumab-mIgG2A (G3), 16-1C4-mHvKv-mIgG1 (G4), 16-1C4-mHvKv-mIgG2A (G5), ushelumab (G6), ushelumab-IgG1 (G7), 16-1C4-mHvKv-IgG1 (G8), and 16-1C4-mHvKv-IgG4 (G9).

[0192] Figure 60 Graph showing the change in percentage of body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with the anti-h4-1BB antibodies ushelumab-mIgG1 (G2), ushelumab-mIgG2A (G3), 16-1C4-mHvKv-mIgG1 (G4), 16-1C4-mHvKv-mIgG2A (G5), ushelumab (G6), ushelumab-IgG1 (G7), 16-1C4-mHvKv-IgG1 (G8), and 16-1C4-mHvKv-IgG4 (G9).

[0193] Figure 61 Graph showing changes in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies ushelumab-mIgG1 (G2), ushelumab-mIgG2A (G3), 16-1C4-mHvKv-mIgG1 (G4), 16-1C4-mHvKv-mIgG2A (G5), ushelumab (G6), ushelumab-IgG1 (G7), 16-1C4-mHvKv-IgG1 (G8), and 16-1C4-mHvKv-IgG4 (G9).

[0194] Figure 62 is a graph showing changes in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with the anti-h4-1BB antibody usurelumab, usurelumab-IgG1, 1C4-mHvKv-IgG1, 1C4-mHvKv-IgG4, 1C4-H1K1-IgG1, 1C4-H1K1-IgG4, 1C4-H1K2-IgG1, 1C4-H1K2-IgG4, 6A5-H1K2-IgG1, 5F9-H1K1-IgG1, and 1C4-mHvKv-IgG1-FC-V11.

[0195] Figure 63is a graph showing the change in percentage of body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with the anti-h4-1BB antibody usurelumab, usurelumab-IgG1, 1C4-mHvKv-IgG1, 1C4-mHvKv-IgG4, 1C4-H1K1-IgG1, 1C4-H1K1-IgG4, 1C4-H1K2-IgG1, 1C4-H1K2-IgG4, 6A5-H1K2-IgG1, 5F9-H1K1-IgG1, and 1C4-mHvKv-IgG1-FC-V11.

[0196] Figure 64 Graph showing changes in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with the anti-h4-1BB antibody usurelumab, usurelumab-IgG1, 1C4-mHvKv-IgG1, 1C4-mHvKv-IgG4, 1C4-H1K1-IgG1, 1C4-H1K1-IgG4, 1C4-H1K2-IgG1, 1C4-H1K2-IgG4, 6A5-H1K2-IgG1, 5F9-H1K1-IgG1, and 1C4-mHvKv-IgG1-FC-V11.

[0197] Figure 65 Graph showing changes in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 1C4-IgG1-H1K1, 1C4-IgG4-H1K1, Urelumab-IgG1, Urelumab-IgG4, Keytruda-IgG4, 1C4-IgG1-H1K1 + Keytruda-IgG4, 1C4-IgG4-H1K1 + Keytruda-IgG4, Urelumab-IgG1 + Keytruda-IgG4, and Urelumab-IgG4 + Keytruda-IgG4.

[0198] Figure 66 Graph showing the change in percentage of body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 1C4-IgG1-H1K1, 1C4-IgG4-H1K1, Urelumab-IgG1, Urelumab-IgG4, Keytruda-IgG4, 1C4-IgG1-H1K1 + Keytruda-IgG4, 1C4-IgG4-H1K1 + Keytruda-IgG4, Urelumab-IgG1 + Keytruda-IgG4, and Urelumab-IgG4 + Keytruda-IgG4.

[0199] Figure 67Graph showing changes in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing MC-38 tumor cells treated with anti-h4-1BB antibodies 1C4-IgG1-H1K1, 1C4-IgG4-H1K1, Urelumab-IgG1, Urelumab-IgG4, Keytruda-IgG4, 1C4-IgG1-H1K1 + Keytruda-IgG4, 1C4-IgG4-H1K1 + Keytruda-IgG4, Urelumab-IgG1 + Keytruda-IgG4, and Urelumab-IgG4 + Keytruda-IgG4.

[0200] Figure 68 Graph showing changes in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing B16-F10 cancer cells treated with different anti-h4-1BB antibodies.

[0201] Figure 69 is a graph showing the change in percentage of body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing B16-F10 cancer cells treated with different anti-h4-1BB antibodies.

[0202] Figure 70 Graph showing the changes in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing B16-F10 cancer cells treated with different anti-h4-1BB antibodies.

[0203] Figure 71 Graph showing changes in body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing EL4 cancer cells treated with different anti-h4-1BB antibodies.

[0204] Figure 72 is a graph showing the change in percentage of body weight over time in humanized 4-1BB mice (B-h4-1BB) bearing EL4 cancer cells treated with different anti-h4-1BB antibodies.

[0205] Figure 73 Graph showing the changes in tumor volume over time in humanized 4-1BB mice (B-h4-1BB) bearing EL4 cancer cells treated with different anti-h4-1BB antibodies.

[0206] Figures 74-75 is a schematic diagram showing two fluorescence-activated cell sorting (FACS) procedures used to analyze spleen samples.

[0207] Figures 76-77 is a schematic diagram showing two FACS procedures used to analyze tumor samples.

[0208] Figure 78Ais a graph showing the percentage of CD45+ cells in tumor cells.

[0209] Figure 78B It is a graph showing the count of CD45+ cells in tumor cells.

[0210] Figure 78C is a graph showing the percentage of CD11b+ cells in tumor cells.

[0211] Figure 78D is a graph showing the percentage of NK cells among CD45+ cells in tumor samples.

[0212] Figure 79A is a graph showing the percentage of CD3+ cells among CD45+ cells in tumor samples.

[0213] Figure 79B is a graph showing the percentage of CD8+ cells among CD3+ cells in tumor samples.

[0214] Figure 79C is a graph showing the percentage of CD4+FoxP3- cells among CD3+ cells in tumor samples.

[0215] Figure 79D is a graph showing the percentage of Treg cells among CD3+ cells in tumor samples.

[0216] Figure 80A is a graph showing the percentage of hCD137+ cells among NK cells in tumor samples.

[0217] Figure 80B is a graph showing the percentage of hCD137+ cells among CD3+ cells in tumor samples.

[0218] Figure 80C is a graph showing the percentage of hCD137+ cells among CD8+ cells in tumor samples.

[0219] Figure 80D is a graph showing the percentage of hCD137+ cells among CD4+FoxP3- cells in tumor samples.

[0220] Figure 80E is a graph showing the percentage of hCD137+ cells among Treg cells in tumor samples.

[0221] Figure 81A is a graph showing the count of hCD137+ cells among NK cells in tumor samples.

[0222] Figure 81B is a graph showing the count of hCD137+ cells among CD3+ cells in tumor samples.

[0223] Figure 81C is a graph showing the count of hCD137+ cells among CD8+ cells in tumor samples.

[0224] Figure 81D is a graph showing the count of hCD137+ cells among CD4+FoxP3- cells in tumor samples.

[0225] Figure 81E is a graph showing the count of hCD137+ cells among Treg cells in tumor samples.

[0226] Figure 82A is a graph showing the percentage of CD8+ / Treg cells among CD3+ cells in tumor samples.

[0227] Figure 82B is a graph showing the percentage of Ki67+ cells among CD8+ cells in tumor samples.

[0228] Figure 82C is a graph showing the percentage of Ki67+ cells among CD4+FoxP3- cells in tumor samples.

[0229] Figure 82D is a graph showing the percentage of Ki67+ cells among Treg cells in tumor samples.

[0230] Figure 83A is a graph showing the count of Eomes+ cells among CD8+ cells in tumor samples.

[0231] Figure 83B is a graph showing the count of Eomes+ cells among CD4+FoxP3+ cells in tumor samples.

[0232] Figure 83C is a graph showing the count of T-bet+ cells among CD8+ cells in tumor samples.

[0233] Figure 83D is a graph showing the count of T-bet+ cells among CD4+FoxP3- cells in tumor samples. DETAILED DESCRIPTION

[0234] The present disclosure provides examples of antibodies, antigen-binding fragments thereof, that bind to TNFRSF9 (Tumor Necrosis Factor Receptor Superfamily Member 9; also known as "4-1BB" or "CD137").

[0235] 4-1BB and Cancer

[0236] The immune system can distinguish between normal cells in the body and those considered "foreign," allowing it to attack foreign cells while leaving normal cells unaffected. This mechanism sometimes involves proteins called immune checkpoints. Immune checkpoints are molecules in the immune system that can either turn up signals (co-stimulatory molecules) or turn down signals.

[0237] Checkpoint inhibitors can prevent the immune system from attacking normal tissues, thereby preventing autoimmune diseases. Many tumor cells also express checkpoint inhibitors. These tumor cells escape immune surveillance by selecting certain immune checkpoint pathways, particularly in T cells specific for tumor antigens (Creelan, Benjamin C. "Update onimmune checkpoint inhibitors in lung cancer." Cancer Control 21.1 (2014): 80-89). Because many immune checkpoints are triggered by ligand-receptor interactions, they can be easily blocked by antibodies directed against ligands and / or their receptors.

[0238] 4-1BB ("TNFRSF9" or "CD137") is a member of the tumor necrosis factor (TNF) receptor family. It has three N-glycosylation sites and one potential O-glycosylation site. It is a type I transmembrane protein and is mainly expressed on the surface of T cells, natural killer (NK) cells, neutrophils and dendritic cells (DC) cells. The human CD137 gene is located in the 1P36 region (chromosome 1), the NCBI gene ID is 3604, and encodes 255 amino acids. The human CD137 protein molecule has two forms: a membrane-bound form and a soluble form, which are encoded by 2.8kb and 1.4kb mRNAs, respectively. The soluble form does not have a transmembrane domain. The ligand of CD137 is CD137L (4-1BBL). CD137L belongs to the TNF superfamily and is expressed on the surface of antigen-presenting cells, including, for example, dendritic cells, B cells and macrophages. The co-stimulatory signal generated by the interaction of CD137 with its receptor CD137L induces the activation and proliferation of T cells and NK cells and the production of cytokines.

[0239] The mouse CD137 gene is located in the 4E2 region (chromosome 4) and has an NCBI gene ID of 21942. The human CD137 protein has approximately 58% identity to the mouse CD137 protein. The cytoplasmic tail region of human CD137 is significantly different from that of mouse CD137. In particular, a single tyrosine residue in the cytoplasmic domain of CD137 was found at position 220 of human CD137 and position 254 of mouse CD137. Human CD137 is also different from mouse CD137 in the putative Lck binding site, wherein mouse CD137 expresses the CXCP Lck binding motif, and in human CD137 this sequence is changed to CXFP. Human CD137 and mouse CD137 bind to TNFR-associated factor 2 at two common sites. The TNFR-associated factor 2 is an adaptor protein necessary for mediating downstream signaling events, which result in the production of cytokines (e.g., IL-2) that respond to CD137L signaling.

[0240] Abnormal expression of CD137 and its ligands in tumor tissues suggests that CD137 and its ligands may have costimulatory signaling disruption or inactivation during tumorigenesis. In particular, CD137 expression in tumor vascular walls is associated with tumor malignancy, and evidence shows that anti-CD137 agonist antibodies can act on tumor endothelial cells to enhance the recruitment of activated T lymphocytes, suggesting that there are additional mechanisms of action that can explain the immunotherapy effects of CD137 agonist antibodies.

[0241] Numerous studies have shown that CD137 is one of the potential targets for anti-tumor biological therapy. Anti-CD137 antibodies can kill tumor cells or inhibit tumor growth by inducing the activation and proliferation of T cells and NK cells, increasing the production of cytokines, upregulating immune responses, and / or recruiting activated T lymphocytes to tumors. To date, two antibodies targeting the CD137 pathway (Bristol-Myers Squibb's urelumab (BMS-663513) and Pfizer's utolumab (PF-05082566)) have been tested in clinical trials for the treatment of melanoma, lymphoma, non-Hodgkin's lymphoma, and some advanced solid tumors. Some clinical trials have achieved promising preliminary clinical results. For example, similar to PD-1 inhibitors, PF-05082566 can reduce follicular lymphoma (FL) by 40% with minimal side effects; PF-05082566 has been used in combination with other drugs including, for example, anti-PD-1 antibodies or anti-OX40 antibodies. Preliminary experimental evidence also shows that cancer-targeted drugs can increase the expression of CD137 on the surface of NK cells. Therefore, if anti-CD137 antibodies are administered in combination with cancer-targeted drugs, it can enhance the killing effect of NK cells and improve the therapeutic effect.

[0242] A detailed description of CD137 and its functions can be found in, for example, Wen et al., “4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function,” The Journal of Immunology 168.10(2002):4897-4906; Broll et al., “CD137 expression in tumor vessel walls: high correlation with malignant tumors,” American journal of clinical pathology 115.4(2001):543-549; and Palazón et al., “Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes,” Cancer research 71.3(2011):801-811; Kang et al., “Anti-CD137 suppresses tumor growth by blocking reverse signaling by CD137 ligand.” Cancer research (2017):canres-0610; each of which is incorporated by reference in its entirety.

[0243] The present disclosure provides anti-4-1BB antibodies, antigen-binding fragments thereof, and methods of using these anti-4-1BB antibodies and antigen-binding fragments to inhibit tumor growth and treat cancer.

[0244] Antibodies and antigen-binding fragments

[0245] The present disclosure provides anti-4-1BB antibodies and antigen-binding fragments thereof, comprising the complementarity determining regions (CDRs), heavy chain variable regions, light chain variable regions, heavy chains, or light chains described herein.

[0246] Typically, antibodies (also known as immunoglobulins) are composed of two types of polypeptide chains, light chains and heavy chains. Non-limiting antibodies of the present disclosure can be complete four immunoglobulin chain antibodies comprising two heavy chains and two light chains. The heavy chain of an antibody can be of any isotype or subclass, including IgM, IgG, IgE, IgA, or IgD, and the subclasses include IgG1, IgG2, IgG2a, IgG2b, IgG3, IgG4, IgE1, IgE2, and the like. The light chain can be a kappa light chain or a lambda light chain. An antibody can comprise two identical copies of a light chain and two identical copies of a heavy chain. Each contains a variable domain (or variable region, V H ) and multiple constant domains (or constant regions) are bound to each other via disulfide bonds within their constant domains to form the "handle" of the antibody. Each contains a variable domain (or variable region, V L ) and a constant domain (or constant region), each bound to a heavy chain via a disulfide bond. The variable region of each light chain pairs with the variable region of the heavy chain to which it is bound. Both the light and heavy chain variable regions contain three hypervariable regions sandwiched between more conserved framework regions (FRs).

[0247] These hypervariable regions, called complementarity determining regions (CDRs), form a loop that comprises the primary antigen-binding surface of the antibody. The four framework regions primarily adopt a β-sheet conformation, and the CDRs form loops that connect, and in some cases form part of, the β-sheet structure. The CDRs in each chain are brought into close proximity by the framework regions and, together with the CDRs from the other chain, form an antigen-binding region.

[0248] Methods for identifying the CDR regions of an antibody by analyzing its amino acid sequence are well known, and many definitions of CDR are commonly used. The Kabat definition is based on sequence variability, while the Chothia definition is based on the position of the structural loop regions. The latest definition of CDR is the IMGT definition. The IMGT definition is based on the IMGT database, which manages nucleotide sequence information for immunoglobulins (IG), T cell receptors (TcR), and major histocompatibility complex (MHC) molecules. It is based on aligning more than 5,000 IG and TcR variable region sequences, taking into account and combining the Kabat definitions of FRs and CDRs, structural data, and Chothia characterization of hypervariable loops, to propose a unified numbering system for IG and TcR sequences. The IMGT numbering scheme does not distinguish between various immunoglobulins (i.e., IG or TcR), chain types (i.e., heavy chains or light chains), or species.These methods for identifying CDR regions and various definitions are described in, for example, Martin, "Protein sequence and structure analysis of antibody variable domains," Antibody engineering, Springer Berlin Heidelberg, 2001. 422-439; Abhinandan et al. "Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains," Molecular immunology 45.14 (2008): 3832-3839; Wu, TT and Kabat, EA (1970) J. Exp. Med. 132: 211-250; Martin et al., Methods Enzymol. 203: 121-53 (1991); Morea et al., Biophys Chem. 68(1-3): 9-16 (October 1997); Morea et al., J Mol Biol. 275(2): 269-94 (January 1998); Chothia et al., Nature 342(6252):877-83 (December 1989); Ponomarenko and Bourne, BMC Structural Biology 7:64 (2007); Lefranc, et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains.” Developmental & Comparative Immunology 27.1 (2003):55-77; Kunik, et al., “Structural consensus among antibodies defines the antigen binding site.” PLoS computational biology 8.2 (2012):e1002388; each of which is incorporated herein by reference in its entirety.

[0249] CDRs are important for recognizing antigenic epitopes. As used herein, an "epitope" is the smallest portion of a target molecule that can be specifically bound by an antibody's antigen-binding domain. The minimum size of an epitope may be approximately three, four, five, six, or seven amino acids, but these amino acids do not necessarily have to be located in a continuous linear sequence within the primary structure of the antigen, as the epitope may depend on the three-dimensional configuration of the antigen based on its secondary and tertiary structures.

[0250] In some embodiments, the antibody is a complete immunoglobulin molecule (e.g., IgG1, IgG2a, IgG2b, IgG3, IgG4, IgM, IgD, IgE, IgA). The IgG subclasses (IgG1, IgG2, IgG3, and IgG4) are highly conserved, differing only in their constant regions, particularly their hinge and CH2 upper domains. The sequences and differences of IgG subclasses are known in the art and are described in, for example, Vidarsson et al., “IgG subclasses and allotypes: from structure to effector functions.” Frontiers in immunology 5 (2014); Irani et al. “Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases.” Molecular immunology 67.2 (2015): 171-182; Shakib, Farouk, ed. The human IgG subclasses: molecular analysis of structure, function and regulation. Elsevier, 2016; each of which is incorporated herein by reference in its entirety.

[0251] Antibodies can also be immunoglobulin molecules derived from any species (e.g., humans, rodents, mice, rats, camelids). Antibodies disclosed herein also include, but are not limited to, polyclonal antibodies, monoclonal antibodies, monospecific antibodies, multispecific antibodies, and chimeric antibodies comprising immunoglobulin binding domains fused to another polypeptide. The term "antigen binding domain" or "antigen binding fragment" is an antibody portion that retains the specific binding activity of a complete antibody, i.e., any portion of an antibody that can specifically bind to an epitope on the target molecule of a complete antibody, including, for example, Fab, Fab', F(ab')2 and variants of these fragments. Therefore, in some embodiments, an antibody or its antigen binding fragment can be, for example, scFv, Fv, Fd, dAb, bispecific antibodies, bispecific scFv, double antibodies, linear antibodies, single-chain antibody molecules, multispecific antibodies formed by antibody fragments, and any polypeptide including an antibody binding domain or a binding domain homologous thereto. Non-limiting examples of antigen binding domains include, e.g., the heavy and / or light chain CDRs of an intact antibody, the heavy and / or light chain variable regions of an intact antibody, the full-length heavy or light chain of an intact antibody, or individual CDRs from the heavy or light chain of an intact antibody.

[0252] In some embodiments, the antigen binding fragment can form a part of a chimeric antigen receptor (CAR). In some embodiments, the chimeric antigen receptor is a fusion of a single-chain variable fragment (scFv) as described herein and a CD3-ζ transmembrane domain and an internal domain. In some embodiments, the chimeric antigen receptor also includes an intracellular signaling domain from a variety of costimulatory protein receptors (e.g., CD28, 41BB, ICOS). In some embodiments, the chimeric antigen receptor includes multiple signaling domains, such as CD3z-CD28-41BB or CD3z-CD28-OX40, to improve effectiveness. Therefore, in one aspect, the present disclosure further provides cells (e.g., T cells) expressing chimeric antigen receptors as described herein.

[0253] In some embodiments, the scFV has one heavy chain variable domain and one light chain variable domain. In some embodiments, the scFV has two heavy chain variable domains and two light chain variable domains. In some embodiments, the scFV has two antigen binding regions, and the two antigen binding regions can bind to their respective target antigens.

[0254] Anti-4-1BB antibodies and antigen-binding fragments

[0255] The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to 4-1BB. The antibodies and antigen-binding fragments described herein are capable of binding to 4-1BB and can promote the 4-1BB signaling pathway, thereby increasing the immune response.

[0256] The present disclosure provides several anti-4-1BB antibodies, such as 16-1C4 ("1C4"), 29-6A5 ("6A5"), 30-5F9 ("5F9"), 45-2B3 ("2B3"), 45-4B9 ("4B9"), 45-7E9 ("7E9"), 45-7G9 ("7G9"), 45-8E11 ("8E11"), 45-8E2 ("8E2"), 45- 8F1 ("8F1"), 54-8B11 ("8B11"), 55-8F6 ("8F6"), 56-2A6 ("2A6"), 59-5E4 ("5E4"), 61-6A7 ("6A7"), 69-3C2 ("3C2"), 70-3F9 ("3F9"), and 70-6F10 ("6F10"), including, for example, mouse antibodies, chimeric antibodies thereof, and humanized antibodies thereof. The CDR sequences (Kabat definition) and the sequences of the heavy chain variable regions and light chain variable regions of some disclosed antibodies are shown in the table below. The CDR sequences (Chothia definition) are shown in Figure 53 Available in.

[0257] Table 1

[0258]

[0259]

[0260] For example, as shown in the table above, Figure 52 and Figure 53 As shown, as defined by Kabat numbering, the CDR sequences of 1C4 and antibodies derived from 1C4 (e.g., chimeric or humanized antibodies) include the CDRs of the heavy chain variable domain, SEQ ID NOs: 1-3, and the CDRs of the light chain variable domain, SEQ ID NOs: 4-6. CDRs can also be defined by the Chothia system. According to Chothia numbering, the CDR sequences of the heavy chain variable domain are shown in SEQ ID NOs: 109-111, and the CDR sequences of the light chain variable domain are shown in SEQ ID NOs: 112-114.

[0261] Similarly, as defined by Kabat numbering, the CDR sequences of 6A5 and 6A5-derived antibodies include the CDRs of the heavy chain variable domain, SEQ ID NOs: 7-9, and the CDRs of the light chain variable domain, SEQ ID NOs: 10- 12. According to Chothia numbering, the CDR sequences of the heavy chain variable domain are shown in SEQ ID NOs: 115-117, and the CDRs of the light chain variable domain are shown in SEQ ID NOs: 118-120.

[0262] As defined by Kabat numbering, the CDR sequences of 5F9 and 5F9-derived antibodies include the CDRs of the heavy chain variable domain, SEQ ID NOs: 13-15, and the CDRs of the light chain variable domain, SEQ ID NOs: 16-18. According to Chothia numbering, the CDR sequences of the heavy chain variable domain are shown in SEQ ID NOs: 121-123, and the CDRs of the light chain variable domain are shown in SEQ ID NOs: 124-126.

[0263] Similarly, the CDR sequences (Kabat) and VH and VL sequences of 2B3, 4B9, 7E9, 7G9, 8E11, 8E2, 8F1, 8B11, 8F6, 2A6, 5E4, 6A7, 3C2, 3F9, 6F10, and antibodies derived therefrom are provided in Table 1. The CDR sequences (Chothia) of 2B3, 4B9, 7E9, 7G9, 8E11, 8E2, 8F1, 8B11, 8F6, 2A6, 5E4, 6A7, 3C2, 3F9, 6F10, and antibodies derived therefrom are found in Table 2. Figure 53 .

[0264] Also provided are the amino acid sequences of the heavy chain variable region and light chain variable region of the humanized antibody. Because there are different ways to humanize mouse antibodies (e.g., sequences can be modified using different amino acid substitutions), the heavy and light chains of the antibody can have more than one form of humanized sequence. The amino acid sequences of the heavy chain variable region of the humanized 1C4 antibody are shown in SEQ ID NOs: 221-224. The amino acid sequences of the light chain variable region of the humanized 1C4 antibody are shown in SEQ ID NOs: 225-228. Any of these heavy chain variable region sequences (SEQ ID NOs: 221-224) can be paired with any of these light chain variable region sequences (SEQ ID NOs: 225-228).

[0265] Similarly, the amino acid sequences of the heavy chain variable regions of the humanized 6A5 antibody are shown in SEQ ID NOs: 229-231. The amino acid sequences of the light chain variable regions of the humanized 6A5 antibody are shown in SEQ ID NOs: 232-235. Any of these heavy chain variable region sequences (SEQ ID NOs: 229-231) can be paired with any of these light chain variable region sequences (SEQ ID NOs: 232-235).

[0266] The amino acid sequences of the heavy chain variable regions of the humanized 5F9 antibody are shown in SEQ ID NOs: 236-238. The amino acid sequences of the light chain variable regions of the humanized 6A5 antibody are shown in SEQ ID NOs: 239-242. Any of these heavy chain variable region sequences (SEQ ID NOs: 236-238) can be paired with any of these light chain variable region sequences (SEQ ID NOs: 239-242).

[0267] like Figures 55-57 , humanization percentage refers to the percentage of identity of the heavy chain or light chain variable region sequence compared to the human antibody sequence in the International Immunogenetics Information System (IMGT) database. The highest hit refers to that the heavy chain or light chain variable region sequence is closer to a specific species relative to other species. For example, the highest hit with people refers to that the sequence is closer to people compared to other species. The highest hit with people and cynomolgus monkey (Macaca fascicular) refers to that the sequence has the same percentage identity as the human sequence and the cynomolgus monkey sequence, and compared with the sequences of other species, these percentage identities are the highest. In some embodiments, the humanization percentage is greater than 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, or 95%. Detailed descriptions of how to determine the percentage of humanization and how to determine the top hits are known in the art and are described in, for example, Jones, Tim D. et al. "The INNs and outs of antibody nonproprietary names." MAbs. Vol. 8. No. 1. Taylor & Francis, 2016, which is incorporated herein by reference in its entirety. A high percentage of humanization generally has various advantages, such as being safer and more effective in humans, being more easily tolerated by human subjects, and / or being less prone to side effects.

[0268] The present disclosure also provides chimeric antibodies. These chimeric antibodies have VH and VL from mouse antibodies. However, the constant domains of these chimeric antibodies are from human antibodies (e.g., human IgG1, human IgG2, human IgG3, or human IgG4). These chimeric antibodies are labeled as mHvKv-IgG.

[0269] Some of the chimeric and humanized antibodies described in this disclosure are shown in the table below.

[0270] Table 2

[0271]

[0272]

[0273] In addition, in some embodiments, the antibodies or antigen-binding fragments thereof described herein may further contain one, two or three heavy chain variable region CDRs selected from the group consisting of SEQ ID NOs: 1-3, SEQ ID NOs: 7-9, SEQ ID NOs: 13-15, SEQ ID NOs: 19-21, SEQ ID NOs: 25-27, SEQ ID NOs: 31-33, SEQ ID NOs: 37-39, SEQ ID NOs: 43-45, SEQ ID NOs: 49-51, SEQ ID NOs: 55-57, SEQ ID NOs: 61-63, SEQ ID NOs: 67-69, SEQ ID NOs: 73-75, SEQ ID NOs: 79-81, SEQ ID NOs: 85-87, SEQ ID NOs: 91-93, SEQ ID NOs: 97-99, or SEQ ID NOs: 103-105; and / or one, two or three light chain variable region CDRs selected from the group consisting of SEQ ID NOs: 4-6, SEQ ID NOs: 10-12, SEQ ID NOs: 10-13, SEQ ID NOs: 10-14, SEQ ID NOs: 10-15 NO:16-18, SEQ ID NO:22-24, SEQ ID NO:28-30, SEQ ID NO:34-36, SEQ ID NO:40-42, SEQ ID NO:46-48, SEQ ID NO:52-54, SEQ ID NO:58-60, SEQ ID NO:64-66, SEQ ID NO:70-72, SEQ ID NO:76-78, SEQ ID NO:82-84, SEQ ID NO:88-90, SEQ ID NO:94-96, SEQ ID NO:100-102, or SEQ ID NO:106-108.

[0274] In some embodiments, the antibody can have a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region comprises complementarity determining regions (CDRs) 1, 2, 3, wherein the CDR1 region comprises or consists of an amino acid sequence that is at least 80%, 85%, 90% or 95% identical to a selected VH CDR1 amino acid sequence, the CDR2 region comprises or consists of an amino acid sequence that is at least 80%, 85%, 90% or 95% identical to a selected VH CDR2 amino acid sequence, and the CDR3 region comprises or consists of an amino acid sequence that is at least 80%, 85%, 90% or 95% identical to a selected VH CDR3 amino acid sequence; and the light chain variable region comprises CDRs 1, 2, 3, wherein the CDR1 region comprises or consists of an amino acid sequence that is at least 80%, 85%, 90% or 95% identical to a selected VL The CDR1 amino acid sequence has or consists of an amino acid sequence that is at least 80%, 85%, 90% or 95% identical, the CDR2 region comprises or consists of an amino acid sequence that is at least 80%, 85%, 90% or 95% identical to the selected VL CDR2 amino acid sequence, and the CDR3 region comprises or consists of an amino acid sequence that is at least 80%, 85%, 90% or 95% identical to the selected VL CDR3 amino acid sequence. Figure 52 (Kabat CDR) and Figure 53 Selected VH CDR 1, 2, 3 amino acid sequences and selected VL CDR 1, 2, 3 amino acid sequences are shown in (Chothia CDR).

[0275] In some embodiments, the antibodies or antigen-binding fragments described herein may contain a heavy chain variable domain containing one, two, or three CDRs selected from the group consisting of SEQ ID NOs: 1-3, SEQ ID NOs: 7-9, SEQ ID NOs: 13-15, SEQ ID NOs: 19-21, SEQ ID NOs: 25-27, SEQ ID NOs: 31-33, SEQ ID NOs: 37-39, SEQ ID NOs: 43-45, SEQ ID NOs: 49-51, SEQ ID NOs: 55-57, SEQ ID NOs: 61-63, SEQ ID NOs: 67-69, SEQ ID NOs: 73-75, SEQ ID NOs: 79-81, SEQ ID NOs: 85-87, SEQ ID NOs: 91-93, SEQ ID NOs: 97-99, or SEQ ID NOs: 103-105 with zero, one, or two amino acid insertions, deletions, or substitutions in one, two, or three of the selected CDRs. For example, the antibodies or antigen-binding fragments described herein can contain a heavy chain variable domain comprising one, two, or three of the following CDRs: SEQ ID NO: 1 with zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 2 with zero, one, or two amino acid insertions, deletions, or substitutions; or SEQ ID NO: 3 with zero, one, or two amino acid insertions, deletions, or substitutions.

[0276] In some embodiments, the antibodies or antigen-binding fragments described herein may contain a light chain variable domain containing one, two, or three CDRs selected from the group consisting of SEQ ID NOs: 4-6, SEQ ID NOs: 10-12, SEQ ID NOs: 16-18, SEQ ID NOs: 22-24, SEQ ID NOs: 28-30, SEQ ID NOs: 34-36, SEQ ID NOs: 40-42, SEQ ID NOs: 46-48, SEQ ID NOs: 52-54, SEQ ID NOs: 58-60, SEQ ID NOs: 64-66, SEQ ID NOs: 70-72, SEQ ID NOs: 76-78, SEQ ID NOs: 82-84, SEQ ID NOs: 88-90, SEQ ID NOs: 94-96, SEQ ID NOs: 100-102, or SEQ ID NOs: 106-108 with zero, one, or two amino acid insertions, deletions, or substitutions in one, two, or three of the selected CDRs. For example, the antibodies or antigen-binding fragments described herein can contain a light chain variable domain comprising one, two, or three of the following CDRs: SEQ ID NO: 4 with zero, one, or two amino acid insertions, deletions, or substitutions; SEQ ID NO: 5 with zero, one, or two amino acid insertions, deletions, or substitutions; or SEQ ID NO: 6 with zero, one, or two amino acid insertions, deletions, or substitutions.

[0277] In some embodiments, the CDRs with zero, one, or two amino acid insertions, deletions, or substitutions are in Table 1, Table 3, Figure 52 ,and Figure 53 As shown in .

[0278] Insertions, deletions and substitutions may be within the CDR sequence, or at one or both termini of the CDR sequence.

[0279] The present disclosure also provides antibodies or antigen-binding fragments thereof that bind to 4-1BB, wherein the antibodies or antigen-binding fragments have VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. In some embodiments, the sequences of VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are determined based on various CDR definitions known in the art, such as the Kabat definition, the Chothia definition, or the IMGT definition. The sequences of VH CDR1, VH CDR2, VH CDR3, VLCDR1, VL CDR2, and VL CDR3 are shown in Tables 1, 3, and 4. Figure 52 and Figure 53 shown.

[0280] The present disclosure also provides antibodies or antigen-binding fragments thereof that bind to 4-1BB. The antibody or its antigen-binding fragment contains a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region comprises an amino acid sequence having at least 80%, 85%, 90% or 95% identity with a selected VH sequence or consists of it, and the light chain variable region comprises or has an amino acid sequence having at least 80%, 85%, 90% or 95% identity with a selected VL sequence or consists of it. In some embodiments, the selected VH sequence and the selected VL sequence are in Table 1 and Table 3. In some embodiments, the selected VH sequence is SEQ ID NO: 221, 222, 223, 224 or 243, and the selected VL sequence is SEQ ID NO: 225, 226, 227, 228 or 244. In some embodiments, the selected VH sequence is SEQ ID NO: 229, 230, 231, or 245, and the selected VL sequence is SEQ ID NO: 232, 233, 234, 235, or 246. In some embodiments, the selected VH sequence is SEQ ID NO: 236, 237, 238, or 247, and the selected VL sequence is SEQ ID NO: 239, 240, 241, 242, or 248.

[0281] The present disclosure also provides nucleic acids comprising polynucleotides encoding polypeptides comprising immunoglobulin heavy chains or immunoglobulin light chains. The immunoglobulin heavy chains or immunoglobulin light chains comprise the polypeptides described in Tables 1, 3, Figure 52 or Figure 53 or have the CDRs shown in Tables 1, 3 and Figures 55-58 When the polypeptide is paired with a corresponding polypeptide (e.g., a corresponding heavy chain variable region or a corresponding light chain variable region), the paired polypeptide binds to 4-1BB (e.g., human 4-1BB).

[0282] In some aspects, the present disclosure also provides antibodies or antigen-binding fragments thereof that cross-compete with a reference antibody or antigen-binding fragment thereof (e.g., any anti-4-1BB antibody or antigen-binding fragment described herein) for binding to 4-1BB (e.g., human 4-1BB).

[0283] Anti-4-1BB antibodies and antigen binding fragments can also be antibody variants (including derivatives and conjugates) and multispecific (e.g., bispecific) antibodies or antibody fragments of antibodies or antibody fragments. Other antibodies provided herein are polyclonal antibodies, monoclonal antibodies, multispecific antibodies (multimeric antibodies, such as bispecific antibodies), human antibodies, chimeric antibodies (e.g., human-mouse chimeras), single-chain antibodies, antibodies produced in cells (i.e., intracellular antibodies) and their antigen binding fragments. The antibody or its antigen binding fragment can be any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY) or any subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2). In some embodiments, the antibody or its antigen binding fragment is an IgG antibody or its antigen binding fragment. In some embodiments, the antibody or its antigen binding fragment is an IgG1 antibody or its antigen binding fragment.

[0284] Antibody fragments are suitable for the methods provided, as long as they retain the desired affinity and specificity of the full-length antibody. Therefore, antibody fragments that bind to 4-1BB will retain the ability to bind to 4-1BB. Fv fragments are antibody fragments containing complete antigen recognition sites and binding sites. This region consists of a tightly bound dimer of a heavy chain variable domain and a light chain variable domain, which can be covalent in nature, such as scFv. In this structure, the three CDRs of each variable domain interact to define the antigen binding site on the surface of the VH-VL dimer. In short, six CDRs or their subsets give the antibody antigen binding specificity. However, even a single variable domain (or half of an Fv that only contains three CDRs that are specific to the antigen) has the ability to recognize and bind to the antigen, although the affinity is usually lower than the entire binding site.

[0285] Single-chain Fv or (scFv) antibody fragments comprise the VH and VL domains (or regions) of an antibody, wherein these domains are present in a single polypeptide chain. Typically, the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains that enables the scFv to form the desired structure for antigen binding.

[0286] The Fab fragment contains the variable and constant domains of the light chain and the variable and first constant domains (CH1) of the heavy chain. The F(ab')2 antibody fragment comprises a pair of Fab fragments, which are typically covalently linked by hinge cysteines between them near their carboxyl termini. Other chemical couplings of antibody fragments are also known in the art.

[0287] Diabodies are small antibody fragments with two antigen-binding sites, which contain a VL linked to a VH (VH and VL) in the same polypeptide chain. By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites.

[0288] Linear antibodies contain a pair of tandem Fd segments (VH-CH1-VH-CH1), which together with complementary light chain polypeptides form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.

[0289] The antibodies and antibody fragments of the disclosure can be modified in the Fc region to provide desired effector function or serum half-life.

[0290] Antibody multimerization can be achieved by natural aggregation of antibodies or by chemical or recombinant ligation techniques known in the art. For example, a certain percentage of purified antibody preparations (e.g., purified IgG1 molecules) spontaneously form protein aggregates containing antibody homodimers and other higher-order antibody multimers.

[0291] Alternatively, antibody homodimers can be formed by chemical connection techniques known in the art. For example, heterobifunctional cross-linkers (including but not limited to SMCC (succinimidyl 4- (maleimidomethyl) cyclohexane -1- carboxylate) and SATA (N- succinimidyl S- ethylthio - acetate)) can be used to form antibody multimers. An exemplary scheme for forming antibody homodimers is described in: Ghetie et al. (Proc. Natl. Acad. Sci. USA 94: 7509-7514, 1997). Antibody homodimers can be converted into Fab'2 homodimers by digestion with pepsin. Another way to form antibody homodimers is by using the autophilic T15 peptide described in: Zhao et al. (J. Immunol. 25: 396-404, 2002).

[0292] In some embodiments, multispecific antibody is a bispecific antibody. Bispecific antibodies can be prepared by maximizing the percentage of the heterodimer recovered from recombinant cell culture by engineering the interface between a pair of antibody molecules. For example, the interface can contain at least a portion of the CH3 domain of an antibody constant domain. In this method, one or more small amino acid side chains from the first antibody molecule interface are replaced by larger side chains (for example, tyrosine or tryptophan). By replacing large amino acid side chains with smaller amino acid side chains (for example alanine or threonine), a compensation " cavity " of the same or similar size as one or more large side chains is produced on the interface of the second antibody molecule. This provides a mechanism for increasing the output of heterodimers relative to other unwanted end products such as homodimers. This method is described in for example WO 96 / 27011, which is incorporated to its entirety by reference.

[0293] Bispecific antibodies include cross-linked or "heteroconjugate" antibodies. For example, one of the antibodies in the heteroconjugate can be coupled to avidin, while the other can be coupled to biotin. Heteroconjugate antibodies can also be prepared using any conventional cross-linking method. Suitable cross-linking agents and cross-linking techniques are well known in the art and are disclosed in U.S. Patent No. 4,676,980, which is incorporated herein by reference and in its entirety.

[0294] Methods for producing bispecific antibodies from antibody fragments are also known in the art. For example, chemical linkage can be used to prepare bispecific antibodies. Brennan et al. (Science 229:81, 1985) described a procedure in which intact antibodies were subjected to proteolytic cleavage to generate F(ab')2 fragments. These fragments were reduced in the presence of a dithiol complexing agent, sodium arsenite, to stabilize adjacent dithiols and prevent intermolecular disulfide bond formation. The generated Fab' fragments were then converted into thionitrobenzoic acid (TNB) derivatives. A Fab'TNB derivative was then converted into a Fab' thiol by reduction with mercaptoethylamine and mixed with another Fab'TNB derivative in an equimolar amount to form a bispecific antibody.

[0295] Any of the antibodies or antigen-binding fragments described herein can be conjugated to a stabilizing molecule (e.g., a molecule that increases the half-life of the antibody or antigen-binding fragment thereof in a subject or solution). Non-limiting examples of stabilizing molecules include polymers (e.g., polyethylene glycol) or proteins (e.g., serum albumin, such as human serum albumin). Conjugation of a stabilizing molecule can increase the half-life of the antibody or antigen-binding fragment or improve its biological activity in vitro (e.g., in tissue culture or when stored as a pharmaceutical composition) or in vivo (e.g., in humans).

[0296] In some embodiments, the antibodies or antigen-binding fragments described herein can be conjugated to therapeutic agents. Antibody-drug conjugates comprising antibodies or antigen-binding fragments thereof can be covalently or non-covalently bound to therapeutic agents. In some embodiments, the therapeutic agent is a cytotoxic agent or a cell growth inhibitor (e.g., cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide (tenoposide), vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxy anthracin, maytansinoids (e.g., DM-1 and DM-4), diketones, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, epirubicin and cyclophosphamide and the like).

[0297] Antibody characteristics

[0298] In some embodiments, the antibodies or antigen-binding fragments thereof described herein can block the binding between 4-1BB and 4-1BB ligand (4-1BBL).

[0299] In some embodiments, by binding to 4-1BB, the antibody can upregulate the immune response. Therefore, in some embodiments, the antibody or its antigen-binding fragment as described herein is a 4-1BB agonist. In some embodiments, the antibody or its antigen-binding fragment is a 4-1BB antagonist.

[0300] In some embodiments, antibodies or antigen-binding fragments thereof as described herein can increase the immune response, activity or number of immune cells (e.g., T cells, natural killer (NK) cells, neutrophils, dendritic cells (DC) cells, macrophages, antigen presenting cells, CD8+ and / or CD4+ T cells) by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 5-fold, 10-fold, or 20-fold. In some embodiments, antibodies or antigen-binding fragments thereof as described herein can reduce the activity or number of immune cells by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 2-fold, 3-fold, 5-fold, 10-fold, or 20-fold.

[0301] In some embodiments, the antibody (or antigen-binding fragment thereof) specifically binds to 4-1BB (e.g., human 4-1BB, monkey 4-1BB, mouse 4-1BB, and / or chimeric 4-1BB) with an off-rate (koff) of less than 0.1 s -1 , less than 0.01s -1 , less than 0.001s -1 , less than 0.0001s-1 or less than 0.00001s -1 In some embodiments, the dissociation rate (koff) is greater than 0.01 s -1 , greater than 0.001s -1 , greater than 0.0001s -1 , greater than 0.00001s -1 or greater than 0.000001s -1 .

[0302] In some embodiments, the association rate (kon) is greater than 1×10 2 / Ms, greater than 1×10 3 / Ms, greater than 1×10 4 / Ms, greater than 1×10 5 / Ms or greater than 1×10 6 / Ms. In some embodiments, the association rate (kon) is less than 1×10 5 / Ms, less than 1×10 6 / Ms or less than 1×10 7 / Ms.

[0303] Affinity can be derived from the quotient of the kinetic rate constants (KD = koff / kon). In some embodiments, KD is less than 1×10 -6 M, less than 1×10 -7 M, less than 1×10 -8 M, less than 1×10 -9 M or less than 1×10 -10 In some embodiments, the KD is less than 50 nM, 40 nM, 30 nM, 20 nM, 15 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, or 1 nM. In some embodiments, the KD is greater than 1×10 -7 M, greater than 1×10 -8 M, greater than 1×10 -9 M, greater than 1×10 -10 M, greater than 1×10 -11 M, or greater than 1×10 -12 In some embodiments, the antibody binds to human 4-1BB with a KD of less than or equal to about 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, or 0.1 nM. In some embodiments, the antibody binds to human 4-1BB with a KD of less than or equal to about 0.5 nM or 0.4 nM.

[0304] Common techniques for measuring the affinity of antibodies for antigens include, for example, ELISA, RIA, and surface plasmon resonance (SPR). In some embodiments, the antibody binds to human 4-1BB (SEQ ID NO: 217), monkey 4-1BB (e.g., rhesus monkey 4-1BB, SEQ ID NO: 219), chimeric 4-1BB (SEQ ID NO: 220), and / or mouse 4-1BB (SEQ ID NO: 218). In some embodiments, the antibody does not bind to human 4-1BB (SEQ ID NO: 217), monkey 4-1BB (e.g., rhesus monkey 4-1BB, SEQ ID NO: 219; or cynomolgus monkey 4-1BB), chimeric 4-1BB (SEQ ID NO: 220), and / or mouse 4-1BB (SEQ ID NO: 218).

[0305] In some embodiments, thermal stability is determined. Antibodies or antigen-binding fragments as described herein can have a Tm greater than 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C or 95°C.

[0306] Because IgG can be described as a multi-domain protein, the melting curve sometimes shows two or three transitions, with a first denaturation temperature, Tm D1, a second denaturation temperature, Tm D2, and optionally a third denaturation temperature, Tm D3. When two peaks are present, one peak indicates denaturation of the Fc domain (Tm D1) and the other peak indicates denaturation of the Fab domain (Tm D2).

[0307] In some embodiments, the antibodies or antigen-binding fragments as described herein have a Tm D1 greater than 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C or 95°C. In some embodiments, the antibodies or antigen-binding fragments as described herein have a Tm D2 greater than 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C or 95°C. In some embodiments, the antibodies or antigen-binding fragments as described herein have a Tm D3 greater than 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C or 95°C.

[0308] In some embodiments, Tm, Tm Dl, Tm D2, Tm D3 is less than 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C or 95°C.

[0309] In some embodiments, the antibodies or antigen-binding fragments as described herein do not form aggregates when the temperature is less than 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C or 95°C.

[0310] In some embodiments, the antibody has a tumor growth inhibition percentage (TGI%) of greater than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, or 200%. In some embodiments, the antibody has a tumor growth inhibition percentage of less than 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, or 200%. For example, TGI % can be determined 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days after the start of treatment, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months after the start of treatment. As used herein, percent tumor growth inhibition (TGI %) is calculated using the following formula:

[0311] TGI(%)=[1-(Ti-T0) / (Vi-V0)]×100

[0312] Ti is the mean tumor volume of the treatment group on day i. T0 is the mean tumor volume of the treatment group on day 0. Vi is the mean tumor volume of the control group on day i. V0 is the mean tumor volume of the control group on day 0.

[0313] In some embodiments, an antibody as described herein or its antigen-binding fragment is a 4-1BB agonist. In some embodiments, an antibody as described herein or its antigen-binding fragment is a 4-1BB antagonist. In some embodiments, an antibody or antigen-binding fragment can increase or decrease 4-1BB signal transduction in target cells expressing 4-1BB.

[0314] In some embodiments, the antibody or antigen-binding fragment can enhance immune cell function (e.g., CD8+ T cells, CD4+ T cells, B cells, natural killer cells, neutrophils, monocytes, macrophages, and / or dendritic cells), for example, by increasing immune cell proliferation and / or increasing cytokine production by immune cells (e.g., compared to proliferation and / or cytokine production before treatment with the antibody or antigen-binding fragment). In some embodiments, the cytokine is gamma interferon.

[0315] In some embodiments, for example, compared to the number of intratumoral (infiltrating) CD8+ T effector cells before treatment, the antibody or antigen binding fragment increases the number of intratumoral (infiltrating) CD8+ effector T cells (e.g., the total number of CD8+ effector T cells, or, for example, the percentage of CD8+ in CD45+ cells). In some embodiments, for example, compared to the number of intratumoral (infiltrating) CD8+ T cells expressing gamma interferon before treatment with anti-human 4-1BB antibodies, the antibody or antigen binding fragment increases the number of intratumoral (infiltrating) CD8+ effector T cells expressing gamma interferon (e.g., the percentage of CD8+ cells expressing gamma interferon in total CD8+ cells).

[0316] In some embodiments, for example, the antibody or antigen-binding fragment increases the number of intratumoral (infiltrating) CD4+ effector T cells (e.g., the total number of CD4+ effector T cells, or, for example, the percentage of CD4+ cells in CD45+ cells) compared to the number of intratumoral (infiltrating) CD4+ T cells before treatment with the antibody or antigen-binding fragment. In some embodiments, for example, the antibody or antigen-binding fragment increases the number of intratumoral (infiltrating) CD4+ effector T cells expressing gamma interferon (e.g., the total gamma interferon expressing CD4+ cells, or, for example, the percentage of gamma interferon expressing CD4+ cells in total CD4+ cells) compared to the number of intratumoral (infiltrating) CD4+ T cells expressing gamma interferon before treatment.

[0317] In some embodiments, the antibody or antigen-binding fragment enhances memory T cell function, for example, by increasing memory T cell proliferation and / or increasing cytokine (eg, interferon gamma) production by memory T cells.

[0318] In some embodiments, the antibody or antigen-binding fragment has a functional Fc region. In some embodiments, the effector function of the functional Fc region is antibody-dependent cell-mediated cytotoxicity (ADCC). In some embodiments, the effector function of the functional Fc region is phagocytosis. In some embodiments, the effector function of the functional Fc region is ADCC and phagocytosis. In some embodiments, the Fc region is human IgG1, human IgG2, human IgG3, or human IgG4.

[0319] In some embodiments, the antibody or antigen-binding fragment does not have a functional Fc region. For example, the antibody or antigen-binding fragment is a Fab, Fab', F(ab')2, and Fv fragment.

[0320] anti-h4-1BB IgG1 antibody

[0321] The present disclosure also shows that IgG1 subclass antibodies unexpectedly have much better tumor suppression than other subclasses. Based on the results but not wishing to be bound by theory, it is speculated that anti-h1BB antibodies inhibit tumor growth mainly through antibody-dependent cell-mediated cytotoxicity (ADCC). FcγRIIIa is the main receptor involved in ADCC activation. The ability of IgG subclasses to bind FcγRIIIa varies, and this difference in binding determines their ability to trigger a series of functional responses (such as ADCC). Therefore, it may be because the IgG1 subclass has a stronger binding affinity to FcγRIIIa, so IgG1 antibodies have better tumor suppression than other subclasses. Therefore, in some embodiments, the present disclosure provides IgG1 antibodies (e.g., human IgG1 antibodies) having CDRs, VHs, and VLs as described herein.

[0322] In some embodiments, the IgG1 antibody or antigen-binding fragment thereof has CDRs (eg, according to the Kabat definition, the Chothia definition, or the IMGT definition), VH, and VL as shown below. Thus, the present disclosure provides an IgG1 antibody (e.g., a human IgG1 antibody or a humanized IgG1 antibody) comprising: a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3, wherein the VH CDR1 region comprises an amino acid sequence at least 80%, 85%, 90%, 95%, or 100% identical to a selected VH CDR1 amino acid sequence, the VH CDR2 region comprises an amino acid sequence at least 80%, 85%, 90%, 95%, or 100% identical to a selected VH CDR2 amino acid sequence, and the VH CDR3 region comprises an amino acid sequence at least 80%, 85%, 90%, 95%, or 100% identical to a selected VH CDR3 amino acid sequence; and a light chain variable region (VL) comprising CDRs 1, 2, and 3, wherein the VL CDR1 region comprises an amino acid sequence at least 80%, 85%, 90%, 95%, or 100% identical to a selected VL The VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 regions comprise an amino acid sequence at least 80%, 85%, 90%, 95%, or 100% identical to the selected VL CDR2 amino acid sequence, the VL CDR2 region comprises an amino acid sequence at least 80%, 85%, 90%, 95%, or 100% identical to the selected VL CDR2 amino acid sequence, and the VL CDR3 region comprises an amino acid sequence at least 80%, 85%, 90%, 95%, or 100% identical to the selected VL CDR3 amino acid sequence, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 are shown in Table 3. In some embodiments, the CDRs of the IgG1 antibody or antigen-binding fragment thereof are defined by the Kabat definition, the Chothia definition, or the IMGT definition. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VLCDR1, VL CDR2, VL CDR3 (CDRs are defined by the Kabat definition) of the IgG1 antibody or antigen-binding fragment thereof have the sequences shown in Table 3. In some embodiments, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, VLCDR3 (CDRs are defined by the IMGT definition) of the IgG1 antibody or antigen-binding fragment thereof have the sequences shown in Table 3.

[0323] In some embodiments, the present disclosure provides an antibody or antigen-binding fragment thereof that binds to 4-1BB, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region (VH) comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to a selected VH sequence, and the light chain variable region (VL) comprises an amino acid sequence that is at least 80%, 85%, 90%, 95%, or 100% identical to a selected VL sequence, wherein the selected VH sequence and the selected VL sequence are shown in the table below.

[0324] Table 3

[0325]

[0326] In addition, antibodies as described herein can have various mutations. In some embodiments, antibody (for example, IgG1 antibody) can have N297A (EU numbering) mutation, FC-S1 mutation (EU numbering: F243L / R292P / Y300L / V305I / P396L) or FC-V11 mutation (EU numbering: G237D / P238D / H268D / P271G / A330R). In some embodiments, the Fc region of antibodies as described herein can have one or more of the following mutations: N297A, F243L, R292P, Y300L, V305I, P396L, G237D, P238D, H268D, P271G, and A330R.

[0327] Method for preparing anti-4-1BB antibodies

[0328] The standard techniques for polyclonal and monoclonal antibody preparation can be used to use the isolated fragments of human 4-1BB as immunogens to produce antibodies. Polyclonal antibodies can be produced in animals by multiple injections (such as subcutaneous or intraperitoneal injections) of antigenic peptides or proteins. In some embodiments, the antigenic peptides or proteins are injected together with at least one adjuvant. In some embodiments, the antigenic peptides or proteins can be conjugated with an immunogenic agent in a species to be immunized. Antigenic peptides or proteins can be injected into animals more than once (such as twice, three times, or four times).

[0329] Full-length polypeptides or proteins can be used;Or, its antigenic peptide fragment can be used as an immunogen.The antigenic peptide of protein includes at least 8 (for example, at least 10, 15, 20 or 30) amino acid residues of the amino acid sequence of 4-1BB, and includes the epitope of protein so that the antibody for the peptide produced forms a specific immune complex with the protein. As described above, the full-length sequence of people 4-1BB is known in the art (SEQ ID NO:217).

[0330] Immunogen is generally used to prepare antibodies by immunizing a suitable subject (such as a person or transgenic animal expressing at least one human immunoglobulin locus). Suitable immunogenic preparations can contain, for example, recombinantly expressed polypeptides or chemically synthesized polypeptides (such as fragments of people 4-1BB). Preparations can further include adjuvants, such as Freund's complete or incomplete adjuvants or similar immunostimulants.

[0331] As described above, it is possible to use 4-1BB polypeptides or their antigenic peptides (for example, a part of 4-1BB) as immunogens to immunize suitable subjects to prepare polyclonal antibodies. The antibody titer of the immunized subject can be monitored over time by standard techniques (such as enzyme-linked immunosorbent assay (ELISA) using immobilized 4-1BB polypeptides or peptides). If necessary, antibody molecules can be separated from mammals (for example, from blood) and further purified to obtain IgG moieties by well-known techniques (such as protein G or protein A chromatography). At a suitable time after immunization, for example, when the specific antibody titer is highest, cells producing the antibody can be obtained from the subject and used to prepare monoclonal antibodies by the following standard techniques: for example, hybridoma technology initially described by Kohler et al. (Nature 256: 495-497, 1975), human B cell hybridoma technology (Kozbor et al., Immunol. Today 4: 72, 1983), EBV hybridoma technology (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96, 1985) or trioma technology. The technology for producing hybridomas is well known (see generally Current Protocols in Immunology, 1994, Coligan et al. (eds.), John Wiley & Sons, Inc., New York, NY). For example, hybridoma cells producing monoclonal antibodies are detected by screening hybridoma culture supernatants for antibodies that bind to target polypeptides or epitopes using standard ELISA assays.

[0332] The variants of antibodies or their antigen-binding fragments as described herein can be prepared by introducing appropriate nucleotide changes into the DNA encoding human antibodies, humanized antibodies or chimeric antibodies or their antigen-binding fragments as described herein or by peptide synthesis. Such variants include, for example, deletions, insertions or substitutions of residues in the amino acid sequence of the antigen-binding site or antigen-binding domains constituting the antibody. In the population of such variants, some antibodies or antigen-binding fragments will have an improved affinity for target protein (such as 4-1BB). Deletion, insertion and / or combination can be combined in any way to obtain antibodies or their antigen-binding fragments with improved binding affinity for the target. The amino acid changes introduced into antibodies or antigen-binding fragments can also change new post-translational modifications or introduce new post-translational modifications into antibodies or antigen-binding fragments, such as changing (for example, increasing or decreasing) the number of glycosylation sites, changing the type of glycosylation sites (for example, changing the amino acid sequence so that the enzyme present in the cell connects different sugars) or introducing new glycosylation sites.

[0333] The antibodies disclosed herein can be derived from any animal species, including mammals. Non-limiting examples of natural antibodies include antibodies derived from humans, primates (e.g., monkeys and apes), cows, pigs, horses, sheep, camelids (e.g., camels and llamas), chickens, goats, and rodents (e.g., rats, mice, hamsters, and rabbits), including transgenic rodents that have been genetically engineered to produce human antibodies.

[0334] Human and humanized antibodies include antibodies having variable and constant regions derived from human germline immunoglobulin sequences (or having an amino acid sequence identical to an amino acid sequence derived from human germline immunoglobulin sequences). Human antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example, in the CDRs.

[0335] Humanized antibodies generally have a human framework (FR) in which non-human CDRs have been transplanted. Therefore, humanized antibodies have one or more amino acid sequences introduced therein from a non-human source. These non-human amino acid residues are generally referred to as "input" residues, which are generally taken from a kind of "input" variable domain. Humanization can basically be carried out by replacing, for example, rodent CDRs or CDR sequences with the corresponding sequences of human antibodies. These methods are described in: for example, Jones et al., Nature, 321: 522-525 (1986); Riechmann et al., Nature, 332: 323-327 (1988); Verhoeyen et al., Science, 239: 1534-1536 (1988); each of which is incorporated herein by reference in its entirety. Therefore, "humanized" antibodies are chimeric antibodies, in which substantially less than a complete human V domain is replaced by a corresponding sequence from a non-human species. In practice, humanized antibodies are generally mouse antibodies, in which some CDR residues and some FR residues are replaced by residues from similar sites in human antibodies.

[0336] The selection of human VH and VL domains for the preparation of humanized antibodies is very important for reducing immunogenicity. According to the so-called "best-fit" method, the sequence of the V domain of mouse antibodies can be screened for the entire library of known human domain sequences. The human sequence closest to the mouse sequence is then accepted as the human FR of the humanized antibody (Sims et al., J. Immunol., 151: 2296 (1993); Chothia et al., J. Mol. Biol., 196: 901 (1987)).

[0337] It is further important that the antibody is humanized while retaining high specificity and affinity to the antigen and other favorable biological properties. In order to achieve this goal, humanized antibodies can be prepared by analyzing the process of the parental sequence and multiple conceptual humanized products using the three-dimensional model of the parental sequence and the humanized sequence. The three-dimensional immunoglobulin model is usually available and is familiar to those of ordinary skill in the art. The computer program that illustrates and displays the possible three-dimensional conformational structure of selected candidate immunoglobulin sequences is available. Inspection of these displays allows analysis of the possible effects of residues in the functioning of the candidate immunoglobulin sequence, i.e., analyzing the residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from receptor sequences and input sequences, thereby reaching required antibody characteristics, as increased affinity for one or more target antigens.

[0338] Typically, amino acid sequence variants of a human anti-4-1BB antibody, humanized anti-4-1BB antibody, or chimeric anti-4-1BB antibody will contain an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the sequence present in the light or heavy chain of the original antibody.

[0339] Identity with respect to the original sequence is typically the percentage of amino acid residues present in the candidate sequence that are identical to the sequence present in the human anti-4-1BB antibody, humanized anti-4-1BB antibody, or chimeric anti-4-1BB antibody, or fragment, after aligning the sequences and introducing gaps (if necessary) to achieve the maximum percentage of sequence identity and not considering any conservative substitutions as part of the sequence identity.

[0340] It is possible to carry out additional modification to 4-1BB antibodies or Fab.For example, one or more cysteine ​​residues can be introduced into the Fc region, thereby allowing the formation of interchain disulfide bonds in this region.The resulting homodimeric antibody can have any increased in vitro and / or in vivo half-life. It is also possible to use the heterodimeric cross-linking linker described in, for example, Wolff et al. (Cancer Res.53:2560-2565,1993) to prepare homodimeric antibodies with increased in vitro and / or in vivo half-life. Alternatively, the antibody with two Fc regions can be engineered (see, for example, Stevenson et al., Anti-Cancer Drug Design 3:219-230,1989).

[0341] In some embodiments, 4-1BB antibodies or their antigen-binding fragments can be covalently modified. These covalent modifications can be carried out by chemical synthesis or enzymatic synthesis or by enzymatic cleavage or chemical cleavage. Other types of covalent modifications of antibodies or antibody fragments are introduced into the molecule by reacting the targeted amino acid residues of the antibody or fragment with an organic derivatizing agent that can react with a selected side chain or N-terminal or C-terminal residue.

[0342] In some embodiments, antibody variants having carbohydrate structures are provided that lack fucose attached (directly or indirectly) to the Fc region. For example, the amount of fucose in such an antibody can be 1% to 80%, 1% to 65%, 5% to 65%, or 20% to 40%. For example, as described in WO 2008 / 077546, the amount of fucose determined is calculated by calculating the average amount of fucose within the Asn297 sugar chain relative to the sum of all sugar structures (e.g., complex, hybrid, and high mannose structures) attached to Asn 297 as measured by MALDI-TOF mass spectrometry. Asn297 refers to the asparagine residue at approximately position 297 in the Fc region (Eu numbering of Fc region residues, or position 314 by Kabat numbering); however, due to minor sequence variations in antibodies, Asn297 may also be located approximately ±3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300. Such fucosylation variants may have improved ADCC function.In some embodiments, to reduce glycan heterogeneity, the Fc region of the antibody may be further engineered to replace asparagine at position 297 with alanine (N297A).

[0343] In some embodiments, in order to improve production efficiency by avoiding Fab-arm exchange, the Fc region of the antibody is further engineered to replace the serine (S228P) at position 228 (EU numbering) of IgG4 with proline. A detailed description of the S228 mutation is described below: for example, Silva et al. "The S228P mutation prevents in vivoand in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation." Journal of Biological Chemistry 290.9(2015):5462-5469, which is incorporated by reference in its entirety.

[0344] In some aspects, the present disclosure also provides use of the antibodies or antigenic fragments thereof described herein for the manufacture of a medicament for the treatment of cancer.

[0345] recombinant vector

[0346] The present disclosure also provides recombinant vectors (e.g., expression vectors) comprising the isolated polynucleotides disclosed herein (e.g., polynucleotides encoding the polypeptides disclosed herein), host cells into which the recombinant vectors have been introduced (i.e., such that the host cells contain the polynucleotides and / or vectors containing the polynucleotides), and recombinant antibody polypeptides or fragments thereof produced by recombinant techniques.

[0347] As used herein, a "vector" is any construct capable of delivering one or more target polynucleotides to a host cell when the vector is introduced into the host cell. An "expression vector" is capable of delivering and expressing one or more target polynucleotides as encoded polypeptides in a host cell into which the expression vector has been introduced. Thus, in an expression vector, the target polynucleotide is positioned in the vector for expression by being operably linked to regulatory elements such as a promoter, an enhancer, and / or a polyadenylation tail, the regulatory elements being located within the vector or at or near or on both sides of the integration site of the target polynucleotide in the genome of the host cell, such that the target polynucleotide will be translated in the host cell into which the expression vector has been introduced.

[0348] The vector can be introduced into the host cell by methods known in the art, such as electroporation, chemical transfection (e.g., DEAE-dextran), transformation, transfection, and infection and / or transduction (e.g., with a recombinant virus). Thus, non-limiting examples of vectors include viral vectors (which can be used to produce recombinant viruses), naked DNA or RNA, plasmids, cosmids, phage vectors, and DNA or RNA expression vectors associated with cationic condensing agents.

[0349] In some embodiments, a polynucleotide disclosed herein (e.g., a polynucleotide encoding a polypeptide disclosed herein) is introduced using a viral expression system (e.g., vaccinia or other poxviruses, retroviruses, or adenoviruses), which may involve the use of non-pathogenic (defective), replication-competent viruses, or replication-defective viruses. In the latter case, viral propagation typically occurs only in complementing virus packaging cells. Suitable systems are disclosed in, for example, Fisher-Hoch et al., 1989, Proc. Natl. Acad. Sci. USA 86:317-321; Flexner et al., 1989, Ann. NY Acad Sci. 569:86-103; Flexner et al., 1990, Vaccine, 8:17-21; U.S. Pat. Nos. 4,603,112, 4,769,330, and 5,017,487; WO 89 / 01973; U.S. Pat. No. 4,777,127; GB 2,200,651; EP 0,345,242; WO 91 / 02805 Berkner-Biotechniques, 6:616-627, 1988; Rosenfeld et al., 1991, Science, 252:431-434; Kolls et al., 1994, Proc. Natl. Acad. Sci. USA, 91:215-219; Kass-Eisler et al., 1993, Proc. Natl. Acad. Sci. USA, 90:11498-11502; Guzman et al., 1993, Circulation, 88:2838-2848; and Guzman et al., 1993, Cir. Res., 73:1202-1207. Techniques for incorporating DNA into such expression systems are well known to those of ordinary skill in the art. The DNA can also be "naked," as described, for example, in Ulmer et al., 1993, Science, 259: 1745-1749, and Cohen, 1993, Science, 259: 1691-1692. Uptake of naked DNA can be increased by coating the DNA on biodegradable beads that can be efficiently transported into cells.

[0350] For expression, the DNA insert sequence comprising the polynucleotide encoding the antibody or polypeptide disclosed herein can be operably linked to a suitable promoter (e.g., a heterologous promoter), such as the bacteriophage lambda PL promoter, the E. coli lac promoter, the E. coli trp promoter, and the E. coli tac promoter, the SV40 early and late promoters, and the promoters of retroviral LTRs, to name a few. Other suitable promoters are known to those skilled in the art. The expression construct may further contain sites for transcription initiation and termination, and (in the transcribed region) a ribosome binding site for translation. The mature transcribed coding portion expressed by the construct may include a translation initiation codon at the beginning and a termination codon (UAA, UGA, or UAG) appropriately positioned at the end of the polypeptide to be translated.

[0351] As noted, the expression vector may include at least one selectable marker. Such markers include dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, and tetracycline or ampicillin resistance genes for culture in Escherichia coli and other bacteria. Representative embodiments of suitable hosts include, but are not limited to, bacterial cells, such as Escherichia coli (E. coli) cells, Streptomyces (Streptomyces) cells, and Salmonella typhimurium (Salmonella typhimurium) cells; fungal cells, such as yeast cells; insect cells, such as Drosophila (Drosophila) S2 cells and Spodoptera (Spodoptera) Sf9 cells; animal cells, such as CHO cells, COS cells, Bowes (Bowes) melanoma cells, and HK 293 cells; and plant cells. Suitable culture media and conditions for host cells described herein are known in the art.

[0352] Non-limiting bacterial vectors include pQE70, pQE60, and pQE-9 available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A available from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, and pRIT5 available from Pharmacia. Non-limiting eukaryotic vectors include pWLNEO, pSV2CAT, pOG44, pXT1, and pSG available from Stratagene; and pSVK3, pBPV, pMSG, and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to those of skill in the art.

[0353] Suitable non-limiting bacterial promoters include the E. coli lacI and lacZ promoters, T3 and T7 promoters, gpt promoter, lambda PR and PL promoters, and trp promoter. Suitable eukaryotic promoters include the CMV immediate early promoter, the HSV thymidine kinase promoter, the SV40 early and late promoters, promoters from retroviral LTRs, such as the Rous sarcoma virus (RSV) promoter, and metallothionein promoters, such as the mouse metallothionein-I promoter.

[0354] In the yeast Saccharomyces cerevisiae, a variety of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH can be used. For review, see Ausubel et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY, and Grant et al., Methods Enzymol., 153:516-544 (1997).

[0355] The construct can be introduced into the host cell by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid mediated transfection, electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986), which is incorporated herein by reference in its entirety.

[0356] The transcription of the DNA encoding the disclosed antibodies by higher eukaryotes can be increased by inserting an enhancer sequence into the vector. An enhancer is a cis-acting element of DNA, typically about 10 to 300 bp, that acts to increase the transcriptional activity of a promoter in a given host cell type. Examples of enhancers include the SV40 enhancer (which is located on the rear side of the replication origin at base pairs 100 to 270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the rear side of the replication origin, and adenovirus enhancers.

[0357] In order to secrete the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space, or the extracellular environment, an appropriate secretion signal can be incorporated into the expressed polypeptide. The signal can be endogenous to the polypeptide or a heterologous signal.

[0358] Polypeptides (e.g., antibodies) can be expressed in modified forms, such as fusion proteins (e.g., GST fusions) or with histidine tags, and can include not only secretion signals but also additional heterologous functional regions. For example, additional amino acids, particularly charged amino acid regions, can be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell during purification or subsequent processing and storage. Similarly, peptide moieties can be added to the polypeptide to promote purification. Such regions can be removed before the final preparation of the polypeptide. Adding peptide moieties to polypeptides to cause secretion or excretion, thereby improving stability and promoting purification, is especially a familiar and conventional technique in the art.

[0359] The present disclosure also provides a nucleic acid sequence having at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to any nucleotide sequence as described herein, And provided is an amino acid sequence having at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity to any amino acid sequence as described herein.

[0360] The present disclosure also provides a nucleic acid sequence having at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% homology to any nucleotide sequence as described herein, And provided is an amino acid sequence having at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% homology to any amino acid sequence as described herein.

[0361] In some embodiments, the disclosure relates to a nucleotide sequence encoding any peptide as described herein, or to any amino acid sequence encoded by any nucleotide sequence as described herein. In some embodiments, the nucleic acid sequence is less than 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 150, 200, 250, 300, 350, 400, 500, or 600 nucleotides. In some embodiments, the amino acid sequence is less than 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 250, 300, 350, or 400 amino acid residues.

[0362] In some embodiments, the amino acid sequence (i) comprises an amino acid sequence; or (ii) consists of an amino acid sequence, wherein the amino acid sequence is any one of the sequences described herein.

[0363] In some embodiments, the nucleic acid sequence (i) comprises a nucleic acid sequence; or (ii) consists of a nucleic acid sequence, wherein the nucleic acid sequence is any one of the sequences described herein.

[0364] To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps are introduced in one or both of the first and second amino acids or the first and second nucleic acid sequences for optimal alignment, and non-homologous sequences are ignored for comparison purposes). The length of the reference sequence for comparison purposes is at least 80% of the length of the reference sequence, and in some embodiments, at least 90%, 95%, or 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at this position (as used herein, amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). Taking into account the number of gaps and the length of each gap, the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, which need to be introduced for optimal alignment of the two sequences. For purposes of the present invention, the comparison of two sequences and determination of percent identity between the two sequences can be accomplished using the Blosum 62 scoring matrix with a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5.

[0365] The percentage of conservative residues such as leucine and isoleucine with similar physicochemical properties (homology percentage) can also be used to measure sequence similarity. Families of amino acid residues with similar physicochemical properties have been defined in the art. These families include, for example, amino acids with following side chains: basic side chains (for example, lysine, arginine, histidine), acidic side chains (for example, aspartic acid, glutamic acid), uncharged polar side chains (for example, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (for example, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), β-branched side chains (for example, threonine, valine, isoleucine) and aromatic side chains (for example, tyrosine, phenylalanine, tryptophan, histidine). In many cases, the homology percentage is higher than the identity percentage.

[0366] Treatment

[0367] One or more antibodies or antigen-binding fragments thereof disclosed herein can be used for a variety of therapeutic purposes. In one aspect, the present disclosure provides methods for treating cancer in a subject, methods for reducing the rate at which a subject's tumor volume increases over time, methods for reducing the risk of metastasis, or methods for reducing the risk of another metastasis in a subject. In some embodiments, treatment can stop, slow, delay, or inhibit the progression of cancer. In some embodiments, treatment can result in a reduction in the number, severity, and / or duration of one or more symptoms of cancer in a subject.

[0368] In one aspect, the disclosure is characterized by following methods, the methods comprising administering a therapeutically effective dose of an antibody disclosed herein or its antigen-binding fragment to a subject in need thereof (e.g., suffering from, or identified as suffering from, or diagnosed as suffering from a subject with cancer), wherein the cancer is, for example, breast cancer (e.g., triple-negative breast cancer), carcinoid, cervical cancer, endometrial cancer, glioma, head and neck cancer, liver cancer, lung cancer, small cell lung cancer, lymphoma, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, kidney cancer, colorectal cancer, gastric cancer, testicular cancer, thyroid cancer, bladder cancer, urethral cancer, or hematological malignancies. In some embodiments, the cancer is unresectable melanoma or metastatic melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), bladder cancer, or metastatic hormone-refractory prostate cancer. In some embodiments, the subject suffers from a solid tumor. In some embodiments, the cancer is squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), triple-negative breast cancer (TNBC), or colorectal cancer. In some embodiments, the subject suffers from Hodgkin lymphoma.In some embodiments, the subject suffers from triple-negative breast cancer (TNBC), gastric cancer, urothelial carcinoma, Merkel cell carcinoma or head and neck cancer.In some embodiments, the antibody or its antigen-binding fragment is an anti-4-1BB antibody or its antigen-binding fragment.In some embodiments, the antibody is an IgG1 anti-4-1BB antibody (e.g., human IgG1 anti-4-1BB antibody).

[0369] In some embodiments, the compositions and methods disclosed herein can be used to treat patients at risk for cancer.A variety of methods known in the art can be used to identify patients with cancer.

[0370] In addition, because anti-4-1BB antibodies can promote immune response, the present disclosure provides a method for treating the infection of a subject. The type of infection includes, for example, bacteria, fungi, viruses, protozoa and parasitic diseases. In some embodiments, treatment can stop, slow down, delay or suppress the progress of the disease. In addition, 4-1BB antibody therapy (for example, agonist antibodies or antagonist antibodies) can also be used to treat autoimmune diseases, asthma, and can also be used as a means of improving vaccination. These methods generally involve administering an antibody or its antigen-binding fragment described herein to a subject in need thereof for treatment of an effective dose.

[0371] As used herein, "effective dose" refers to an amount or dosage sufficient to achieve beneficial or desired results, including stopping, slowing, delaying, or inhibiting the progression of a disease, such as cancer or an autoimmune disease. The effective dose will depend on, for example, the age and weight of the subject to whom the antibody, antigen-binding fragment, polynucleotide encoding the antibody, vector comprising the polynucleotide, and / or composition thereof is to be administered, the severity of the symptoms, and the route of administration, and thus can be determined on an individual basis.

[0372] The effective dose can be administered once or multiple times. For example, the effective dose of an antibody or antigen-binding fragment is an amount sufficient to improve, terminate, stabilize, reverse, inhibit, slow down and / or delay the progression of a patient's cancer, or an amount sufficient to improve, stop, stabilize, reverse, slow down and / or delay the proliferation of cells in vitro (e.g., biopsy cells, any cancer cell described herein, or cell line (e.g., cancer cell line)). As understood in the art, the effective dose of an antibody or antigen-binding fragment may vary, specifically depending on the patient's medical history and other factors, such as the type (and / or dosage) of the antibody used.

[0373] The effective dose and regimen of the antibodies, polynucleotides encoding antibodies and / or compositions disclosed herein can be determined empirically, and it is within the technical scope of the art to perform such determinations. It will be understood by those skilled in the art that the dosage that must be administered will depend on, for example, the mammal to which the antibodies, polynucleotides encoding antibodies and / or compositions disclosed herein will be administered, the route of administration, the specific type of the antibodies, polynucleotides encoding antibodies, antigen-binding fragments and / or compositions disclosed herein used, and other drugs administered to the mammal. Guidance for selecting the appropriate dose of an antibody or antigen-binding fragment can be found in the literature on the therapeutic use of antibodies and antigen-binding fragments, such as Handbook of Monoclonal Antibodies, Ferrone et al., ed., Noges Publications, Park Ridge, NJ, 1985, ch. 22 and pp. 303-357; Smith et al., Antibodies in Human Diagnosis and Therapy, Haber et al., ed., Raven Press, New York, 1977, pp. 365-389.

[0374] The typical daily dosage of an effective dose of an antibody is 0.01 mg / kg to 100 mg / kg. In some embodiments, the dosage can be less than 100 mg / kg, 10 mg / kg, 9 mg / kg, 8 mg / kg, 7 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg, 2 mg / kg, 1 mg / kg, 0.5 mg / kg, or 0.1 mg / kg. In some embodiments, the dosage can be greater than 10 mg / kg, 9 mg / kg, 8 mg / kg, 7 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg, 2 mg / kg, 1 mg / kg, 0.5 mg / kg, 0.1 mg / kg, 0.05 mg / kg, or 0.01 mg / kg. In some embodiments, the dose is about 10 mg / kg, 9 mg / kg, 8 mg / kg, 7 mg / kg, 6 mg / kg, 5 mg / kg, 4 mg / kg, 3 mg / kg, 2 mg / kg, 1 mg / kg, 0.9 mg / kg, 0.8 mg / kg, 0.7 mg / kg, 0.6 mg / kg, 0.5 mg / kg, 0.4 mg / kg, 0.3 mg / kg, 0.2 mg / kg, or 0.1 mg / kg.

[0375] In any of the methods described herein, at least one antibody, its Fab or pharmaceutical composition (e.g., any antibody, Fab or pharmaceutical composition described herein) and optionally at least one additional therapeutic agent can be administered to the subject at least once a week (e.g., once a week, twice a week, three times a week, four times a week, once a day, twice a day, or three times a day). In some embodiments, at least two different antibodies and / or Fabs are administered with the same composition (e.g., liquid composition). In some embodiments, at least one antibody or Fab and at least one additional therapeutic agent are administered with the same composition (e.g., liquid composition). In some embodiments, the at least one antibody or Fab and at least one additional therapeutic agent are administered with two different compositions (e.g., a liquid composition containing at least one antibody or Fab and a solid oral composition containing at least one additional therapeutic agent). In some embodiments, the at least one additional therapeutic agent is administered in the form of a pill, tablet, or capsule. In some embodiments, the at least one additional therapeutic agent is administered with a sustained-release oral formulation.

[0376] In some embodiments, the one or more additional therapeutic agents can be administered to the subject before or after administration of the at least one antibody, antigen-binding antibody fragment, or pharmaceutical composition (e.g., any antibody, antigen-binding antibody fragment, or pharmaceutical composition described herein). In some embodiments, the one or more additional therapeutic agents and at least one antibody, antigen-binding antibody fragment, or pharmaceutical composition (e.g., any antibody, antigen-binding antibody fragment, or pharmaceutical composition described herein) are administered to the subject such that the biological activity periods of the one or more additional therapeutic agents and the at least one antibody or antigen-binding fragment (e.g., any antibody or antigen-binding fragment described herein) in the subject overlap.

[0377] In some embodiments, at least one antibody, antigen-binding antibody fragment, or pharmaceutical composition (e.g., any of the antibodies, antigen-binding antibody fragments, or pharmaceutical compositions described herein) can be administered to a subject over an extended period of time (e.g., over a period of at least 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 1 year, 2 years, 3 years, 4 years, or 5 years). A skilled medical professional can determine the length of the treatment period using any of the methods described herein for diagnosing or following up on the effectiveness of treatment (e.g., observing at least one symptom of cancer). As described herein, a skilled medical professional can also change the type and amount (e.g., increase or decrease) of the antibody or antigen-binding antibody fragment (and / or one or more additional therapeutic agents) administered to the subject, and can also adjust (e.g., increase or decrease) the dose or frequency of at least one antibody or antigen-binding antibody fragment (and / or one or more additional therapeutic agents) administered to the subject based on an assessment of the effectiveness of treatment (e.g., using any of the methods described herein and known in the art).

[0378] In some embodiments, one or more other therapeutic agents can be administered to the subject. Other therapeutic agents can include one or more inhibitors selected from the group consisting of: B-Raf inhibitors, EGFR inhibitors, MEK inhibitors, ERK inhibitors, K-Ras inhibitors, c-Met inhibitors, anaplastic lymphoma kinase (ALK) inhibitors, phosphatidylinositol 3-kinase (PI3K) inhibitors, Akt inhibitors, mTOR inhibitors, PI3K / mTOR dual inhibitors, Bruton (Bruton) tyrosine kinase (BTK) inhibitors), and isocitrate dehydrogenase 1 (IDH1) inhibitors and / or isocitrate dehydrogenase 2 (IDH2) inhibitors. In some embodiments, other therapeutic agents are indoleamine 2,3-dioxygenase-1 (IDO1) inhibitors, such as epacadostat.

[0379] In some embodiments, the additional therapeutic agent may comprise one or more inhibitors selected from the group consisting of: a HER3 inhibitor, a LSD1 inhibitor, an MDM2 inhibitor, a BCL2 inhibitor, a CHK1 inhibitor, an activated hedgehog signaling pathway inhibitor, and an agent that selectively degrades the estrogen receptor.

[0380] In some embodiments, the additional therapeutic agent can include one or more therapeutic agents selected from the group consisting of: Trabectedin, Nab-paclitaxel, trebananib, pazopanib, cediranib, palbociclib, everolimus, fluoropyrimidine, IFL, regorafenib, Reolysin, Axinda, ceritinib, sunitinib, temsirolimus, axitinib, everolimus, sorafenib, Votrient, pazopanib, IMA-901, AGS-003, cabozantinib, vinflunine, Hsp90 inhibitors, Ad-GM-CSF, temozolomide, IL-2, interferon nab, vinblastine, thalidomide, dacarbazine, cyclophosphamide, lenalidomide, azacytidine, lenalidomide, bortezomid, amrubicin, carfilzomib, pralatrexate, and enzastaurin.

[0381] In some embodiments, the additional therapeutic agent may comprise one or more therapeutic agents selected from the group consisting of an adjuvant, a TLR agonist, tumor necrosis factor (TNF) α, IL-1, HMGB1, an IL-10 antagonist, an IL-4 antagonist, an IL-13 antagonist, an IL-17 antagonist, an HVEM antagonist, an ICOS agonist, a CX3CL1-targeted therapy, a CXCL9-targeted therapy, a CXCL10-targeted therapy, a CCL5-targeted therapy, an LFA-1 agonist, an ICAM1 agonist, and a select agonist.

[0382] In some embodiments, the subject is administered carboplatin, nab-paclitaxel, paclitaxel, cisplatin, pemetrexed, gemcitabine, FOLFOX, or FOLFIRI.

[0383] In some embodiments, the additional therapeutic agent is an anti-OX40 antibody, an anti-PD-L1 antibody, an anti-PD-L2 antibody, an anti-LAG-3 antibody, an anti-TIGIT antibody, an anti-BTLA antibody, an anti-CTLA-4 antibody, or an anti-GITR antibody.

[0384] In some embodiments, the additional therapy is chemotherapy or chemoradiotherapy. In some embodiments, the additional therapeutic agent is an anti-CTLA4 antibody (e.g., ipilimumab), an anti-CD20 antibody (e.g., rituximab), an anti-EGFR antibody (e.g., cetuximab), an anti-CD319 antibody (e.g., elotuzumab), or an anti-PD1 antibody (e.g., nivolumab).

[0385] In some embodiments, the additional therapeutic agent is an antibody that specifically binds PD-1, CTLA-4, BTLA, PD-L1, CD27, CD28, CD40, CD47, CD137, CD154, TIGIT, TIM-3, GITR, or OX40.

[0386] The disclosure also shows that the combination of anti-4-1BB IgG4 subclass antibodies and some other therapeutic agents has a better tumor inhibitory effect than the combination of anti-4-1BB IgG1 subclass antibodies and other therapeutic agents. Therefore, in one aspect, the disclosure provides a method for treating the subject or killing the tumor by administering a therapeutically effective dose of an anti-4-1BB IgG1 antibody or its antigen-binding fragment and another therapeutic agent to the subject. In some embodiments, the other therapeutic agent is an anti-PD-1 antibody, an anti-CTLA4 antibody, or an anti-OX40 antibody.

[0387] Pharmaceutical compositions and routes of administration

[0388] Also provided herein are pharmaceutical compositions containing at least one (e.g., one, two, three, or four) of the antibodies or antigen-binding fragments described herein. Two or more (e.g., two, three, or four) of any of the antibodies or antigen-binding fragments described herein can be present in the pharmaceutical composition in any combination. The pharmaceutical composition can be formulated in any manner known in the art.

[0389] Pharmaceutical composition is formulated into and is compatible with its expected route of administration (for example intravenous, intra-arterial, intramuscular, intradermal, subcutaneous or peritoneal). Composition can include sterile diluent (for example sterile water or sterile saline), fixed oil, polyethylene glycol, glycerine, propylene glycol or other synthetic solvents, antibacterial or antifungal (for example benzyl alcohol or methyl parahydroxybenzoate, chlorobutanol, phenol, ascorbic acid, thimerosal etc.), antioxidant (for example ascorbic acid or sodium bisulfite), chelating agent (for example ethylenediaminetetraacetic acid), buffer (for example acetate, citrate or phosphate) and isotonic agent (for example sugar, such as glucose), polyol (for example mannitol or sorbitol) or salt (for example sodium chloride) or its any combination. Liposomal suspension can also be used as pharmaceutically acceptable carrier (see for example U.S. Patent number 4,522,811). The preparation of composition can be prepared and is packaged in ampoule, disposable syringe or multidose bottle. If desired (e.g., in the form of an injectable formulation), suitable fluidity can be maintained, for example, by using a coating such as lecithin or a surfactant. Absorption of the antibody or its antigen-binding fragment can be prolonged by integrating agents that delay absorption (e.g., aluminum monostearate and gelatin). Alternatively, controlled release can be achieved by implants and microencapsulated delivery systems (which can include biodegradable, biocompatible polymers (e.g., ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid; Alza Corporation and Nova Pharmaceutical, Inc.).

[0390] Compositions containing one or more of any of the antibodies or antigen-binding fragments described herein can be formulated for parenteral (e.g., intravenous, intraarterial, intramuscular, intradermal, subcutaneous, or intraperitoneal) administration in dosage unit form (i.e., physically discrete units containing a predetermined quantity of active compound for ease of administration and uniformity of dosage).

[0391] The toxicity and therapeutic efficacy of the composition can be determined by standard pharmaceutical procedures in cell culture or experimental animals (e.g., monkeys). For example, the LD50 (lethal dose for 50% of the population) and the ED50 (the therapeutically effective dose for 50% of the population) can be determined: the therapeutic index is the ratio of LD50:ED50. Agents that exhibit a high therapeutic index are preferred. When an agent exhibits adverse side effects, care should be taken to minimize potential damage (i.e., reduce undesirable side effects). Toxicity and therapeutic efficacy can be determined by other standard pharmaceutical procedures.

[0392] The data obtained from cell culture assays and animal studies can be used to prepare any given medicament for use in a subject (e.g., people) of appropriate dose. The therapeutically effective dose of one or more (e.g., one, two, three, or four) antibodies or their antigen-binding fragments (e.g., any antibody or antibody fragment described herein) will be in a subject (e.g., a human subject identified as having cancer or identified as having a subject in a risk of developing a disease, such as a subject previously suffering from cancer but now cured) to treat the disease of the subject (e.g., killing cancer cells), reducing the severity, frequency, and / or duration of one or more symptoms of the subject (e.g., people). Methods known in the art can be used, and by observing one or more symptoms of the subject (e.g., people), the effectiveness and administration of any antibody or antigen-binding fragment described herein can be determined by a healthcare professional or veterinary professional. Certain factors (e.g., the severity of the disease or disorder, previous treatment, the general health status of the subject and / or age, and other diseases present) can affect the dosage and time course required for the effective treatment of the subject.

[0393] Exemplary dosages include milligram or microgram amounts per kilogram of subject body weight of any antibody or antigen-binding fragment described herein (e.g., about 1 μg / kg to about 500 mg / kg; about 100 μg / kg to about 500 mg / kg; about 100 μg / kg to about 50 mg / kg; about 10 μg / kg to about 5 mg / kg; about 10 μg / kg to about 0.5 mg / kg; or about 1 μg / kg to about 50 μg / kg; about 500 μg / kg to about 5 mg / kg; or about 500 μg / kg to about 2 mg / kg). Although these dosages cover a wide range, it will be understood by those of ordinary skill in the art that therapeutic agents, including antibodies and antigen-binding fragments thereof, differ in their efficacy and that effective dosages can be determined by methods known in the art. Typically, a relatively low dose is first administered, and the attending healthcare professional or veterinary professional (in the case of therapeutic applications) or researcher (when still in the development stage) can subsequently and gradually increase the dose until an appropriate response is obtained. Furthermore, it will be understood that the specific dosage level for any particular subject will depend on a variety of factors, including the activity of the specific compound used, the subject's age, weight, general health, sex, and diet, time of administration, route of administration, rate of excretion, and in vivo half-life of the antibody or antibody fragment.

[0394] The pharmaceutical composition can be included in a container, pack, or dispenser together with instructions for administration.The present disclosure also provides methods of making antibodies or antigen-binding fragments thereof for the various uses as described herein.

[0395] Example

[0396] The present invention is further described in the following examples, which do not limit the scope of the invention described in the claims.

[0397] Example 1. Generation of mouse anti-h4-1BB antibodies

[0398] To generate mouse antibodies against human 4-1BB (h4-1BB; SEQ ID NO: 217), female BALB / c mice aged 6-8 weeks were immunized with human 4-1BB. Figure 1 and Figure 2 Anti-h4-1BB antibodies were collected using the method shown in .

[0399] Mouse immunization

[0400] The human 4-1BB protein of His mark with a concentration of 100 μg / ml is immunized with 20 μg / mouse in female BALB / c mice of 6-8 weeks of age. The human 4-1BB protein of His mark is emulsified with adjuvant and injected into four positions of the back of the mouse. For the first subcutaneous (sc) injection, the diluted antigen is emulsified with an equal volume of complete Freund's adjuvant (CFA). In subsequent subcutaneous injections, the protein is emulsified with an equal volume of incomplete Freund's adjuvant (IFA). Three days after the third injection or booster immunization, blood (serum) is collected and its antibody titer is analyzed using ELISA.

[0401] In another experiment, female BALB / c mice of 6-8 weeks old were immunized by injecting an expression plasmid encoding human 4-1BB into mice. By using a gene gun, a plasmid encoding an antigen at a concentration of 1000 μg / ul was injected into the tibialis anterior muscle of mice (intramuscular injection; im injection) with 60 μg / mouse. At least four injections were performed, with at least 14 days between the two injections. Blood (serum) was collected seven days after the last immunization, and the antibody titer of serum was tested by ELISA.

[0402] In addition, a booster immunization program (by plasmid injection or protein injection) was performed at least 14 days after the previous immunization. CHO cells expressing 4-1BB antigen on the surface were injected intravenously into the mice through the tail vein. The spleens were then collected four days after the injection.

[0403] Fusion of SP2 / 0 cells and spleen cells

[0404] Spleen tissue was ground. Splenocytes were first selected using CD3ε microbeads and anti-mouse IgM microbeads and then fused with SP2 / 0 cells. The cells were then seeded in 96-well plates with hypoxanthine-aminopterin-thymidine (HAT) medium.

[0405] Initial screening of hybridomas

[0406] Hybridoma supernatants were initially screened in 96-well plates using fluorescence-activated cell sorting (FACS) according to standard procedures. Before screening, Chinese hamster ovary (CHO) cells were added to 96-well plates (2 × 10 4 cells / well). 50 μl of supernatant was used. The antibodies used in the experiment were

[0407] (1) AffiniPure F(ab)2 fragment goat anti-mouse IgG conjugated with fluorescein (FITC), Fcγ fragment specific, and

[0408] (2) Conjugated with Alexa 647 AffiniPure F(ab)2 Fragment Goat Anti-Human IgG, Fcγ fragment specific.

[0409] Subcloning

[0410] Subcloning was performed using ClonePix2. Briefly, positive wells identified during the primary screening were transferred to semi-solid culture medium, and IgG-positive clones were identified and tested. FITC anti-mouse IgG Fc antibody was used.

[0411] Ascites antibodies

[0412] 1×10 6 Positive hybridoma cells were injected intraperitoneally into B-NDG TM Monoclonal antibodies are produced in mice (Beijing Biocytogen, Beijing, China). Hybridoma cells are grown in the mouse peritoneal cavity. The hybridoma cells multiply in the mouse abdomen and produce ascites. This fluid contains high concentrations of antibodies and can be collected for later use.

[0413] Antibody purification

[0414] The antibodies in the ascites were purified using GE AKTA protein chromatography (GE Healthcare, Chicago, Illinois, USA). At least 27 mouse antibodies were produced. Some antibodies were selected based on the desired properties. These selected mouse antibodies produced by the methods described below include, for example, 16-1C4 ("1C4"), 29-6A5 ("6A5"), 30-5F9 ("5F9"), 45-2B3 ("2B3"), 45-4B9 ("4B9"), 45-7E9 ("7E9"), 45-7G9 ("7G9"), 45-8E11 ("8E11"), 45- 8E2 ("8E2"), 45-8F1 ("8F1"), 54-8B11 ("8B11"), 55-8F6 ("8F6"), 56-2A6 ("2A6"), 59-5E4 ("5E4"), 61-6A7 ("6A7"), 69-3C2 ("3C2"), 70-3F9 ("3F9"), and 70-6F10 ("6F10"), etc.

[0415] The VH, VL and CDR regions of the antibodies were determined. The amino acid sequences of the heavy chain CDR1, CDR2, CDR3, and the light chain CDR1, CDR2, and CDR3 of these antibodies are shown in Tables 1, Figure 52 and Figure 53 As shown in .

[0416] Example 2. Humanization of mouse antibodies

[0417] The starting point of humanization is mouse antibodies (e.g., 1C4, 6A5, and 5F9). The amino acid sequences of the heavy chain variable regions and light chain variable regions of these mouse antibodies are determined.

[0418] Four humanized heavy chain variable region variants (SEQ ID NOs: 221-224) and four humanized light chain variable region variants (SEQ ID NOs: 225-228) of 1C4 were constructed containing different modifications or substitutions.

[0419] Three humanized heavy chain variable region variants (SEQ ID NOs: 229-231) and four humanized light chain variable region variants (SEQ ID NOs: 232-235) of 6A5 were constructed, containing different modifications or substitutions.

[0420] Three humanized heavy chain variable region variants (SEQ ID NOs: 236-238) and four humanized light chain variable region variants (SEQ ID NOs: 239-242) of 5F9 were constructed, containing different modifications or substitutions.

[0421] These humanized heavy chain variable region variants can be combined with any light chain variable region variant derived from the same mouse antibody. For example, 1C4-H1 (SEQ ID NO: 221) can be combined with any humanized light chain variable region variant based on the same mouse antibody 1C4 (e.g., SEQ ID NOs: 225-228), and the antibodies will be labeled accordingly. For example, if 1C4-H1 is combined with 1C4-K3 (SEQ ID NO: 227), the antibody is labeled 1C4-H1K3.

[0422] Example 3. Binding activity of anti-h4-1BB antibodies against human 4-1BB

[0423] Anti-h4-1BB antibodies were collected from mouse ascites and purified by chromatography. 25 μl of CHO cells transiently transfected with human 4-1BB were added to each well of the plate. The purified antibodies were titrated to a final concentration of 10, 1, 0.1, 0.01, and 0.001 μg / ml. The titrated antibodies were added to each well and incubated at 4°C for 30 minutes.

[0424] After washing twice with phosphate-buffered saline (PBS) (1200 rpm, 5 minutes), 50 μl of FITC-labeled anti-mouse IgG Fc antibody (anti-mIgG Fc-FITC) diluted 1:100 was added to each well and incubated at 4°C for 30 minutes, followed by washing with PBS (1200 rpm, 5 minutes). FITC signals were detected by flow cytometry.

[0425] like Figure 3 As shown in Figure 2, 1C4 and 5F9 have strong binding activity to h4-1BB. Figure 3 NC stands for negative control.

[0426] The table below summarizes the percentage of cells tested that had FITC signal in flow cytometry analysis. Higher percentages indicate higher binding affinity at lower antibody concentrations.

[0427] Table 4

[0428]

[0429]

[0430] Example 4. Cross-reactivity of anti-h4-1BB antibodies against monkey, mouse, and human-mouse chimeric 4-1BB

[0431] In each experiment, CHO cells were transfected with mouse 4-1BB (m4-1BB, SEQ ID NO: 218), monkey (rhesus) 4-1BB (r4-1BB, SEQ ID NO: 219), or chimeric (mouse and human) 4-1BB (c4-1BB, SEQ ID NO: 220).

[0432] 25 μl of CHO cells were added to each well. 25 μl of purified anti-h4-1BB antibody (1 μg / ml) was added to each well and incubated at 4°C for 30 minutes.

[0433] After washing twice with PBS (1200 rpm, 5 min), 50 μl of FITC-labeled anti-mouse IgG Fc antibody (anti-mIgG Fc-FITC) diluted 1:100 was added to each well and then incubated at 4°C for 30 minutes, followed by washing with PBS (1200 rpm, 5 min). In some cases, PE-labeled anti-mouse IgG-Fc antibody (anti-mIgG-Fc-PE) was used to label the antibody and added to each test well at a 1:500 dilution. The signals of FITC and PE were determined by flow cytometry.

[0434] like Figure 4 As shown, 1C4 and 5F9 do not cross-react with mouse 4-1BB, but have strong cross-reactivity with monkey 4-1BB (r4-1BB) and chimeric 4-1BB (c4-1BB). Figure 4 NC stands for negative control.

[0435] The cross-reactivity of the tested antibodies to monkey (r4-1BB), mouse (m4-1BB), and human-mouse chimeric 4-1BB (c4-1BB) is summarized in the table below.

[0436] Table 5

[0437] h4-1BB (human) r4-1BB (Monkey) m4-1BB (mouse) C4-1BB (chimeric) 16-1C4 have have none have 30-5F9 have have none have 29-4A10 have have none have 29-5F10 have have none have 29-6A5 have have none have 45-4B9 have have none have 45-8F1 have have none have 45-2B3 have have none have 45-2C11 have have none have 45-7E9 have have none have 45-7G9 have have none have 45-8E2 have have none have 54-8B11 have have none have 54-1A11 have have none have 55-1E3 have have none have 55-8H5 have have none have 55-8F6 have have none have 56-1G6 have none none have 61-6A7 have have none have 58-4B8 have have none have 56-2A6 have Very weak none have 69-3C2 have have none have 70-3F9 have have none have 70-6F10 have have none have 69-4B11 have have none have

[0438] Example 5. Binding affinity of anti-h4-1BB antibodies

[0439] The binding affinity of anti-h4-1BB antibodies was measured by surface plasmon resonance (SPR) using a Biacore (Biacore, INC, Piscataway NJ) T200 biosensor equipped with a pre-immobilized Protein A sensor chip.

[0440] Chimeric anti-h4-1BB antibody 16-1C4-mHvKv-IgG4 (1 μ g / mL) is injected into BiacoreT200 biosensor according to 10 μ L / min for about 20 seconds, to reach desired protein density (about 51.6 response units (RU)).Then histidine-tagged human 4-1BB protein (h4-1BB-His) is injected 180 seconds with 800, 200, 50, 12.5, 3.125nM concentration, according to 30 μ L / min. Monitor and dissociate 300 seconds. After the last injection of each glycine titration (pH 2.0, 30 μ L / min, for 5 seconds), the chip is regenerated. Figure 5 Results for 16-1C4-mHvKv-IgG4 are shown.

[0441] The data were fitted to a 1:1 Langmuir binding model (Karlsson, R. Roos, H. Fagerstam, L. Petersson, B., 1994. Methods Enzymology 6.99-110) using Biacore T200 Evaluation Software 3.0, thereby simultaneously obtaining association rates (k on ) and dissociation rates (k off ). Affinity was calculated from the quotient of the kinetic rate constants (K D = k off / k on ).

[0442] As will be understood by one of ordinary skill in the art, the same method is performed for each antibody tested, with appropriate adjustments made to the parameters (e.g., antibody concentration). For example, Figure 6 Results for 29-6A5-mHvKv-IgG2 are shown. The table below summarizes the results for the antibodies tested.

[0443] Table 6

[0444]

[0445]

[0446]

[0447] As described in Example 1, 16-1C4, 29-6A5, 30-5F9, 45-2B3, 45-4B9, 45-7E9, 45-7G9, 45-8E11, 45-8E2, 45-8F1, 54-8B11, 55-8F6, 56-2A6, 59-5E4, 61-6A7, 69-3C2, 70-3F9, and 70-6F10 are mouse anti-h4-1BB antibodies. Based on these mouse anti-h4-1BB antibodies, chimeric anti-h4-1BB antibodies were generated, including, for example, 16-1C4-mHvKv-IgG4, 29-6A5-mHvKv-IgG2, 30-5F9-mHvKv-IgG4, 45-2B3-mHvKv-IgG2, 45-4B9-mHvKv-IgG2, 45-7E9-mHvKv-IgG2, 45-7G9-mHvKv-IgG2, 45-8E11-mHvKv-IgG2, 4 5-8E2-mHvKv-IgG2, 45-8F1-mHvKv-IgG2, 54-8B11-mHvKv-IgG2, 55-8F6-mHvKv-IgG2, 56-2A6-mHvKv-IgG2, 59-5E4-mHvKv-IgG2, 61-6A7-mHvKv-IgG2, 69-3C2-mHvKv-IgG2, 70-3F9-mHvKv-IgG2, and 70-6F10-mHvKv-IgG2. The chimeric antibodies have heavy and light chain variable domains from the corresponding mouse anti-h4-1BB antibodies and constant domains from human IgG antibodies (including, for example, CL, CH1, CH2, and CH3 domains).

[0448] Antibodies tested also include humanized antibodies, for example, 1C4-H1K1-IgG4, 1C4-H1K2-IgG4, 1C4-H1K3-IgG4, 1C4-H1K4-IgG4, 1C4-H2K1-IgG4, 1C4-H2K2-IgG4, 1C4-H2K3-IgG4, 1C4-H2K4-IgG4, 1C4-H3K1-IgG4, 1C4-H3K2-IgG4, 1C4-H3K3-IgG4, 1C4-H3K4-IgG4, 1C4-H4K1-IgG4, 1C4-H4K2-IgG4, 1C4-H4K3-IgG4, 1C4-H4K4-IgG4, 5F9-H1K1-IgG4, 5F9-H1K2-IgG4, 5F9-H1K3-IgG4, 5F9-H1K4-IgG4. K4-IgG4, 5F9-H2K1-IgG4, 5F9-H2K2-IgG4, 5F9-H2K3-IgG4, 5F9-H2K4-IgG4, 5F9-H3K1 -IgG4, 5F9-H3K2-IgG4, 5F9-H3K3-IgG4, 5F9-H3K4-IgG4, 6A5-H1K1-IgG2, 6A5-H1K2-Ig The humanized antibodies are IgG2, 6A5-H1K3-IgG2, 6A5-H1K4-IgG2, 6A5-H2K1-IgG2, 6A5-H2K2-IgG2, 6A5-H2K3-IgG2, 6A5-H2K4-IgG2, 6A5-H3K1-IgG2, 6A5-H3K2-IgG2, 6A5-H3K3-IgG2, and 6A5-H3K4-IgG2, etc. The humanized antibodies have human antibody constant domains (including, for example, CL, CH1, CH2, and CH3 domains). The humanized variable domains of the heavy chain are numbered H1, H2, H3, etc.; and the humanized variable domains of the light chain are numbered K1, K2, K3, etc. Figure 55 、 Figure 56 ,and Figure 57 The sequences of the humanized variable domains are summarized. For example, 1C4-H1K1-IgG4 is based on the mouse antibody 1C4 and has a humanized heavy chain variable domain H1 (SEQ ID NO: 221) and a humanized light chain variable domain K1 (SEQ ID NO: 225). Similarly, 5F9-H1K2-IgG4 is based on the mouse antibody 5F9 and has a humanized heavy chain variable domain H1 (SEQ ID NO: 236) and a humanized light chain variable domain K2 (SEQ ID NO: 240).

[0449] Example 6. Thermal stability of anti-h4-1BB antibodies

[0450] Using Protein Thermal ShiftTM Dye kit (Thermo Fisher Scientific) and QuantStudio TM Thermofluor assays were performed using a 5-well real-time PCR system (Thermo Fisher Scientific). The assay measures thermal stability using a fluorescent dye that binds to hydrophobic patches exposed when proteins unfold.

[0451] The experiment was performed according to the manufacturer's protocol. 2 μL of antibody, 10.5 μL of water, 5 μL of Protein ThermalShift buffer, and 2.5 μL of diluted Protein ThermalShift dye were mixed. The sample was heated to 25°C at 1.6°C / second and then to 99°C at 0.05°C / second.

[0452] The table below summarizes the Tm values ​​of several humanized or chimeric anti-h4-1BB antibodies.

[0453] Table 7

[0454]

[0455] The results showed that the Tm of the anti-h4-1BB antibodies described herein was higher than that of utolumab and urelumab.

[0456] Example 7. In vivo testing of mouse anti-h4-1BB antibodies

[0457] In order to test anti-h4-1BB antibodies in vivo and predict the effects of these antibodies in the human body, a humanized 4-1BB mouse model was produced. The humanized 4-1BB mouse model was engineered to express chimeric 4-1BB protein (SEQ ID NO: 220), wherein a portion of the extracellular region of the mouse 4-1BB protein was replaced by the corresponding human 4-1BB extracellular region. The amino acid residues 1-183 of mouse 4-1BB (SEQ ID NO: 218) were replaced by the amino acid residues 1-184 of human 4-1BB (SEQ ID NO: 217). The humanized mouse model (B-h4-1BB) provides a new tool for testing new therapeutic treatments in a clinical setting by significantly reducing the difference between the clinical results of humans and common mice expressing mouse 4-1BB. A detailed description of the humanized 4-1BB mouse model can be found in PCT / CN 2017 / 120388, which is incorporated herein by reference in its entirety.

[0458] The effect of anti-h4-1BB antibodies on tumor growth in vivo was tested in a colon cancer model. 5MC-38 cancer cells (colon adenocarcinoma cells) were injected subcutaneously into B-h4-1BB mice. When the tumor volume of the mice reached 150±50mm 3 The mice were randomly divided into different groups according to the volume of tumor.

[0459] Mice were then injected with physiological saline (PS) and anti-h4-1BB antibody via intraperitoneal (ip) administration.

[0460] The injection volume was calculated based on the weight of the mouse at 1 mg / kg or 3 mg / kg. The lengths of the long and short axes of the tumor were measured, and the volume of the tumor was calculated as 0.5 × (long axis) × (short axis). 2 Body weights of mice were measured before injection, when mice were divided into different groups (before the first antibody injection), twice a week during the antibody injection period, and before euthanasia.

[0461] The tumor growth inhibition percentage (TGI%) was calculated using the following formula: TGI (%) = [1-(Ti-T0) / (Vi-V0)] x 100. Ti is the mean tumor volume of the treatment group on day i. T0 is the mean tumor volume of the treatment group on day zero. Vi is the mean tumor volume of the control group on day i. V0 is the mean tumor volume of the control group on day zero.

[0462] T-test was performed for statistical analysis. TGI% higher than 60% indicated that tumor growth was significantly inhibited. P<0.05 was the threshold value indicating a significant difference.

[0463] In vivo results of mouse anti-h4-1BB antibodies 16-1C4 (“1C4”) and 30-5F9 (“5F9”)

[0464] In each group, B-h4-1BB mice were injected with normal saline (PS) (G1), 1 mg / kg usurelumab (G2), 3 mg / kg usurelumab (G3), 1 mg / kg of mouse anti-h4-1BB antibody 16-1C4 (G4), 3 mg / kg of 16-1C4 (G5), 1 mg / kg of mouse anti-h4-1BB antibody 30-5F9 (G6), or 3 mg / kg of 30-5F9 (G7).

[0465] Table 8

[0466]

[0467] The body weight of mice was monitored during the entire treatment period. The average body weight of mice in different groups increased to varying degrees ( Figure 7 and Figure 8At the end of the treatment period, no significant differences in body weight were observed between the different groups. The results showed that 1C4 and 6A5 were well tolerated and had no significant toxicity to mice.

[0468] Tumor volumes decreased in the groups treated with urelumab, 1C4, or 6A5 ( Figure 9 ).

[0469] As shown in the table below, TGI % on day 19 (19 days after grouping) was also calculated.

[0470] Table 9

[0471]

[0472] The results showed that the anti-h4-1BB antibodies 1C4 and 5F9 significantly inhibited tumor growth. In addition, at 1 mg / kg and 3 mg / kg, 1C4 and 5F9 had similar TGI%. This result indicates that higher doses of 1C4 and 5F9 did not significantly improve tumor inhibition.

[0473] In vivo results of mouse anti-h4-1BB antibodies 29-6A5 ("6A5"), 29-4A10 ("4A10"), 29-5F10 ("5F10"), 45-8F1 ("8F1"), and 45-4B9 ("4B9")

[0474] B-h4-1BB mice were injected with saline (PS) as a control (G1), 3 mg / kg 29-6A5 (G2), 3 mg / kg 29-4A10 (G3), 3 mg / kg 29-5F10 (G4), 3 mg / kg 45-8F1 (G5), and 3 mg / kg 45-4B9 (G6). For comparative purposes, mice were also administered 3 mg / kg Urelumab (G7).

[0475] Table 10

[0476]

[0477] The body weight of the mice was monitored throughout the treatment period. At the end of the treatment period, the body weight of the mice in the different groups had all increased ( Figure 10 and Figure 11 ). No significant differences in body weight were observed among the different groups. The results showed that these anti-h4-1BB antibodies were well tolerated and had no significant toxicity to mice. The tumor volumes of the groups treated with 29-6A5, 29-4A10, 29-5F10, 45-8F1, and 45-4B9 were Figure 12 As shown in .

[0478] As shown in the table below, TGI % on day 17 (17 days after grouping) was also calculated.

[0479] Table 11

[0480]

[0481]

[0482] The results showed that anti-h4-1BB antibodies 6A5, 4A10, 8F1, and 4B9 all inhibited tumor growth. In addition, 6A5 and 8F1 had higher TGI% than other tested antibodies (e.g., Urelumab).

[0483] In vivo results of mouse anti-h4-1BB antibodies 45-8E2 ("8E2"), 45-7E9 ("7E9"), 45-7G9 ("7G9"), 45-2B3 ("2B3"), and 45-2C11 ("2C11")

[0484] B-h4-1BB mice were injected with saline (PS) as a control (G1), 1 mg / kg 45-8E2 (G2), 1 mg / kg 45-7E9 (G3), 1 mg / kg 45-7G9 (G4), 1 mg / kg 45-2B3 (G5), and 1 mg / kg 45-2C11 (G6). For comparative purposes, mice were also administered 1 mg / kg Urelumab (G7).

[0485] Table 12

[0486]

[0487] The body weight of the mice was monitored throughout the treatment period. At the end of the treatment period, the average body weight of the mice in the different groups had increased ( Figure 13 and Figure 14 No significant differences in body weight were observed among the different groups. The results showed that these anti-h4-1BB antibodies were well tolerated and had no obvious toxicity to mice.

[0488] Compared with the control group, 45-8E2, 45-7E9, 45-7G9, 45-2B3, and 45-2C11 all inhibited tumor growth ( Figure 15 ). As shown in the table below, TGI% on day 24 (24 days after grouping) was also calculated.

[0489] Table 13

[0490]

[0491] The results showed that the anti-h4-1BB antibodies 45-8E2, 45-7E9, 45-7G9, 45-2B3, and 45-2C11 all significantly inhibited tumor growth. In addition, 45-8E2, 45-7E9, 45-7G9, 45-2B3, and 45-2C11 all had higher TGI% than Urelumab.

[0492] In vivo results of mouse anti-h4-1BB antibodies 16-1C4 ("1C4"), 55-8F6 ("8F6"), and 54-8B11 ("8B11")

[0493] B-h4-1BB mice were injected with saline (PS) as a control (G1), 1 mg / kg 16-1C4 (G2), 1 mg / kg 55-8F6 (G3), and 1 mg / kg 54-8B11 (G4). For comparative purposes, mice were also administered 1 mg / kg Urelumab (G5).

[0494] Table 14

[0495]

[0496] The body weight of the mice was monitored throughout the treatment period. At the end of the treatment period, the average body weight of the mice in the different groups had increased ( Figure 16 and Figure 17 ). No significant differences in body weight were observed among the different groups. The results showed that these anti-h4-1BB antibodies were well tolerated and had no significant toxicity to mice. Compared with the control group, 16-1C4, 55-8F6, and 54-8B11 all inhibited tumor growth ( Figure 18 ).

[0497] As shown in the table below, TGI % on day 24 (24 days after grouping) was also calculated.

[0498] Table 15

[0499]

[0500] The results showed that the anti-h4-1BB antibodies 16-1C4, 55-8F6, and 54-8B11 all significantly inhibited tumor growth.

[0501] In vivo results of mouse anti-h4-1BB antibodies 54-1A11 ("1A11"), 55-1E3 ("1E3"), 55-8H5 ("8H5"), and 56-2A6 ("2A6")

[0502] B-h4-1BB mice were injected with saline (PS) (G1), 1 mg / kg 54-1A11 (G2), 1 mg / kg 55-1E3 (G3), 1 mg / kg 55-8H5 (G4), and 1 mg / kg 56-2A6 (G5). For comparative purposes, mice were also administered 1 mg / kg ureumab (G6).

[0503] Table 16

[0504]

[0505]

[0506] The body weight of the mice was monitored throughout the treatment period. At the end of the treatment period, the average body weight of the mice in the different groups had increased ( Figure 19 and Figure 20 ). No significant differences in body weight were observed among the different groups. The results showed that these anti-h4-1BB antibodies were well tolerated and had no significant toxicity to mice. The tumor volume of each group is shown in Figure 21 middle.

[0507] As shown in the table below, TGI % on day 24 (24 days after grouping) was also calculated.

[0508] Table 17

[0509]

[0510] The results showed that anti-h4-1BB antibodies 54-1A11, 55-8H5, and 56-2A6 all significantly inhibited tumor growth, while 55-1E3 was ineffective in inhibiting tumor growth.

[0511] In vivo results of mouse anti-h4-1BB antibodies 58-4B8 (“4B8”), 69-3C2 (“3C2”), and 69-4B11 (“4B11”)

[0512] B-h4-1BB mice were injected with saline (PS) (G1), 1 mg / kg 58-4B8 (G2), 1 mg / kg 69-3C2 (G3), and 1 mg / kg 69-4B11 (G4). For comparative purposes, mice were also administered 1 mg / kg Urelumab (G5).

[0513] Table 18

[0514]

[0515] The body weight of the mice was monitored throughout the treatment period. The body weight of the mice in the different groups increased ( Figure 22 and Figure 23). No significant differences in body weight were observed among the different groups. The results showed that these anti-h4-1BB antibodies were well tolerated and had no significant toxicity to mice. The tumor volume of each group is shown in Figure 24 middle.

[0516] As shown in the table below, TGI % on day 25 (25 days after grouping) was also calculated.

[0517] Table 19

[0518]

[0519] The results showed that anti-h4-1BB antibodies 58-4B8, 69-3C2, and 69-4B11 all significantly inhibited tumor growth.

[0520] Example 8. In vivo testing of chimeric anti-h4-1BB antibodies

[0521] Chimeric anti-h4-1BB antibodies were tested in 4-1BB humanized mice (B-h4-1BB) to determine their effect on tumor growth in vivo. MC-38 carcinoma cells (colon adenocarcinoma cells) were injected subcutaneously into B-h4-1BB mice. When the tumor volume of the mice reached 150 ± 50 mm 3 The mice were randomly divided into different groups according to the volume of tumor.

[0522] In vivo results of 30-5F9-mHvKv-IgG2, 30-5F9-mHvKv-IgG4, 16-1C4-mHvKv-IgG2, 16-1C4-mHvKv-IgG4, and 16-1C4-mHvKv-IgG1

[0523] B-h4-1BB mice were injected with normal saline (PS) (G1), 30-5F9-mHvKv-IgG2 (G2), 30-5F9-mHvKv-IgG4 (G3), 16-1C4-mHvKv-IgG2 (G4), 16-1C4-mHvKv-IgG4 (G5), 16-1C4-mHvKv-IgG1 (G6), 30-5F9 (G7), 16-1C4 (G8), uxellumab (G9), and ureumab (G10).

[0524] Table 20

[0525]

[0526] The body weight of the mice was monitored throughout the treatment period. At the end of the treatment period, the average body weight of the mice in the different groups had increased ( Figure 25 and Figure 26). No significant differences in body weight were observed among the different groups. The results showed that these anti-h4-1BB antibodies were well tolerated and had no significant toxicity to mice. The tumor volume of each group is shown in Figure 27 middle.

[0527] As shown in the table below, TGI % on day 24 (24 days after grouping) was also calculated.

[0528] Table 21

[0529]

[0530]

[0531] The results showed that all these anti-h4-1BB antibodies could inhibit tumor growth. In particular, the IgG1 subclass (G6) of 16-1C4-mHvKv had a higher TGI% than the IgG2 subclass (G4) and IgG4 subclass (G5).

[0532] In vivo results of 16-1C4-mHvKv-IgG2, 29-6A5-mHvKv-IgG2, 30-5F9-mHvKv-IgG2, 45-2B3-mHvKv-IgG2, 45-7E9-mHvKv-IgG2, 45-7G9-mHvKv-IgG2, 45-8E2-mHvKv-IgG2, and 45-8F1-mHvKv-IgG2

[0533] B-h4-1BB mice were injected with normal saline (PS) (G1), 16-1C4-mHvKv-IgG2 (G2), 29-6A5-mHvKv-IgG2 (G3), 30-5F9-mHvKv-IgG2 (G4), 45-2B3-mHvKv-IgG2 (G5), 45-7E9-mHvKv-IgG2 (G6), 45-7G9-mHvKv-IgG2 (G7), 45-8E2-mHvKv-IgG2 (G8), 45-8F1-mHvKv-IgG2 (G9), and ureumab (G10).

[0534] Table 22

[0535]

[0536]

[0537] The body weight of the mice was monitored throughout the treatment period. At the end of the treatment period, the average body weight of the mice in the different groups had increased ( Figure 28 and Figure 29). No significant differences in body weight were observed among the different groups. The results showed that these anti-h4-1BB antibodies were well tolerated and had no significant toxicity to mice. The tumor volume of each group is shown in Figure 30 middle.

[0538] As shown in the table below, TGI % on day 21 (21 days after grouping) was also calculated.

[0539] Table 23

[0540]

[0541] The results showed that all these chimeric antibodies could inhibit tumor growth to varying degrees.

[0542] Example 9. In vivo testing of humanized anti-h4-1BB antibodies

[0543] Humanized anti-h4-1BB antibodies were tested in 4-1BB humanized mice (B-h4-1BB) to demonstrate their effect on tumor growth in vivo. MC-38 carcinoma cells (colon adenocarcinoma cells) were injected subcutaneously into B-h4-1BB mice. When the tumor volume of the mice reached 150 ± 50 mm 3 The mice were randomly divided into different groups according to the volume of tumor.

[0544] In vivo results of humanized anti-4-1BB antibodies 6A5-H1K2-IgG2, 6A5-H1K3-IgG2, and 6A5-H2K2-IgG2

[0545] In the G1 group, B-h4-1BB mice were injected with normal saline (PS) as a control. In the treatment groups, mice were administered 6A5-H1K2-IgG2 (G2), 6A5-H1K3-IgG2 (G3), 6A5-H2K2-IgG2 (G4), 6A5 (G5), and Urelumab (G6).

[0546] Table 24

[0547]

[0548] The body weight of the mice was monitored throughout the treatment period. At the end of the treatment period, the average body weight of the mice in the different groups had increased ( Figure 31 and Figure 32 ). No significant differences in body weight were observed among the different groups. The results showed that these anti-h4-1BB antibodies were well tolerated and had no significant toxicity to mice. The tumor volume of each group is shown in Figure 33 middle.

[0549] As shown in the table below, TGI % on day 21 (21 days after grouping) was also calculated.

[0550] Table 25

[0551]

[0552]

[0553] The results showed that all these humanized anti-h4-1BB antibodies (G2, G3 and G4) could inhibit tumor growth.

[0554] In vivo results of humanized anti-4-1BB antibodies 1C4-H1K1-IgG4, 1C4-H1K2-IgG4, 5F9-H1K1-IgG4, and 30-5F9-H1K2-IgG4

[0555] In the G1 group, B-h4-1BB mice were injected with normal saline (PS) as a control. In the treatment groups, mice were administered 1C4-H1K1-IgG4 (G2), 1C4-H1K2-IgG4 (G3), 5F9-H1K1-IgG4 (G4), 5F9-H1K2-IgG4 (G5), 16-1C4 (G6), 30-5F9 (G7), and Urelumab (G8).

[0556] Table 26

[0557]

[0558] The body weight of the mice was monitored throughout the treatment period. At the end of the treatment period, the average body weight of the mice in the different groups had increased ( Figure 34 and Figure 35 ). No significant differences in body weight were observed among the different groups. The results showed that these anti-h4-1BB antibodies were well tolerated and had no significant toxicity to mice. The tumor volume of each group is shown in Figure 36 middle.

[0559] As shown in the table below, TGI % on day 25 (25 days after grouping) was also calculated.

[0560] Table 27

[0561]

[0562] The results showed that these humanized anti-h4-1BB antibodies had different tumor inhibitory effects.

[0563] Example 10. In vivo testing of IgG1, IgG2, and IgG4 antibodies

[0564] MC-38 cancer cells (colon adenocarcinoma cells) were injected subcutaneously into B-h4-1BB mice. When the tumor volume of the mice reached 150 ± 50 mm 3The mice were randomly divided into different groups according to the volume of tumor.

[0565] In the G1 group, B-h4-1BB mice were injected with normal saline (PS) as a control. Mice were administered chimeric anti-h4-1BB antibodies 16-1C4-mHvKv-IgG1 (G2), 16-1C4-mHvKv-IgG2 (G3), 16-1C4-mHvKv-IgG4 (G4), mouse anti-h4-1BB antibody 16-1C4 (G5), and Urelumab (G6).

[0566] Table 28

[0567]

[0568] The body weight of the mice was monitored throughout the treatment period. At the end of the treatment period, the average body weight of the mice in the different groups had increased ( Figure 37 and Figure 38 ). No significant differences in body weight were observed among the different groups. The results showed that these anti-h4-1BB antibodies were well tolerated and had no significant toxicity to mice. The tumor volume of each group is shown in Figure 39 middle.

[0569] As shown in the table below, TGI % on day 25 (25 days after grouping) was also calculated.

[0570] Table 29

[0571]

[0572] The results showed that all of these anti-h4-1BB antibodies inhibited tumor growth. In particular, the IgG1 subclass had a higher TGI% than the IgG2 and IgG4 subclasses.

[0573] Example 11. In vivo testing of chimeric anti-4-1BB IgG2 antibodies

[0574] MC-38 cancer cells (colon adenocarcinoma cells) were injected subcutaneously into B-h4-1BB mice. When the tumor volume of the mice reached 150 ± 50 mm 3 The mice were randomly divided into different groups according to the volume of tumor.

[0575] In the G1 group, B-h4-1BB mice were injected with normal saline (PS) as a control. In the treatment group, chimeric anti-h4-1BB antibodies 54-8B11-mHvKv-IgG2 (G2), 55-8F6-mHvKv-IgG2 (G3), 56-2A6-mHvKv-IgG2 (G4), 69-3C2-mHvKv-IgG2 (G5), 61-6A7-mHvKv-IgG2 (G6), 70-6F10-mHvKv-IgG2 (G7), 70-3F9-mHvKv-IgG2 (G8), 45-4B9-mHvkv-IgG2 (G9), and Urelumab (G10) were administered to mice by intraperitoneal (ip) injection.

[0576] Table 30

[0577]

[0578]

[0579] The body weight of the mice was monitored throughout the treatment period. At the end of the treatment period, the average body weight of the mice in the different groups had increased ( Figure 40 and Figure 41 ). No significant differences in body weight were observed among the different groups. The results showed that these anti-h4-1BB antibodies were well tolerated and had no significant toxicity to mice. The tumor volume of each group is shown in Figure 42 middle.

[0580] As shown in the table below, TGI % on day 27 (27 days after grouping) was also calculated.

[0581] Table 31

[0582]

[0583]

[0584] The results showed that these chimeric anti-h4-1BB antibodies had different tumor inhibitory effects.

[0585] Example 12. In vivo testing of humanized and chimeric anti-4-1BB IgG2 antibodies

[0586] MC-38 carcinoma cells were injected subcutaneously into B-h4-1BB mice. When the tumor volume of the mice reached 150 ± 50 mm 3 At the same time, mice were randomly divided into different groups according to the volume of tumor and administered with different antibodies as shown in the table below.

[0587] Table 32

[0588]

[0589] The body weight of the mice was monitored throughout the treatment period. At the end of the treatment period, the average body weight of the mice in the different groups had increased ( Figure 43 and Figure 44 ). No significant differences in body weight were observed among the different groups. The results showed that these anti-h4-1BB antibodies were well tolerated and had no significant toxicity to mice. The tumor volume of each group is shown in Figure 45 middle.

[0590] As shown in the table below, TGI % on day 21 (21 days after grouping) was also calculated.

[0591] Table 33

[0592]

[0593] The results showed that these humanized and chimeric antibodies had different tumor inhibitory effects.

[0594] Example 13. Human anti-4-1BB IgG1 antibody has better efficacy than other IgG subclasses

[0595] Based on the results of 16-1C4-mHvKv-IgG1 as described above, it is speculated that for the same VH and VL, the IgG1 subclass has a better tumor inhibitory effect than other IgG subclasses. Different subclasses of anti-h4-1BB IgG antibodies were tested in 4-1BB humanized mice (B-h4-1BB) to determine their effects on tumor growth in vivo. In addition, IgG1 antibodies with N297A (EU numbering) mutations, IgG1 antibodies with FC-SI mutations (EU numbering: F243L / R292P / Y300L / V305I / P396L), and IgG1 antibodies with FC-V11 mutations (G237D / P238D / H268D / P271G / A330R) were also tested. The N297A mutation can reduce ADCC effects. The FC-SI mutation can increase binding affinity to almost all FC receptors, especially FcγRIIIA / IIA, and may increase ADCC effects. Moreover, the FC-V11 mutation can increase the binding affinity to FcγRIIB, but will not increase the binding affinity to FcγRIIA, thereby reducing the binding affinity to FcγRIIIA.

[0596] MC-38 cancer cells (colon adenocarcinoma cells) were injected subcutaneously into B-h4-1BB mice. When the tumor volume of the mice reached 150 ± 50 mm 3At the time of the trial, mice were randomly divided into different groups according to tumor volume and administered different antibodies as shown in the table below. Urelumab is a fully human IgG4 monoclonal antibody. The antibody Urelumab-IgG1 has VH and VL from Urelumab, and the constant domains are from the IgG1 subclass. Similarly, the antibody Urelumab-IgG2 has VH and VL from Urelumab, and the constant domains are from the IgG2 subclass. The antibody Urelumab-IgG4 has constant domains from human IgG4.

[0597] Table 34

[0598]

[0599] The body weight of the mice was monitored throughout the treatment period. At the end of the treatment period, the average body weight of the mice in the different groups had increased ( Figure 46 and Figure 47 ). No significant differences in body weight were observed among the different groups. The results showed that these anti-h4-1BB antibodies were well tolerated and had no significant toxicity to mice. The tumor volume of each group is shown in Figure 48 middle.

[0600] As shown in the table below, TGI % on day 25 (25 days after grouping) was also calculated.

[0601] Table 35

[0602]

[0603]

[0604] The results confirmed that the anti-h4-1BB IgG1 subclass had a higher tumor inhibitory effect compared with the IgG2 and IgG4 subclasses.

[0605] Example 14. Chimeric anti-4-1BB IgG1 antibody has better efficacy than other IgG subclasses

[0606] The experiment was repeated to test different subclasses of anti-h4-1BB IgG antibodies. MC-38 carcinoma cells (colon adenocarcinoma cells) were injected subcutaneously into B-h4-1BB mice. When the tumor volume of the mice reached 150 ± 50 mm 3 At the same time, mice were randomly divided into different groups according to the volume of tumors and administered with different antibodies once a week (QW) as shown in the table below.

[0607] Table 36

[0608]

[0609] The body weight of the mice was monitored throughout the treatment period. At the end of the treatment period, the average body weight of the mice in the different groups had increased ( Figure 49 and Figure 50 ). No significant differences in body weight were observed among the different groups. The results showed that these anti-h4-1BB antibodies were well tolerated and had no significant toxicity to mice. The tumor volume of each group is shown in Figure 51 middle.

[0610] As shown in the table below, TGI % on day 25 (25 days after grouping) was also calculated.

[0611] Table 37

[0612]

[0613] The results again confirmed that the IgG1 subclass had a higher tumor inhibitory effect compared with the IgG2 and IgG4 subclasses.

[0614] Example 15. Chimeric and human anti-4-1BB IgG1 antibodies have better efficacy than other IgG subclasses

[0615] The experiment was repeated to test different subclasses of chimeric and human anti-h4-1BB IgG antibodies. mIgG2A and human IgG1 had good ADCC effects, while mIgG1 and human IgG4 had weak or no ADCC effects. MC-38 cancer tumor cells (colon adenocarcinoma cells) were injected subcutaneously into B-h4-1BB mice. When the tumor volume of the mice reached 150 ± 50 mm 3 At the same time, mice were randomly divided into different groups according to the volume of tumors and administered with different antibodies once a week (QW) as shown in the table below.

[0616] Table 38

[0617]

[0618]

[0619] The body weight of the mice was monitored throughout the treatment period. At the end of the treatment period, the average body weight of the mice in the different groups had increased ( Figure 59 and Figure 60 ). No significant differences in body weight were observed among the different groups. The results showed that these anti-h4-1BB antibodies were well tolerated and had no significant toxicity to mice. The tumor volume of each group is shown in Figure 61 middle.

[0620] As shown in the table below, TGI % on day 24 (24 days after grouping) was also calculated.

[0621] Table 39

[0622]

[0623] The results again confirmed that mIgG2A or human IgG1 subclass had a higher tumor inhibitory effect than mIgG1 or human IgG4 subclass. Therefore, the results show that anti-4-1BB antibodies inhibit tumor growth mainly through ADCC.

[0624] Example 16. Anti-4-1BB IgG1 Antibody Has Higher Tumor Inhibitory Effect Compared to Anti-4-1BB IgG4 Antibody

[0625] MC-38 carcinoma cells (colon adenocarcinoma cells) were injected subcutaneously into B-h4-1BB mice. When the tumor volume of the mice reached 100 to 150 mm 3 At 4 hr, mice were randomly divided into different groups based on tumor volume and administered different antibodies as shown in the table below. As discussed below, Urelumab is a fully human IgG4 monoclonal antibody. The antibody Urelumab-IgG1 has VH and VL from Urelumab, and the constant domains are from the IgG1 subclass.

[0626] Table 40

[0627]

[0628] The body weight of the mice was monitored throughout the treatment period. At the end of the treatment period, the average body weight of the mice in the different groups had increased ( Figure 62 and Figure 63 ). No significant differences in body weight were observed among the different groups. The results showed that these anti-h4-1BB antibodies were well tolerated and had no significant toxicity to mice. The tumor volume of each group is shown in Figure 64 middle.

[0629] As shown in the table below, TGI % on day 24 (24 days after grouping) was also calculated.

[0630] Table 41

[0631]

[0632]

[0633] The results confirmed that the Urelumab-IgG1 antibody had a higher tumor inhibitory effect than Urelumab (IgG4); the 16-1C4-mHvKv-IgG1 antibody had a higher tumor inhibitory effect than the 16-1C4-mHvKv-IgG4 antibody; the 1C4-H1K1-IgG1 antibody had a higher tumor inhibitory effect than the 1C4-H1K2-IgG4 antibody; and the 1C4-H1K2-IgG1 antibody had a higher tumor inhibitory effect than the 1C4-H1K2-IgG4 antibody. Overall, the results showed that for the same antigen-binding domain, the IgG1 antibody had a higher tumor inhibitory effect than the IgG4 antibody.

[0634] Example 17. Anti-h4-1BB Antibody Combination Therapy

[0635] MC-38 cancer cells (colon adenocarcinoma cells) expressing human PD-L1 were subcutaneously injected into B-h4-1BB mice. When the tumor volume of the mice reached approximately 400 mm 3 At the same time, mice were randomly divided into different groups according to the volume of the tumor and administered with different antibodies as shown in the table below. Keytruda (pembrolizumab) is a humanized anti-PD-1 IgG4 antibody.

[0636] Table 42

[0637]

[0638]

[0639] The body weight of the mice was monitored throughout the treatment period. At the end of the treatment period, the average body weight of the mice in the different groups had increased ( Figure 65 and Figure 66 ). No significant differences in body weight were observed among the different groups. The results showed that these anti-h4-1BB antibodies were well tolerated and had no significant toxicity to mice. The tumor volume of each group is shown in Figure 67 middle.

[0640] As shown in the table below, TGI % on day 25 (25 days after grouping) was also calculated.

[0641] Table 43

[0642]

[0643] The results confirmed that the 1C4-H1K1-IgG1 antibody had a higher tumor inhibitory effect than the 1C4-H1K1-IgG4 antibody, and that the urelumab-IgG1 antibody had a higher tumor inhibitory effect than the urelumab-IgG4 antibody. Furthermore, the results showed that the combination of an anti-4-1BB antibody and an anti-PD-1 antibody had a higher tumor inhibitory effect than treatment with either an anti-4-1 antibody or an anti-PD-1 antibody alone. Furthermore, the combination of an anti-4-1BB IgG1 antibody and an anti-PD-1 antibody had a higher tumor inhibitory effect than the combination of an anti-4-1BB IgG4 antibody and an anti-PD-1 antibody.

[0644] Example 18. In vivo testing of melanoma cancer cells

[0645] B16-F10 cells (a melanoma cell line) expressing human PD-L1 were subcutaneously injected into B-h4-1BB mice. When the tumor volume of the mice reached 100 to 150 mm 3 At the same time, mice were randomly divided into different groups according to the volume of tumor and administered with different antibodies as shown in the table below.

[0646] Table 44

[0647]

[0648] The body weight of the mice was monitored throughout the treatment period. At the end of the treatment period, the average body weight of the mice in the different groups had increased ( Figure 68 and Figure 69 ). No significant differences in body weight were observed among the different groups. The results showed that these anti-h4-1BB antibodies were well tolerated and had no significant toxicity to mice. The tumor volume of each group is shown in Figure 70 middle.

[0649] As shown in the table below, TGI % on day 18 (18 days after grouping) was also calculated.

[0650] Table 45

[0651]

[0652] The results showed that the anti-h4-1BB IgG1 antibody had excellent tumor suppression against melanoma cancer cells, and the combination of the anti-h4-1BB IgG1 antibody and the anti-PD-1 antibody further enhanced the tumor suppression effect. When the TGI% of G3 was 81.0%, the TGI% was calculated based on only 4 surviving mice, and the survival rate of G3 was only 4 / 8. In contrast, the survival rate of G4 was 7 / 8. The results showed that the combination treatment significantly improved the survival rate.

[0653] Example 19. In vivo testing of lymphoma cancer cells

[0654] EL4 cells (lymphoma cancer cells) were injected subcutaneously into B-h4-1BB mice. When the tumor volume of the mice reached 100 to 150 mm 3 At the same time, mice were randomly divided into different groups according to the volume of tumor and administered with different antibodies as shown in the table below.

[0655] Table 46

[0656]

[0657] The body weight of the mice was monitored throughout the treatment period. At the end of the treatment period, the average body weight of the mice in the different groups had increased ( Figure 71 and Figure 72 ). No significant differences in body weight were observed among the different groups. The results showed that these anti-h4-1BB antibodies were well tolerated and had no significant toxicity to mice. The tumor volume of each group is shown in Figure 73 middle.

[0658] As shown in the table below, TGI % on day 17 (17 days after grouping) was also calculated.

[0659] Table 47

[0660]

[0661] The results showed that anti-h4-1BB IgG1 antibody has excellent tumor inhibitory effect on lymphoma cancer cells, and the combination of anti-h4-1BB IgG1 antibody and anti-PD-1 antibody can further enhance the tumor inhibitory effect.

[0662] Example 20. Further analysis of the effects of humanized anti-4-1BB antibodies

[0663] MC-38 cancer cells (colon adenocarcinoma cells) were injected subcutaneously into B-h4-1BB mice. When the tumor volume of the mice reached approximately 200 ± 50 mm 3 At the same time, mice were randomly divided into different groups according to the volume of tumor and administered with different antibodies as shown in the table below.

[0664] Table 48

[0665]

[0666] Two days after administration, the mice were sacrificed. Tumor and spleen samples were collected for further analysis. The body weights of the mice were recorded as shown in the table below. No significant differences in body weight were observed among the different groups.

[0667] Table 49

[0668]

[0669] The collected tumor and spleen samples were ground and treated with digestive enzymes. The mixture was incubated at 37°C for 60 minutes, filtered, washed, and resuspended into a single-cell suspension.

[0670] The cells were incubated with fluorescently labeled antibodies and analyzed by flow cytometry. Figure 74 and Figure 75 Tumor samples were processed by the procedure shown in Figure 76 and Figure 77 Processing is performed according to the procedure shown.

[0671] The results are shown in Figures 78-83. Figure 79D As shown in the results of the study, anti-4-1BB IgG1 antibody can effectively reduce the percentage of Treg cells in tumors, thereby increasing the immune response. Figure 82A , where a lower ratio of CD8 to Treg was associated with poor outcome. Figure 82A The results also explain that the 1C4 anti-4-1BB antibody has a higher tumor inhibitory effect than urelumab.

[0672] Example 21. Further testing of anti-h4-1BB IgG1 antibodies

[0673] The experiment was repeated to test different subclasses of anti-h4-1BB IgG antibodies.

[0674] MC-38 cancer cells (colon adenocarcinoma cells) were injected subcutaneously into B-h4-1BB mice. When the tumor volume of the mice reached 150 ± 50 mm 3 When the tumor volume was quantified, mice were randomly divided into different groups (e.g., n=5) according to the volume of the tumor and administered ip at a dose of 1 mg / kg or 3 mg / kg twice a week with IgG1, IgG2, and IgG4 forms of an antibody selected from Table 1, Table 2, and / or Table 4. A total of 6 administrations were performed. One group of mice was administered with physiological saline (PS) as a control.

[0675] The body weight and tumor volume of the mice were monitored throughout the treatment period. The TGI% was calculated at the end of the treatment period.

[0676] It is expected that the anti-h4-1BB IgG1 subclass has a higher TGI% compared to the IgG2 and IgG4 subclasses and therefore has a better tumor inhibitory effect.

[0677] Other implementation plans

[0678] It should be understood that although the invention has been described in conjunction with specific embodiments, the foregoing description is intended to illustrate rather than limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. Sequence Listing <110> Eucure (Beijing) Biopharma Co., Ltd <120> Anti-TNFRSF9 antibodies and uses thereof <130> IDC210057 <160> 518 <170> PatentIn version 3.5 <210> 1 <211> 5 <212> PRT <213> Artificial sequence <400> 1 Ser Ser Tyr Ile Asn 1 5 <210> 2 <211> 17 <212> PRT <213> Artificial sequence <400> 2 Trp Ile Phe Ala Gly Thr Gly Gly Thr Tyr Tyr Asn Gln Lys Phe Thr 1 5 10 15 Gly <210> 3 <211> 10 <212> PRT <213> Artificial sequence <400> 3 His Ser Pro Arg Ala Thr Leu Phe Asp Phe 1 5 10 <210> 4 <211> 10 <212> PRT <213> Artificial sequence <400> 4 Arg Ala Ser Ser Ser Val Asn His Met His 1 5 10 <210> 5 <211> 7 <212> PRT <213> Artificial sequence <400> 5 Ala Thr Ser Asn Leu Ala Ser 1 5 <210> 6 <211> 9 <212> PRT <213> Artificial sequence <400> 6 Gln Gln Trp Ser Ser Asn Pro Tyr Thr 1 5 <210> 7 <211> 5 <212> PRT <213> Artificial sequence <400> 7 Ser Tyr Trp Ile Asn 1 5 <210> 8 <211> 17 <212> PRT <213> Artificial sequence <400> 8 Asn Ile Tyr Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe Lys 1 5 10 15 Asp <210> 9 <211> 12 <212> PRT <213> Artificial sequence <400> 9 Thr Trp Glu Phe Tyr Tyr Asp Ser Val Phe Asp Tyr 1 5 10 <210> 10 <211> 11 <212> PRT <213> Artificial sequence <400> 10 Lys Ala Ser Gln Asp Ile Asn Ser Tyr Leu Ser 1 5 10 <210> 11 <211> 7 <212> PRT <213> Artificial sequence <400> 11 Arg Ala Asn Arg Leu Val Asp 1 5 <210> 12 <211> 9 <212> PRT <213> Artificial sequence <400> 12 Leu Gln Tyr Asp Glu Leu Pro Pro Thr 1 5 <210> 13 <211> 5 <212> PRT <213> Artificial sequence <400> 13 Thr Tyr Asp Ile Ser 1 5 <210> 14 <211> 16 <212> PRT <213> Artificial sequence <400> 14 Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Ser Ser Phe Met Ser 1 5 10 15 <210> 15 <211> 3 <212> PRT <213> Artificial sequence <400> 15 Val Asp Tyr 1 <210> 16 <211> 16 <212> PRT <213> Artificial sequence <400> 16 Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His 1 5 10 15 <210> 17 <211> 7 <212> PRT <213> Artificial sequence <400> 17 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 18 <211> 9 <212> PRT <213> Artificial sequence <400> 18 Ser Gln Asn Thr His Val Pro Trp Thr 1 5 <210> 19 <211> 5 <212> PRT <213> Artificial sequence <400> 19 Thr Ser Trp Met Asn 1 5 <210> 20 <211> 17 <212> PRT <213> Artificial sequence <400> 20 Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Arg Phe Lys 1 5 10 15 Gly <210> twenty one <211> 12 <212> PRT <213> Artificial sequence <400> twenty one Leu Asp Gly Tyr Tyr Glu Val Phe Tyr Phe Asp Tyr 1 5 10 <210> twenty two <211> 16 <212> PRT <213> Artificial sequence <400> twenty two Lys Ser Ser Gln Ser Leu Leu Tyr Ser Asn Gly Lys Thr Tyr Leu Asn 1 5 10 15 <210> twenty three <211> 7 <212> PRT <213> Artificial sequence <400> twenty three Leu Val Ser Lys Leu Asp Ser 1 5 <210> twenty four <211> 9 <212> PRT <213> Artificial sequence <400> twenty four Phe Gln Gly Thr His Phe Pro Trp Thr 1 5 <210> 25 <211> 5 <212> PRT <213> Artificial sequence <400> 25 Thr Tyr Val Met Tyr 1 5 <210> 26 <211> 17 <212> PRT <213> Artificial sequence <400> 26 Tyr Ile Asn Pro Tyr Asn Asp Asp Ile Arg Tyr Asn Glu Lys Phe Lys 1 5 10 15 Gly <210> 27 <211> 5 <212> PRT <213> Artificial sequence <400> 27 Gln Gly Gly Asp Tyr 1 5 <210> 28 <211> 11 <212> PRT <213> Artificial sequence <400> 28 Arg Ala Ser Lys Asn Ile Asn Lys Tyr Leu Ala 1 5 10 <210> 29 <211> 7 <212> PRT <213> Artificial sequence <400> 29 Ser Gly Ser Thr Leu Gln Ser 1 5 <210> 30 <211> 9 <212> PRT <213> Artificial sequence <400> 30 Gln Gln Tyr Asn Glu Tyr Pro Leu Thr 1 5 <210> 31 <211> 5 <212> PRT <213> Artificial sequence <400> 31 Thr Tyr Gly Val His 1 5 <210> 32 <211> 16 <212> PRT <213> Artificial sequence <400> 32 Val Ile Trp Ser Asp Gly Asn Thr Asp Tyr Asn Asp Ala Phe Ile Ser 1 5 10 15 <210> 33 <211> 10 <212> PRT <213> Artificial sequence <400> 33 Asn Ser Ile Thr Ser Val Ser Phe Asp Cys 1 5 10 <210> 34 <211> 11 <212> PRT <213> Artificial sequence <400> 34 Lys Ala Ser Gln Asn Val Gly Thr Thr Val Ala 1 5 10 <210> 35 <211> 7 <212> PRT <213> Artificial sequence <400> 35 Ser Ala Ser Tyr Arg Tyr Ser 1 5 <210> 36 <211> 9 <212> PRT <213> Artificial sequence <400> 36 Gln Gln Tyr Asn Ser Tyr Pro Leu Thr 1 5 <210> 37 <211> 5 <212> PRT <213> Artificial sequence <400> 37 Asn Tyr Trp Ile His 1 5 <210> 38 <211> 17 <212> PRT <213> Artificial sequence <400> 38 Asn Ile Tyr Pro Ala Ser Asp Tyr Thr Asn Tyr Asp Glu Lys Phe Lys 1 5 10 15 Asn <210> 39 <211> 8 <212> PRT <213> Artificial sequence <400> 39 Gly Tyr Phe Gly Ser Leu Asp Tyr 1 5 <210> 40 <211> 11 <212> PRT <213> Artificial sequence <400> 40 Arg Ala Ser Gln Pro Ile Gly Thr Gly Ile His 1 5 10 <210> 41 <211> 7 <212> PRT <213> Artificial sequence <400> 41 Ser Ala Ser Glu Ser Ile Ser 1 5 <210> 42 <211> 9 <212> PRT <213> Artificial sequence <400> 42 Gln Gln Ser Tyr Ser Trp Pro Thr Thr 1 5 <210> 43 <211> 5 <212> PRT <213> Artificial sequence <400> 43 Ser Asn Trp Met His 1 5 <210> 44 <211> 17 <212> PRT <213> Artificial sequence <400> 44 Val Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Asn Gln Lys Phe Lys 1 5 10 15 Gly <210> 45 <211> 8 <212> PRT <213> Artificial sequence <400> 45 Gly Ile Thr Thr Ala Pro Glu Tyr 1 5 <210> 46 <211> 11 <212> PRT <213> Artificial sequence <400> 46 Lys Ala Ser Glu Asn Val Gly Ile Tyr Val Ser 1 5 10 <210> 47 <211> 7 <212> PRT <213> Artificial sequence <400> 47 Gly Ala Ser Asn Arg Tyr Thr 1 5 <210> 48 <211> 9 <212> PRT <213> Artificial sequence <400> 48 Gly His Thr Tyr Asn Tyr Pro Phe Thr 1 5 <210> 49 <211> 5 <212> PRT <213> Artificial sequence <400> 49 Arg Tyr Trp Met Ser 1 5 <210> 50 <211> 17 <212> PRT <213> Artificial sequence <400> 50 Glu Ile His Pro Asp Ser Ser Ala Ile Asn Tyr Thr Pro Ser Leu Lys 1 5 10 15 Asp <210> 51 <211> 9 <212> PRT <213> Artificial sequence <400> 51 Ser Tyr Tyr Gly Arg Val Phe Asp Tyr 1 5 <210> 52 <211> 11 <212> PRT <213> Artificial sequence <400> 52 Arg Ala Ser Gln Ser Ile Ser Asp Tyr Leu His 1 5 10 <210> 53 <211> 7 <212> PRT <213> Artificial sequence <400> 53 Tyr Ala Ser Gln Ser Ile Ser 1 5 <210> 54 <211> 9 <212> PRT <213> Artificial sequence <400> 54 Gln Asp Gly His Ser Phe Pro Pro Thr 1 5 <210> 55 <211> 5 <212> PRT <213> Artificial sequence <400> 55 Ser Tyr Trp Met His 1 5 <210> 56 <211> 17 <212> PRT <213> Artificial sequence <400> 56 Val Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Asn Gln Lys Phe Lys 1 5 10 15 Gly <210> 57 <211> 8 <212> PRT <213> Artificial sequence <400> 57 Gly Ile Thr Thr Ala Pro Asp Tyr 1 5 <210> 58 <211> 11 <212> PRT <213> Artificial sequence <400> 58 Lys Ala Ser Glu Asn Val Gly Ile His Val Ser 1 5 10 <210> 59 <211> 7 <212> PRT <213> Artificial sequence <400> 59 Gly Ala Ser Ser Gly Tyr Asn 1 5 <210> 60 <211> 9 <212> PRT <213> Artificial sequence <400> 60 Gly Gln Thr Tyr Ser Tyr Pro Phe Thr 1 5 <210> 61 <211> 5 <212> PRT <213> Artificial sequence <400> 61 Asn Tyr Gly Met Asn 1 5 <210> 62 <211> 17 <212> PRT <213> Artificial sequence <400> 62 Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys 1 5 10 15 Gly <210> 63 <211> 10 <212> PRT <213> Artificial sequence <400> 63 Arg Glu Tyr Tyr Pro Trp Val Phe Val Tyr 1 5 10 <210> 64 <211> 10 <212> PRT <213> Artificial sequence <400> 64 Ser Ala Ser Ser Ser Val Ser Tyr Met His 1 5 10 <210> 65 <211> 7 <212> PRT <213> Artificial sequence <400> 65 Asp Thr Ser Lys Leu Ala Ser 1 5 <210> 66 <211> 9 <212> PRT <213> Artificial sequence <400> 66 Phe Gln Gly Ser Gly Tyr Pro Leu Thr 1 5 <210> 67 <211> 5 <212> PRT <213> Artificial sequence <400> 67 Ser Tyr Trp Ile Asn 1 5 <210> 68 <211> 17 <212> PRT <213> Artificial sequence <400> 68 Asn Ile Tyr Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe Lys 1 5 10 15 Asp <210> 69 <211> 10 <212> PRT <213> Artificial sequence <400> 69 Phe His Tyr Gly Ser Ser Pro Phe Asp Asn 1 5 10 <210> 70 <211> 11 <212> PRT <213> Artificial sequence <400> 70 Arg Ala Ser Gln Asp Ile Ser His Tyr Leu Asn 1 5 10 <210> 71 <211> 7 <212> PRT <213> Artificial sequence <400> 71 Tyr Thr Ser Arg Leu His Ser 1 5 <210> 72 <211> 9 <212> PRT <213> Artificial sequence <400> 72 Gln Gln Gly His Thr Leu Pro Arg Thr 1 5 <210> 73 <211> 5 <212> PRT <213> Artificial sequence <400> 73 Asn Tyr Gly Met Asn 1 5 <210> 74 <211> 17 <212> PRT <213> Artificial sequence <400> 74 Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys 1 5 10 15 Gly <210> 75 <211> 9 <212> PRT <213> Artificial sequence <400> 75 Arg Asp Tyr Leu Gly Ala Met Asp Tyr 1 5 <210> 76 <211> 12 <212> PRT <213> Artificial sequence <400> 76 Arg Ala Ser Ser Ser Val Ser Ser Ser Tyr Leu His 1 5 10 <210> 77 <211> 7 <212> PRT <213> Artificial sequence <400> 77 Ser Thr Ser Asn Leu Ala Ser 1 5 <210> 78 <211> 9 <212> PRT <213> Artificial sequence <400> 78 Gln Gln Tyr Ser Ala Tyr Leu Tyr Thr 1 5 <210> 79 <211> 5 <212> PRT <213> Artificial sequence <400> 79 Thr Tyr Trp Ile Asn 1 5 <210> 80 <211> 17 <212> PRT <213> Artificial sequence <400> 80 Asn Ile Tyr Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe Lys 1 5 10 15 Asp <210> 81 <211> 13 <212> PRT <213> Artificial sequence <400> 81 Glu Ala Gly Asp Gly Thr His Tyr Tyr Ala Ile Asp Tyr 1 5 10 <210> 82 <211> 11 <212> PRT <213> Artificial sequence <400> 82 Lys Ala Ser Glu Asn Val Gly Thr Tyr Val Ser 1 5 10 <210> 83 <211> 7 <212> PRT <213> Artificial sequence <400> 83 Gly Ala Ser Asn Arg Tyr Pro 1 5 <210> 84 <211> 9 <212> PRT <213> Artificial sequence <400> 84 Gly Gln Gly Tyr Ser Tyr Leu Arg Thr 1 5 <210> 85 <211> 5 <212> PRT <213> Artificial sequence <400> 85 Asp Tyr Tyr Met His 1 5 <210> 86 <211> 17 <212> PRT <213> Artificial sequence <400> 86 Trp Ile Asp Pro Glu Asn Gly Asn Thr Ile Tyr Asp Pro Lys Phe Gln 1 5 10 15 Asp <210> 87 <211> 8 <212> PRT <213> Artificial sequence <400> 87 Gly Leu Pro Trp Tyr Phe Asp Tyr 1 5 <210> 88 <211> 10 <212> PRT <213> Artificial sequence <400> 88 Ser Ala Ser Ser Ser Ser Val Ser Asp Met Asn 1 5 10 <210> 89 <211> 7 <212> PRT <213> Artificial sequence <400> 89 Leu Thr Ser Asn Leu Ser Ser 1 5 <210> 90 <211> 9 <212> PRT <213> Artificial sequence <400> 90 Gln Gln Trp Ser Gly Asn Pro Leu Thr 1 5 <210> 91 <211> 5 <212> PRT <213> Artificial sequence <400> 91 Ser Phe Gly Met His 1 5 <210> 92 <211> 17 <212> PRT <213> Artificial sequence <400> 92 Tyr Ile Ser Ser Gly Ser Ser Ala Ile Tyr Tyr Ala Asp Thr Val Lys 1 5 10 15 Gly <210> 93 <211> 5 <212> PRT <213> Artificial sequence <400> 93 Asp Trp Val Asp Tyr 1 5 <210> 94 <211> 11 <212> PRT <213> Artificial sequence <400> 94 Arg Ala Ser Glu Asn Ile Tyr Ser Asn Leu Val 1 5 10 <210> 95 <211> 7 <212> PRT <213> Artificial sequence <400> 95 Thr Ala Thr Lys Leu Thr Asn 1 5 <210> 96 <211> 9 <212> PRT <213> Artificial sequence <400> 96 Gln His Phe Trp Asp Thr Pro Tyr Thr 1 5 <210> 97 <211> 5 <212> PRT <213> Artificial sequence <400> 97 Ser Tyr Trp Ile Asn 1 5 <210> 98 <211> 17 <212> PRT <213> Artificial sequence <400> 98 Asn Ile Phe Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe Lys 1 5 10 15 Asp <210> 99 <211> 14 <212> PRT <213> Artificial sequence <400> 99 Phe Gly Ser Ser Gly Tyr Pro Asp Tyr Tyr Thr Met Glu Tyr 1 5 10 <210> 100 <211> 11 <212> PRT <213> Artificial sequence <400> 100 Arg Ala Ser Gly Asn Ile Asp Asn Tyr Leu Ala 1 5 10 <210> 101 <211> 7 <212> PRT <213> Artificial sequence <400> 101 Asn Ala Lys Thr Leu Ala Glu 1 5 <210> 102 <211> 9 <212> PRT <213> Artificial sequence <400> 102 Gln Gln Tyr Trp Thr Ile Pro Tyr Thr 1 5 <210> 103 <211> 5 <212> PRT <213> Artificial sequence <400> 103 Asn Ser Trp Met Asn 1 5 <210> 104 <211> 17 <212> PRT <213> Artificial sequence <400> 104 Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe Lys 1 5 10 15 Gly <210> 105 <211> 12 <212> PRT <213> Artificial sequence <400> 105 Leu Asp Gly Asn Tyr Tyr Tyr Trp Tyr Phe Asp Val 1 5 10 <210> 106 <211> 16 <212> PRT <213> Artificial sequence <400> 106 Lys Ser Ser Gln Ser Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn 1 5 10 15 <210> 107 <211> 7 <212> PRT <213> Artificial sequence <400> 107 Leu Val Ser Lys Leu Asp Ser 1 5 <210> 108 <211> 9 <212> PRT <213> Artificial sequence <400> 108 Trp Gln Gly Thr His Phe Pro Gln Thr 1 5 <210> 109 <211> 10 <212> PRT <213> Artificial sequence <400> 109 Gly Phe Thr Phe Ser Ser Ser Tyr Ile Asn 1 5 10 <210> 110 <211> 6 <212> PRT <213> Artificial sequence <400> 110 Phe Ala Gly Thr Gly Gly 1 5 <210> 111 <211> 10 <212> PRT <213> Artificial sequence <400> 111 His Ser Pro Arg Ala Thr Leu Phe Asp Phe 1 5 10 <210> 112 <211> 10 <212> PRT <213> Artificial sequence <400> 112 Arg Ala Ser Ser Ser Val Asn His Met His 1 5 10 <210> 113 <211> 7 <212> PRT <213> Artificial sequence <400> 113 Ala Thr Ser Asn Leu Ala Ser 1 5 <210> 114 <211> 9 <212> PRT <213> Artificial sequence <400> 114 Gln Gln Trp Ser Ser Asn Pro Tyr Thr 1 5 <210> 115 <211> 10 <212> PRT <213> Artificial sequence <400> 115 Gly Tyr Thr Phe Ser Ser Tyr Trp Ile Asn 1 5 10 <210> 116 <211> 6 <212> PRT <213> Artificial sequence <400> 116 Tyr Pro Ser Asp Ser Tyr 1 5 <210> 117 <211> 12 <212> PRT <213> Artificial sequence <400> 117 Thr Trp Glu Phe Tyr Tyr Asp Ser Val Phe Asp Tyr 1 5 10 <210> 118 <211> 11 <212> PRT <213> Artificial sequence <400> 118 Lys Ala Ser Gln Asp Ile Asn Ser Tyr Leu Ser 1 5 10 <210> 119 <211> 7 <212> PRT <213> Artificial sequence <400> 119 Arg Ala Asn Arg Leu Val Asp 1 5 <210> 120 <211> 9 <212> PRT <213> Artificial sequence <400> 120 Leu Gln Tyr Asp Glu Leu Pro Pro Thr 1 5 <210> 121 <211> 10 <212> PRT <213> Artificial sequence <400> 121 Gly Phe Ser Leu Thr Thr Tyr Asp Ile Ser 1 5 10 <210> 122 <211> 5 <212> PRT <213> Artificial sequence <400> 122 Trp Thr Gly Gly Gly 1 5 <210> 123 <211> 3 <212> PRT <213> Artificial sequence <400> 123 Val Asp Tyr 1 <210> 124 <211> 16 <212> PRT <213> Artificial sequence <400> 124 Arg Ser Ser Gln Ser Leu Val His Ser Asn Gly Asn Thr Tyr Leu His 1 5 10 15 <210> 125 <211> 7 <212> PRT <213> Artificial sequence <400> 125 Lys Val Ser Asn Arg Phe Ser 1 5 <210> 126 <211> 9 <212> PRT <213> Artificial sequence <400> 126 Ser Gln Asn Thr His Val Pro Trp Thr 1 5 <210> 127 <211> 10 <212> PRT <213> Artificial sequence <400> 127 Gly Tyr Ala Phe Ser Thr Ser Trp Met Asn 1 5 10 <210> 128 <211> 6 <212> PRT <213> Artificial sequence <400> 128 Tyr Pro Gly Asp Gly Asp 1 5 <210> 129 <211> 12 <212> PRT <213> Artificial sequence <400> 129 Leu Asp Gly Tyr Tyr Glu Val Phe Tyr Phe Asp Tyr 1 5 10 <210> 130 <211> 16 <212> PRT <213> Artificial sequence <400> 130 Lys Ser Ser Gln Ser Leu Leu Tyr Ser Asn Gly Lys Thr Tyr Leu Asn 1 5 10 15 <210> 131 <211> 7 <212> PRT <213> Artificial sequence <400> 131 Leu Val Ser Lys Leu Asp Ser 1 5 <210> 132 <211> 9 <212> PRT <213> Artificial sequence <400> 132 Phe Gln Gly Thr His Phe Pro Trp Thr 1 5 <210> 133 <211> 10 <212> PRT <213> Artificial sequence <400> 133 Gly Tyr Thr Phe Thr Thr Tyr Val Met Tyr 1 5 10 <210> 134 <211> 6 <212> PRT <213> Artificial sequence <400> 134 Asn Pro Tyr Asn Asp Asp 1 5 <210> 135 <211> 5 <212> PRT <213> Artificial sequence <400> 135 Gln Gly Gly Asp Tyr 1 5 <210> 136 <211> 11 <212> PRT <213> Artificial sequence <400> 136 Arg Ala Ser Lys Asn Ile Asn Lys Tyr Leu Ala 1 5 10 <210> 137 <211> 7 <212> PRT <213> Artificial sequence <400> 137 Ser Gly Ser Thr Leu Gln Ser 1 5 <210> 138 <211> 9 <212> PRT <213> Artificial sequence <400> 138 Gln Gln Tyr Asn Glu Tyr Pro Leu Thr 1 5 <210> 139 <211> 10 <212> PRT <213> Artificial sequence <400> 139 Gly Phe Ser Leu Thr Thr Tyr Gly Val His 1 5 10 <210> 140 <211> 5 <212> PRT <213> Artificial sequence <400> 140 Trp Ser Asp Gly Asn 1 5 <210> 141 <211> 10 <212> PRT <213> Artificial sequence <400> 141 Asn Ser Ile Thr Ser Val Ser Phe Asp Cys 1 5 10 <210> 142 <211> 11 <212> PRT <213> Artificial sequence <400> 142 Lys Ala Ser Gln Asn Val Gly Thr Thr Val Ala 1 5 10 <210> 143 <211> 7 <212> PRT <213> Artificial sequence <400> 143 Ser Ala Ser Tyr Arg Tyr Ser 1 5 <210> 144 <211> 9 <212> PRT <213> Artificial sequence <400> 144 Gln Gln Tyr Asn Ser Tyr Pro Leu Thr 1 5 <210> 145 <211> 10 <212> PRT <213> Artificial sequence <400> 145 Gly Tyr Thr Phe Ser Asn Tyr Trp Ile His 1 5 10 <210> 146 <211> 6 <212> PRT <213> Artificial sequence <400> 146 Tyr Pro Ala Ser Asp Tyr 1 5 <210> 147 <211> 8 <212> PRT <213> Artificial sequence <400> 147 Gly Tyr Phe Gly Ser Leu Asp Tyr 1 5 <210> 148 <211> 11 <212> PRT <213> Artificial sequence <400> 148 Arg Ala Ser Gln Pro Ile Gly Thr Gly Ile His 1 5 10 <210> 149 <211> 7 <212> PRT <213> Artificial sequence <400> 149 Ser Ala Ser Glu Ser Ile Ser 1 5 <210> 150 <211> 9 <212> PRT <213> Artificial sequence <400> 150 Gln Gln Ser Tyr Ser Trp Pro Thr Thr 1 5 <210> 151 <211> 10 <212> PRT <213> Artificial sequence <400> 151 Gly Tyr Ser Phe Thr Ser Asn Trp Met His 1 5 10 <210> 152 <211> 6 <212> PRT <213> Artificial sequence <400> 152 Tyr Pro Gly Asn Ser Asp 1 5 <210> 153 <211> 8 <212> PRT <213> Artificial sequence <400> 153 Gly Ile Thr Thr Ala Pro Glu Tyr 1 5 <210> 154 <211> 11 <212> PRT <213> Artificial sequence <400> 154 Lys Ala Ser Glu Asn Val Gly Ile Tyr Val Ser 1 5 10 <210> 155 <211> 7 <212> PRT <213> Artificial sequence <400> 155 Gly Ala Ser Asn Arg Tyr Thr 1 5 <210> 156 <211> 9 <212> PRT <213> Artificial sequence <400> 156 Gly His Thr Tyr Asn Tyr Pro Phe Thr 1 5 <210> 157 <211> 10 <212> PRT <213> Artificial sequence <400> 157 Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser 1 5 10 <210> 158 <211> 6 <212> PRT <213> Artificial sequence <400> 158 His Pro Asp Ser Ser Ala 1 5 <210> 159 <211> 9 <212> PRT <213> Artificial sequence <400> 159 Ser Tyr Tyr Gly Arg Val Phe Asp Tyr 1 5 <210> 160 <211> 11 <212> PRT <213> Artificial sequence <400> 160 Arg Ala Ser Gln Ser Ile Ser Asp Tyr Leu His 1 5 10 <210> 161 <211> 7 <212> PRT <213> Artificial sequence <400> 161 Tyr Ala Ser Gln Ser Ile Ser 1 5 <210> 162 <211> 9 <212> PRT <213> Artificial sequence <400> 162 Gln Asp Gly His Ser Phe Pro Pro Thr 1 5 <210> 163 <211> 10 <212> PRT <213> Artificial sequence <400> 163 Gly Tyr Ser Phe Thr Ser Tyr Trp Met His 1 5 10 <210> 164 <211> 6 <212> PRT <213> Artificial sequence <400> 164 Tyr Pro Gly Asn Ser Asp 1 5 <210> 165 <211> 8 <212> PRT <213> Artificial sequence <400> 165 Gly Ile Thr Thr Ala Pro Asp Tyr 1 5 <210> 166 <211> 11 <212> PRT <213> Artificial sequence <400> 166 Lys Ala Ser Glu Asn Val Gly Ile His Val Ser 1 5 10 <210> 167 <211> 7 <212> PRT <213> Artificial sequence <400> 167 Gly Ala Ser Ser Gly Tyr Asn 1 5 <210> 168 <211> 9 <212> PRT <213> Artificial sequence <400> 168 Gly Gln Thr Tyr Ser Tyr Pro Phe Thr 1 5 <210> 169 <211> 10 <212> PRT <213> Artificial sequence <400> 169 Lys Phe Thr Phe Thr Asn Tyr Gly Met Asn 1 5 10 <210> 170 <211> 6 <212> PRT <213> Artificial sequence <400> 170 Asn Thr Tyr Thr Gly Glu 1 5 <210> 171 <211> 10 <212> PRT <213> Artificial sequence <400> 171 Arg Glu Tyr Tyr Pro Trp Val Phe Val Tyr 1 5 10 <210> 172 <211> 10 <212> PRT <213> Artificial sequence <400> 172 Ser Ala Ser Ser Ser Val Ser Tyr Met His 1 5 10 <210> 173 <211> 7 <212> PRT <213> Artificial sequence <400> 173 Asp Thr Ser Lys Leu Ala Ser 1 5 <210> 174 <211> 9 <212> PRT <213> Artificial sequence <400> 174 Phe Gln Gly Ser Gly Tyr Pro Leu Thr 1 5 <210> 175 <211> 10 <212> PRT <213> Artificial sequence <400> 175 Gly Tyr Ile Phe Thr Ser Tyr Trp Ile Asn 1 5 10 <210> 176 <211> 6 <212> PRT <213> Artificial sequence <400> 176 Tyr Pro Ser Asp Ser Tyr 1 5 <210> 177 <211> 10 <212> PRT <213> Artificial sequence <400> 177 Phe His Tyr Gly Ser Ser Pro Phe Asp Asn 1 5 10 <210> 178 <211> 11 <212> PRT <213> Artificial sequence <400> 178 Arg Ala Ser Gln Asp Ile Ser His Tyr Leu Asn 1 5 10 <210> 179 <211> 7 <212> PRT <213> Artificial sequence <400> 179 Tyr Thr Ser Arg Leu His Ser 1 5 <210> 180 <211> 9 <212> PRT <213> Artificial sequence <400> 180 Gln Gln Gly His Thr Leu Pro Arg Thr 1 5 <210> 181 <211> 10 <212> PRT <213> Artificial sequence <400> 181 Gly Tyr Thr Phe Thr Asn Tyr Gly Met Asn 1 5 10 <210> 182 <211> 6 <212> PRT <213> Artificial sequence <400> 182 Asn Thr Tyr Thr Gly Glu 1 5 <210> 183 <211> 9 <212> PRT <213> Artificial sequence <400> 183 Arg Asp Tyr Leu Gly Ala Met Asp Tyr 1 5 <210> 184 <211> 12 <212> PRT <213> Artificial sequence <400> 184 Arg Ala Ser Ser Ser Val Ser Ser Ser Tyr Leu His 1 5 10 <210> 185 <211> 7 <212> PRT <213> Artificial sequence <400> 185 Ser Thr Ser Asn Leu Ala Ser 1 5 <210> 186 <211> 9 <212> PRT <213> Artificial sequence <400> 186 Gln Gln Tyr Ser Ala Tyr Leu Tyr Thr 1 5 <210> 187 <211> 10 <212> PRT <213> Artificial sequence <400> 187 Gly Tyr Thr Phe Thr Thr Tyr Trp Ile Asn 1 5 10 <210> 188 <211> 6 <212> PRT <213> Artificial sequence <400> 188 Tyr Pro Ser Asp Ser Tyr 1 5 <210> 189 <211> 13 <212> PRT <213> Artificial sequence <400> 189 Glu Ala Gly Asp Gly Thr His Tyr Tyr Ala Ile Asp Tyr 1 5 10 <210> 190 <211> 11 <212> PRT <213> Artificial sequence <400> 190 Lys Ala Ser Glu Asn Val Gly Thr Tyr Val Ser 1 5 10 <210> 191 <211> 7 <212> PRT <213> Artificial sequence <400> 191 Gly Ala Ser Asn Arg Tyr Pro 1 5 <210> 192 <211> 9 <212> PRT <213> Artificial sequence <400> 192 Gly Gln Gly Tyr Ser Tyr Leu Arg Thr 1 5 <210> 193 <211> 10 <212> PRT <213> Artificial sequence <400> 193 Gly Phe Asn Ile Lys Asp Tyr Tyr Met His 1 5 10 <210> 194 <211> 6 <212> PRT <213> Artificial sequence <400> 194 Asp Pro Glu Asn Gly Asn 1 5 <210> 195 <211> 8 <212> PRT <213> Artificial sequence <400> 195 Gly Leu Pro Trp Tyr Phe Asp Tyr 1 5 <210> 196 <211> 10 <212> PRT <213> Artificial sequence <400> 196 Ser Ala Ser Ser Ser Ser Val Ser Asp Met Asn 1 5 10 <210> 197 <211> 7 <212> PRT <213> Artificial sequence <400> 197 Leu Thr Ser Asn Leu Ser Ser 1 5 <210> 198 <211> 9 <212> PRT <213> Artificial sequence <400> 198 Gln Gln Trp Ser Gly Asn Pro Leu Thr 1 5 <210> 199 <211> 10 <212> PRT <213> Artificial sequence <400> 199 Gly Phe Ser Phe Ser Ser Ser Phe Gly Met His 1 5 10 <210> 200 <211> 6 <212> PRT <213> Artificial sequence <400> 200 Ser Ser Gly Ser Ser Ala 1 5 <210> 201 <211> 5 <212> PRT <213> Artificial sequence <400> 201 Asp Trp Val Asp Tyr 1 5 <210> 202 <211> 11 <212> PRT <213> Artificial sequence <400> 202 Arg Ala Ser Glu Asn Ile Tyr Ser Asn Leu Val 1 5 10 <210> 203 <211> 7 <212> PRT <213> Artificial sequence <400> 203 Thr Ala Thr Lys Leu Thr Asn 1 5 <210> 204 <211> 9 <212> PRT <213> Artificial sequence <400> 204 Gln His Phe Trp Asp Thr Pro Tyr Thr 1 5 <210> 205 <211> 10 <212> PRT <213> Artificial sequence <400> 205 Gly Tyr Thr Phe Thr Ser Tyr Trp Ile Asn 1 5 10 <210> 206 <211> 6 <212> PRT <213> Artificial sequence <400> 206 Phe Pro Ser Asp Ser Tyr 1 5 <210> 207 <211> 14 <212> PRT <213> Artificial sequence <400> 207 Phe Gly Ser Ser Gly Tyr Pro Asp Tyr Tyr Thr Met Glu Tyr 1 5 10 <210> 208 <211> 11 <212> PRT <213> Artificial sequence <400> 208 Arg Ala Ser Gly Asn Ile Asp Asn Tyr Leu Ala 1 5 10 <210> 209 <211> 7 <212> PRT <213> Artificial sequence <400> 209 Asn Ala Lys Thr Leu Ala Glu 1 5 <210> 210 <211> 9 <212> PRT <213> Artificial sequence <400> 210 Gln Gln Tyr Trp Thr Ile Pro Tyr Thr 1 5 <210> 211 <211> 10 <212> PRT <213> Artificial sequence <400> 211 Gly Tyr Ala Phe Asn Asn Ser Trp Met Asn 1 5 10 <210> 212 <211> 6 <212> PRT <213> Artificial sequence <400> 212 Tyr Pro Gly Asp Gly Asp 1 5 <210> 213 <211> 12 <212> PRT <213> Artificial sequence <400> 213 Leu Asp Gly Asn Tyr Tyr Tyr Trp Tyr Phe Asp Val 1 5 10 <210> 214 <211> 16 <212> PRT <213> Artificial sequence <400> 214 Lys Ser Ser Gln Ser Leu Leu Asp Ser Asp Gly Lys Thr Tyr Leu Asn 1 5 10 15 <210> 215 <211> 7 <212> PRT <213> Artificial sequence <400> 215 Leu Val Ser Lys Leu Asp Ser 1 5 <210> 216 <211> 9 <212> PRT <213> Artificial sequence <400> 216 Trp Gln Gly Thr His Phe Pro Gln Thr 1 5 <210> 217 <211> 255 <212> PRT <213> people <400> 217 Met Gly Asn Ser Cys Tyr Asn Ile Val Ala Thr Leu Leu Leu Val Leu 1 5 10 15 Asn Phe Glu Arg Thr Arg Ser Leu Gln Asp Pro Cys Ser Asn Cys Pro 20 25 30 Ala Gly Thr Phe Cys Asp Asn Asn Arg Asn Gln Ile Cys Ser Pro Cys 35 40 45 Pro Pro Asn Ser Phe Ser Ser Ala Gly Gly Gln Arg Thr Cys Asp Ile 50 55 60 Cys Arg Gln Cys Lys Gly Val Phe Arg Thr Arg Lys Glu Cys Ser Ser 65 70 75 80 Thr Ser Asn Ala Glu Cys Asp Cys Thr Pro Gly Phe His Cys Leu Gly 85 90 95 Ala Gly Cys Ser Met Cys Glu Gln Asp Cys Lys Gln Gly Gln Glu Leu 100 105 110 Thr Lys Lys Gly Cys Lys Asp Cys Cys Phe Gly Thr Phe Asn Asp Gln 115 120 125 Lys Arg Gly Ile Cys Arg Pro Trp Thr Asn Cys Ser Leu Asp Gly Lys 130 135 140 Ser Val Leu Val Asn Gly Thr Lys Glu Arg Asp Val Val Cys Gly Pro 145 150 155 160 Ser Pro Ala Asp Leu Ser Pro Gly Ala Ser Ser Val Thr Pro Pro Ala 165 170 175 Pro Ala Arg Glu Pro Gly His Ser Pro Gln Ile Ile Ser Phe Phe Leu 180 185 190 Ala Leu Thr Ser Thr Ala Leu Leu Phe Leu Leu Phe Phe Leu Thr Leu 195 200 205 Arg Phe Ser Val Val Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe 210 215 220 Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly 225 230 235 240 Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu 245 250 255 <210> 218 <211> 256 <212> PRT <213> Mouse <400> 218 Met Gly Asn Asn Cys Tyr Asn Val Val Val Ile Val Leu Leu Leu Val 1 5 10 15 Gly Cys Glu Lys Val Gly Ala Val Gln Asn Ser Cys Asp Asn Cys Gln 20 25 30 Pro Gly Thr Phe Cys Arg Lys Tyr Asn Pro Val Cys Lys Ser Cys Pro 35 40 45 Pro Ser Thr Phe Ser Ser Ile Gly Gly Gln Pro Asn Cys Asn Ile Cys 50 55 60 Arg Val Cys Ala Gly Tyr Phe Arg Phe Lys Lys Phe Cys Ser Ser Thr 65 70 75 80 His Asn Ala Glu Cys Glu Cys Ile Glu Gly Phe His Cys Leu Gly Pro 85 90 95 [[ID=*]]Gln Cys Thr Arg Cys Glu Lys Asp Cys Arg Pro Gly Gln Glu Leu Thr 100 105 110 Lys Gln Gly Cys Lys Thr Cys Ser Leu Gly Thr Phe Asn Asp Gln Asn 115 120 125 Gly Thr Gly Val Cys Arg Pro Trp Thr Asn Cys Ser Leu Asp Gly Arg 130 135 140 Ser Val Leu Lys Thr Gly Thr Thr Glu Lys Asp Val Val Cys Gly Pro 145 150 155 160 Pro Val Val Ser Phe Ser Pro Ser Thr Thr Ile Ser Val Thr Pro Glu 165 170 175 Gly Gly Pro Gly Gly His Ser Leu Gln Val Leu Thr Leu Phe Leu Ala 180 185 190 Leu Thr Ser Ala Leu Leu Leu Ala Leu Ile Phe Ile Thr Leu Leu Phe 195 200 205 Ser Val Leu Lys Trp Ile Arg Lys Lys Phe Pro His Ile Phe Lys Gln 210 215 220 Pro Phe Lys Lys Thr Thr Gly Ala Ala Gln Glu Glu Asp Ala Cys Ser 225 230 235 240 Cys Arg Cys Pro Gln Glu Glu Glu Gly Gly Gly Gly Gly Tyr Glu Leu 245 250 255 <210> 219 <211> 254 <212> PRT <213> Monkey <400> 219 Met Gly Asn Ser Cys Tyr Asn Ile Val Ala Thr Leu Leu Leu Val Leu 1 5 10 15 Asn Phe Glu Arg Thr Arg Ser Leu Gln Asp Leu Cys Ser Asn Cys Pro 20 25 30 Ala Gly Thr Phe Cys Asp Asn Asn Arg Ser Gln Ile Cys Ser Pro Cys 35 40 45 Pro Pro Asn Ser Phe Ser Ser Ala Gly Gly Gln Arg Thr Cys Asp Ile 50 55 60 Cys Arg Gln Cys Lys Gly Val Phe Lys Thr Arg Lys Glu Cys Ser Ser 65 70 75 80 Thr Ser Asn Ala Glu Cys Asp Cys Ile Ser Gly Tyr His Cys Leu Gly 85 90 95 Ala Glu Cys Ser Met Cys Glu Gln Asp Cys Lys Gln Gly Gln Glu Leu 100 105 110 Thr Lys Lys Gly Cys Lys Asp Cys Cys Phe Gly Thr Phe Asn Asp Gln 115 120 125 Lys Arg Gly Ile Cys Arg Pro Trp Thr Asn Cys Ser Leu Asp Gly Lys 130 135 140 Ser Val Leu Val Asn Gly Thr Lys Glu Arg Asp Val Val Cys Gly Pro 145 150 155 160 Ser Pro Ala Asp Leu Ser Pro Gly Ala Ser Ser Ala Thr Pro Pro Ala 165 170 175 Pro Ala Arg Glu Pro Gly His Ser Pro Gln Ile Ile Phe Phe Leu Ala 180 185 190 Leu Thr Ser Thr Val Val Leu Phe Leu Leu Phe Phe Leu Val Leu Arg 195 200 205 Phe Ser Val Val Lys Arg Ser Arg Lys Lys Leu Leu Tyr Ile Phe Lys 210 215 220 Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys 225 230 235 240 Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu 245 250 <210> 220 <211> 257 <212> PRT <213> artificial sequence <400> 220 Met Gly Asn Ser Cys Tyr Asn Ile Val Ala Thr Leu Leu Leu Val Leu 1 5 10 15 Asn Phe Glu Arg Thr Arg Ser Leu Gln Asp Pro Cys Ser Asn Cys Pro 20 25 30 Ala Gly Thr Phe Cys Asp Asn Asn Arg Asn Gln Ile Cys Ser Pro Cys 35 40 45 Pro Pro Asn Ser Phe Ser Ser Ala Gly Gly Gln Arg Thr Cys Asp Ile 50 55 60 Cys Arg Gln Cys Lys Gly Val Phe Arg Thr Arg Lys Glu Cys Ser Ser 65 70 75 80 Thr Ser Asn Ala Glu Cys Asp Cys Thr Pro Gly Phe His Cys Leu Gly 85 90 95 Ala Gly Cys Ser Met Cys Glu Gln Asp Cys Lys Gln Gly Gln Glu Leu 100 105 110 Thr Lys Lys Gly Cys Lys Asp Cys Cys Phe Gly Thr Phe Asn Asp Gln 115 120 125 Lys Arg Gly Ile Cys Arg Pro Trp Thr Asn Cys Ser Leu Asp Gly Lys 130 135 140 Ser Val Leu Val Asn Gly Thr Lys Glu Arg Asp Val Val Cys Gly Pro 145 150 155 160 Ser Pro Ala Asp Leu Ser Pro Gly Ala Ser Ser Val Thr Pro Pro Ala 165 170 175 Pro Ala Arg Glu Pro Gly His Ser Leu Gln Val Leu Thr Leu Phe Leu 180 185 190 Ala Leu Thr Ser Ala Leu Leu Leu Ala Leu Ile Phe Ile Thr Leu Leu 195 200 205 Phe Ser Val Leu Lys Trp Ile Arg Lys Lys Phe Pro His Ile Phe Lys 210 215 220 Gln Pro Phe Lys Lys Thr Thr Gly Ala Ala Gln Glu Glu Asp Ala Cys 225 230 235 240 Ser Cys Arg Cys Pro Gln Glu Glu Glu Gly Gly Gly Gly Gly Tyr Glu 245 250 255 Leu <210> 221 <211> 119 <212> PRT <213> Artificial Sequence <400> 221 Gln Val Gln Met Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Phe Thr Phe Ser Ser Ser 20 25 30 Tyr Ile Asn Trp Leu Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Met 35 40 45 Gly Trp Ile Phe Ala Gly Thr Gly Gly Thr Tyr Tyr Asn Gln Lys Phe 50 55 60 Thr Gly Arg Val Thr Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg His Ser Pro Arg Ala Thr Leu Phe Asp Phe Trp Gly Gln Gly 100 105 110 Thr Thr Leu Thr Val Ser Ser 115 <210> 222 <211> 119 <212> PRT <213> Artificial sequence <400> 222 Gln Val Gln Met Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Phe Thr Phe Ser Ser Ser 20 25 30 Tyr Ile Asn Trp Leu Arg Gln Ala Pro Gly Gln Ser Leu Glu Trp Ile 35 40 45 Gly Trp Ile Phe Ala Gly Thr Gly Gly Thr Tyr Tyr Asn Gln Lys Phe 50 55 60 Thr Gly Arg Val Gln Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg His Ser Pro Arg Ala Thr Leu Phe Asp Phe Trp Gly Gln Gly 100 105 110 Thr Thr Leu Thr Val Ser Ser 115 <210> 223 <211> 119 <212> PRT <213> Artificial Sequence <400> 223 Gln Val Gln Met Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Phe Thr Phe Ser Ser Ser 20 25 30 Tyr Ile Asn Trp Leu Arg Gln Ala Pro Gly Gln Ser Leu Glu Trp Ile 35 40 45 Gly Trp Ile Phe Ala Gly Thr Gly Gly Thr Tyr Tyr Asn Gln Lys Phe 50 55 60 Thr Gly Arg Ala Gln Ile Thr Arg Asp Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg His Ser Pro Arg Ala Thr Leu Phe Asp Phe Trp Gly Gln Gly 100 105 110 Thr Thr Leu Thr Val Ser Ser 115 <210> 224 <211> 119 <212> PRT <213> Artificial Sequence <400> 224 Gln Gly Gln Met Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Thr Ser Gly Phe Thr Phe Ser Ser Ser 20 25 30 Tyr Ile Asn Trp Leu Arg Gln Ala Pro Gly Gln Ser Leu Glu Trp Ile 35 40 45 Ala Trp Ile Phe Ala Gly Thr Gly Gly Thr Tyr Tyr Asn Gln Lys Phe 50 55 60 Thr Gly Arg Ala Gln Leu Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg His Ser Pro Arg Ala Thr Leu Phe Asp Phe Trp Gly Gln Gly 100 105 110 Thr Thr Leu Thr Val Ser Ser 115 <210> 225 <211> 106 <212> PRT <213> Synthetic Sequence <400> 225 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Ser Ser Val Asn His Met 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Ala Leu Ile Tyr 35 40 45 Ala Thr Ser Asn Leu Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu 65 70 75 80 Asp Phe Ala Val Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Tyr Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 226 <211> 106 <212> PRT <213> Artificial Sequence <400> 226 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Ser Ser Val Asn His Met 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Ala Leu Ile Tyr 35 40 45 Ala Thr Ser Asn Leu Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu 65 70 75 80 Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Tyr Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 227 <211> 106 <212> PRT <213> Synthetic Sequence <400> 227 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Met Ser Cys Arg Ala Ser Ser Ser Val Asn His Met 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Phe Ser Pro Arg Ala Trp Ile Tyr 35 40 45 Ala Thr Ser Asn Leu Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu 65 70 75 80 Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Tyr Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 228 <211> 106 <212> PRT <213> Synthetic Sequence <400> 228 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Ala Ser Pro Gly 1 5 10 15 Glu Arg Val Thr Met Ser Cys Arg Ala Ser Ser Ser Val Asn His Met 20 25 30 His Trp Tyr Gln Gln Arg Pro Gly Phe Ser Pro Arg Ala Trp Ile Tyr 35 40 45 Ala Thr Ser Asn Leu Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Leu Glu Pro Glu [[ID=??]]65 70 75 80 / / 原文中此处应为 Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Tyr Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys ??? 100 105 <210> 229 <211> 121[[ID=??]] / / 原文中此处应为<??]]<212> PRT / / 原文中此处应为<212> PRT 注:原文中部分行号和标签存在重复或错误标注的情况,我按照正确的逻辑进行了翻译,但可能会与原文的编号体系不完全对应,你可根据实际情况进一步核对。 另外,原文中 “65 70 75 80 ” 处误写为 “ ”,“100 105 ” 处误写为 “??? 100 105 ”,“ ” 处误写为 “[[ID=??]] ”,“<212> PRT ” 处误写为 “[[ID=??]]<212> PRT ”,请你检查或修正后再使用。 <213> artificial sequence <400> 229 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr 20 25 30 Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Asn Ile Tyr Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Arg Val Thr Leu Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Thr Trp Glu Phe Tyr Tyr Asp Ser Val Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 230 <211> 121 <212> PRT <213> artificial sequence <400> 230 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr 20 25 30 Trp Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asn Ile Tyr Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Arg Ala Thr Leu Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Thr Trp Glu Phe Tyr Tyr Asp Ser Val Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 231 <211> 121 <212> PRT <213> artificial sequence <400> 231 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr 20 25 30 Trp Ile Asn Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asn Ile Tyr Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Thr Trp Glu Phe Tyr Tyr Asp Ser Val Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 232 <211> 107 <212> PRT <213> artificial sequence <400> 232 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 20 25 30 Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Gln Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Glu Leu Pro Pro 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 233 <211> 107 <212> PRT <213> artificial sequence <400> 233 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 20 25 30 Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Thr Leu Ile 35 40 45 Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Gln Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Glu Leu Pro Pro 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 234 <211> 107 <212> PRT <213> Artificial sequence <400> 234 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 20 25 30 Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Thr Leu Ile 35 40 45 Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Gln Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Glu Leu Pro Pro 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 235 <211> 107 <212> PRT <213> artificial sequence <400> 235 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 20 25 30 Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro Lys Thr Leu Ile 35 40 45 Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Gln Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Glu Leu Pro Pro 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 236 <211> 111 <212> PRT <213> artificial sequence <400> 236 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 20 25 30 Asp Ile Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Ser Ser Phe Met 50 55 60 Ser Arg Val Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Glu 85 90 95 Arg Val Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 <210> 237 <211> 111 <212> PRT <213> Artificial Sequence <400> 237 Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 20 25 30 Asp Ile Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45 Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Ser Ser Phe Met 50 55 60 Ser Arg Val Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Ile Tyr Tyr Cys Glu 85 90 95 Arg Val Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 100 105 110 <210> 238 <211> 111 <212> PRT <213> artificial sequence <400> 238 Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 20 25 30 Asp Ile Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45 Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Ser Ser Phe Met 50 55 60 Ser Arg Val Thr Ile Ser Lys Asp Asn Ser Lys Asn Gln Val Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Ile Tyr Tyr Cys Glu 85 90 95 Arg Val Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser 100 105 110 <210> 239 <211> 112 <212> PRT <213> Artificial sequence <400> 239 Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu His Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Phe Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Asn 85 90 95 Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 240 <211> 112 <212> PRT <213> Artificial sequence <400> 240 Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu His Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Phe Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Asn 85 90 95 Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 110 <210> 241 <211> 112 <212> PRT <213> Artificial Sequence <400> 241 Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu His Trp Tyr Gln Gln Arg Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Phe Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Asn 85 90 95 Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 242 <211> 112 <212> PRT <213> Artificial Sequence <400> 242 Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly 1 5 10 15 Asp Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Arg Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Phe Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Asn 85 90 95 Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 243 <211> 119 <212> PRT <213> Synthetic Sequence <400> 243 Gln Gly Gln Met Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Thr Ser Gly Phe Thr Phe Ser Ser Ser 20 25 30 Tyr Ile Asn Trp Leu Lys Gln Lys Pro Gly Gln Ser Leu Glu Trp Ile 35 40 45 Ala Trp Ile Phe Ala Gly Thr Gly Gly Thr Tyr Tyr Asn Gln Lys Phe 50 55 60 Thr Gly Lys Ala Gln Leu Thr Val Asp Thr Ser Ser Gly Thr Ala Tyr 65 70 75 80 Met Gln Phe Ser Ser Leu Thr Thr Glu Asp Ser Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg His Ser Pro Arg Ala Thr Leu Phe Asp Phe Trp Gly Gln Gly 100 105 110 Thr Thr Leu Thr Val Ser Ser 115 <210> 244 <211> 106 <212> PRT <213> Synthetic sequence <400> 244 Gln Ile Val Leu Ser Gln Ser Pro Ala Ile Leu Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Asn His Met 20 25 30 His Trp Tyr Gln Gln Arg Thr Gly Phe Ser Pro Lys Ala Trp Ile Tyr 35 40 45 Ala Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Arg Val Glu Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Tyr Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 245 <211> 121 <212> PRT <213> Synthetic sequence <400> 245 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr 20 25 30 Trp Ile Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asn Ile Tyr Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Pro Thr Ser Asp Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Thr Trp Glu Phe Tyr Tyr Asp Ser Val Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 246 <211> 107 <212> PRT <213> artificial sequence <400> 246 Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 1 5 10 15 Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 20 25 30 Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 35 40 45 Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr 65 70 75 80 Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Tyr Asp Glu Leu Pro Pro 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 247 <211> 111 <212> PRT <213> artificial sequence <400> 247 Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 1 5 10 15 Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr 20 25 30 Asp Ile Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 35 40 45 Gly Val Ile Trp Thr Gly Gly Gly Thr Asn Tyr Asn Ser Ser Phe Met 50 55 60 Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Asn Gln Val Phe Leu 65 70 75 80 Lys Met Asn Ser Leu Gln Val Asp Asp Thr Ala Ile Tyr Tyr Cys Glu 85 90 95 Arg Val Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser 100 105 110 <210> 248 <211> 112 <212> PRT <213> Artificial Sequence <400> 248 Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser 20 25 30 Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Phe Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gln Asn 85 90 95 Thr His Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 249 <211> 121 <212> PRT <213> Artificial Sequence <400> 249 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Ala Phe Ser Thr Ser 20 25 30 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Arg Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Val Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Leu Asp Gly Tyr Tyr Glu Val Phe Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Thr Thr Leu Thr Val Ser Ser 115 120 <210> 250 <211> 112 <212> PRT <213> Artificial sequence <400> 250 Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 20 25 30 Asn Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 35 40 45 Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 50 55 60 Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Phe Gln Gly 85 90 95 Thr His Phe Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 251 <211> 114 <212> PRT <213> Artificial sequence <400> 251 Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Val Met Tyr Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Asn Pro Tyr Asn Asp Asp Ile Arg Tyr Asn Glu Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ser Asp Arg Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Leu Cys 85 90 95 Ala Arg Gln Gly Gly Asp Tyr Trp Gly Gln Gly Thr Ile Leu Thr Val 100 105 110 Looking Looking <210> 252 <211> 107 <212> PRT <213> artificial sequence <400> 252 Asp Val Gln Ile Thr Gln Ser Pro Ser Tyr Leu Ala Ala Ser Pro Gly 1 5 10 15 Glu Thr Ile Thr Val Asn Cys Arg Ala Ser Lys Asn Ile Asn Lys Tyr 20 25 30 Leu Ala Trp Tyr Gln Glu Lys Pro Gly Lys Thr Asn Lys Leu Leu Ile 35 40 45 Tyr Ser Gly Ser Thr Leu Gln Ser Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr His Cys Gln Gln Tyr Asn Glu Tyr Pro Leu 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Met Lys 100 105 <210> 253<​​​​​​​​​​​​​​​​​​​​​​​​Ser Arg Leu Ser Ile Thr Lys Asp Asn Ser Thr Ser Gln Val Phe Phe 65 70 75 80 Lys Met Asn Gly Leu Gln Ala Asp Asp Thr Ala Ile Tyr Tyr Cys Ala 85 90 95 Arg Asn Ser Ile Thr Ser Val Ser Phe Asp Cys Trp Gly Gln Gly Thr 100 105 110 Thr Leu Thr Val Ser Ser 115 <210> 254 <211> 107 <212> PRT <213> Artificial Sequence <400> 254 Asp Ile Val Met Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly 1 5 10 15 Asp Arg Val Ser Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Thr 20 25 30 Val Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ser Pro Lys Ala Leu Ile 35 40 45 Cys Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser 65 70 75 80 Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 85 90 95 Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 255 <211> 117 <212> PRT <213> Artificial Sequence <400> 255 Gln Val Gln Leu Gln Gln Pro Gly Ser Ala Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Asn Tyr 20 25 30 Trp Ile His Trp Val Lys Gln Arg His Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asn Ile Tyr Pro Ala Ser Asp Tyr Thr Asn Tyr Asp Glu Lys Phe 50 55 60 Lys Asn Lys Gly Thr Leu Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met His Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ser Arg Gly Tyr Phe Gly Ser Leu Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ala 115 <210> 256 <211> 107 <212> PRT <213> Artificial sequence <400> 256 Asp Ile Leu Leu Thr Gln Ser Pro Ala Ile Leu Ser Val Asn Pro Gly 1 5 10 15 Glu Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Pro Ile Gly Thr Gly 20 25 30 Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile 35 40 45 Lys Ser Ala Ser Glu Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Asn Val Glu Ser 65 70 75 80 Asp Asp Val Gly Asp Tyr Tyr Cys Gln Gln Ser Tyr Ser Trp Pro Thr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Lys Ile Asn 100 105 <210> 257 <211> 117 <212> PRT <213> Artificial sequence <400> 257 Glu Val Gln Leu Gln Gln Ser Gly Thr Val Leu Ala Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Asn 20 25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Val Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Lys Leu Thr Ala Val Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Thr Asn Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Gly Ile Thr Thr Ala Pro Glu Tyr Trp Gly Gln Gly Thr Thr 100 105 110 Leu Thr Val Ser Ser 115 <210> 258 <211> 107 <212> PRT <213> Synthetic Sequence <400> 258 Asn Ile Val Met Thr Gln Ser Pro Lys Ser Met Ser Met Ser Val Gly 1 5 10 15 Glu Arg Val Thr Leu Ser Cys Lys Ala Ser Glu Asn Val Gly Ile Tyr 20 25 30 Val Ser Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro 65 70 75 80 Glu Asp Leu Ala Asp Tyr His Cys Gly His Thr Tyr Asn Tyr Pro Phe 85 90 95 Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 259 <211> 118 <212> PRT <213> Artificial Sequence <400> 259 Glu Val Lys Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr 20 25 30 Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile His Pro Asp Ser Ser Ala Ile Asn Tyr Thr Pro Ser Leu 50 55 60 Lys Asp Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Ala Arg Ser Tyr Tyr Gly Arg Val Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Leu Thr Val Ser Ser 115 <210> 260 <211> 107 <212> PRT <213> artificial sequence <400> 260 Asp Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly 1 5 10 15 Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Asp Tyr 20 25 30 Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile 35 40 45 Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Pro Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Ser Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Pro 65 70 75 80 Glu Asp Val Gly Met Tyr Tyr Cys Gln Asp Gly His Ser Phe Pro Pro 85 90 95 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 <210> 261 <211> 117 <212> PRT <213> Artificial Sequence <400> 261 Glu Val Gln Leu Gln Gln Ser Gly Thr Val Leu Ala Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Val Ile Tyr Pro Gly Asn Ser Asp Thr Ser Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Lys Leu Thr Ala Val Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Asp Leu Ser Ser Leu Thr Asn Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Gly Ile Thr Thr Ala Pro Asp Tyr Trp Gly Gln Gly Thr Thr 100 105 110 Leu Thr Val Ser Ser 115 <210> 262 <211> 107 <212> PRT <213> Artificial sequence <400> 262 Asn Ile Val Met Thr Gln Ser Pro Lys Ser Met Ser Met Ser Val Gly 1 5 10 15 Glu Arg Val Thr Leu Ser Cys Lys Ala Ser Glu Asn Val Gly Ile His 20 25 30 Val Ser Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Ser Gly Tyr Asn Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Pro 65 70 75 80 Glu Asp Leu Ala Asp Tyr His Cys Gly Gln Thr Tyr Ser Tyr Pro Phe 85 90 95 Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 263 <211> 119 <212> PRT <213> Artificial sequence <400> 263 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Lys Phe Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Ala Leu Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Asp Phe Ser Leu Glu Thr Ser Ala Thr Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Arg Glu Tyr Tyr Pro Trp Val Phe Val Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ala 115 <210> 264 <211> 106 <212> PRT <213> Synthetic Sequence <400> 264 Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 20 25 30 His Trp Tyr Gln Gln Lys Ser Ser Thr Ser Pro Lys Leu Trp Ile Tyr 35 40 45 Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Gly Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Asn Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 65 70 75 80 Asp Val Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Leu Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 265 <211> 119 <212> PRT <213> Artificial Sequence <400> 265 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Tyr 20 25 30 Trp Ile Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asn Ile Tyr Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Phe His Tyr Gly Ser Ser Pro Phe Asp Asn Trp Gly Gln Gly 100 105 110 Thr Thr Leu Thr Val Ser Ser 115 <210> 266 <211> 107 <212> PRT <213> artificial sequence <400> 266 Asp Ile Gln Met Thr Gln Ser Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser His Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly His Thr Leu Pro Arg 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 267 <211> 118 <212> PRT <213> Artificial sequence <400> 267 Gln Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Phe Lys Trp Met 35 40 45 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe 50 55 60 Lys Gly Arg Phe Ala Phe Ser Leu Glu Ile Ser Ala Ser Thr Ala Tyr 65 70 75 80 Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95 Ala Arg Arg Asp Tyr Leu Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <210> 268 <211> 108 <212> PRT <213> artificial sequence <400> 268 Glu Asn Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Ser Ser 20 25 30 Tyr Leu His Trp Tyr Gln Gln Lys Ser Gly Ala Ser Pro Lys Leu Trp 35 40 45 Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Val Glu 65 70 75 80 Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Ala Tyr Leu 85 90 95 Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 269 <211> 122 <212> PRT <213> artificial sequence <400> 269 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Trp Ile Asn Trp Val Arg Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asn Ile Tyr Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Lys Ala Ser Leu Thr Val Asp Lys Ser Ser Asn Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Ala Gly Asp Gly Thr His Tyr Tyr Ala Ile Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 270 <211> 107 <212> PRT <213> artificial sequence <400> 270 Asn Ile Val Met Thr Gln Ser Pro Lys Ser Met Ser Met Ser Val Gly 1 5 10 15 Glu Arg Val Thr Leu Ser Cys Lys Ala Ser Glu Asn Val Gly Thr Tyr 20 25 30 Val Ser Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Asn Arg Tyr Pro Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala 65 70 75 80 Glu Asp Leu Ala Asp Tyr His Cys Gly Gln Gly Tyr Ser Tyr Leu Arg 85 90 95 Thr Phe Gly Gly Gly Thr Asn Leu Glu Ile Lys 100 105 <210> 271 <211> 117 <212> PRT <213> Artificial Sequence <400> 271 Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Leu Val Lys Leu Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Tyr 20 25 30 Tyr Met His Trp Val Lys Arg Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Trp Ile Asp Pro Glu Asn Gly Asn Thr Ile Tyr Asp Pro Lys Phe 50 55 60 Gln Asp Lys Ala Ser Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Glu Gly Leu Pro Trp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr 100 105 110 Leu Thr Val Ser Ser 115 <210> 272 <211> 106 <212> PRT <213> artificial sequence <400> 272 Gln Ile Ile Leu Thr Gln Ser Pro Ala Leu Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Asp Met 20 25 30 Asn Trp Tyr Gln Gln Lys Pro Arg Ser Ser Pro Thr Pro Trp Ile Tyr 35 40 45 Leu Thr Ser Asn Leu Ser Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Gly Asn Pro Leu Thr 85 90 95 Phe Gly Ala Gly Thr Arg Leu Glu Leu Lys 100 105 <210> 273 <211> 114 <212> PRT <213> Synthetic sequence <400> 273 Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Arg Lys Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Phe 20 25 30 Gly Met His Trp Met Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val 35 40 45 Ala Tyr Ile Ser Ser Gly Ser Ser Ala Ile Tyr Tyr Ala Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Pro Lys Asn Thr Leu Phe 65 70 75 80 Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Asp Trp Val Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val 100 105 110 Ser Ser <210> 274 <211> 107 <212> PRT <213> Artificial sequence <400> 274 Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Val Ser Val Gly 1 5 10 15 Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Asn 20 25 30 Leu Val Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val 35 40 45 Tyr Thr Ala Thr Lys Leu Thr Asn Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Ser 65 70 75 80 Glu Asp Phe Gly Thr Tyr Tyr Cys Gln His Phe Trp Asp Thr Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Met Lys 100 105 <210> 275 <211> 123 <212> PRT <213> Artificial sequence <400> 275 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Ile Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Asn Ile Phe Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Arg Ala Lys Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Phe Gly Ser Ser Gly Tyr Pro Asp Tyr Tyr Thr Met Glu Tyr 100 105 110 Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <210> 276 <211> 107 <212> PRT <213> artificial sequence <400> 276 Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn Ile Asp Asn Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro Gln Leu Leu Val 35 40 45 Tyr Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Tyr Ser Leu Lys Ile Asn Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Gly Ser Tyr His Cys Gln Gln Tyr Trp Thr Ile Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 277 <211> 121 <212> PRT <213> Artificial Sequence <400> 277 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Asn Asn Ser 20 25 30 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asp Tyr Asn Gly Lys Phe 50 55 60 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Val Asp Ser Ala Val Tyr Phe Cys 85 90 95 Ala Arg Leu Asp Gly Asn Tyr Tyr Tyr Trp Tyr Phe Asp Val Trp Gly 100 105 110 Ala Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 278 <211> 112 <212> PRT <213> artificial sequence <400> 278 Asp Val Val Met Thr Gln Thr Pro Leu Thr Leu Ser Val Thr Ile Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser 20 25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 35 40 45 Pro Lys Arg Leu Ile Tyr Leu Val Ser Lys Leu Asp Ser Gly Val Pro 50 55 60 Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly 85 90 95 Thr His Phe Pro Gln Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 279 <211> 5 <212> PRT <213> Artificial sequence <400> 279 Gly Tyr Tyr Trp Ser 1 5 <210> 280 <211> 16 <212> PRT <213> Artificial sequence <400> 280 Glu Ile Asn His Gly Gly Tyr Val Thr Tyr Asn Pro Ser Leu Glu Ser 1 5 10 15 <210> 281 <211> 13 <212> PRT <213> Artificial sequence <400> 281 Asp Tyr Gly Pro Gly Asn Tyr Asp Trp Tyr Phe Asp Leu 1 5 10 <210> 282 <211> 11 <212> PRT <213> Artificial sequence <400> 282 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 283 <211> 7 <212> PRT <213> Artificial sequence <400> 283 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 284 <211> 11 <212> PRT <213> Artificial sequence <400> 284 Gln Gln Arg Ser Asn Trp Pro Pro Ala Leu Thr 1 5 10 <210> 285 <211> 5 <212> PRT <213> Artificial sequence <400> 285 Asp Tyr Trp Met Ser 1 5 <210> 286 <211> 17 <212> PRT <213> Artificial sequence <400> 286 Asp Ile Lys Asn Asp Gly Ser Tyr Thr Asn Tyr Ala Pro Ser Leu Thr 1 5 10 15 Asn <210> 287 <211> 5 <212> PRT <213> Artificial sequence <400> 287 Glu Leu Thr Gly Thr 1 5 <210> 288 <211> 17 <212> PRT <213> Artificial sequence <400> 288 Lys Ser Ser Gln Ser Leu Leu Ser Ser Gly Asn Gln Lys Asn Tyr Leu 1 5 10 15 Ala <210> 289 <211> 7 <212> PRT <213> Artificial sequence <400> 289 Tyr Ala Ser Thr Arg Gln Ser 1 5 <210> 290 <211> 9 <212> PRT <213> Artificial sequence <400> 290 Leu Gln Tyr Asp Arg Tyr Pro Phe Thr 1 5 <210> 291 <211> 6 <212> PRT <213> Artificial sequence <400> 291 Ser Thr Tyr Trp Ile Ser 1 5 <210> 292 <211> 17 <212> PRT <213> Artificial sequence <400> 292 Lys Ile Tyr Pro Gly Asp Ser Tyr Thr Asn Tyr Ser Pro Ser Phe Gln 1 5 10 15 Gly <210> 293 <211> 8 <212> PRT <213> Artificial sequence <400> 293 Arg Gly Tyr Gly Ile Phe Asp Tyr 1 5 <210> 294 <211> 11 <212> PRT <213> Artificial sequence <400> 294 Ser Gly Asp Asn Ile Gly Asp Gln Tyr Ala His 1 5 10 <210> 295 <211> 7 <212> PRT <213> Artificial sequence <400> 295 Gln Asp Lys Asn Arg Pro Ser 1 5 <210> 296 <211> 11 <212> PRT <213> Artificial sequence <400> 296 Ala Thr Tyr Thr Gly Phe Gly Ser Leu Ala Val 1 5 10 <210> 297 <211> 5 <212> PRT <213> Artificial sequence <400> 297 Asp Tyr Tyr Met Asn 1 5 <210> 298 <211> 19 <212> PRT <213> Artificial sequence <400> 298 Tyr Ile Ser Ser Ser Ala Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser 1 5 10 15 Val Lys Gly <210> 299 <211> 13 <212> PRT <213> Artificial sequence <400> 299 Val Val Pro Ala Gly Ser Gly Trp Arg Trp Phe Asp Pro 1 5 10 <210> 300 <211> 14 <212> PRT <213> Artificial sequence <400> 300 Thr Gly Ile Ser Ser Asp Val Gly Ala Tyr Asp Tyr Val Ser 1 5 10 <210> 301 <211> 7 <212> PRT <213> Artificial sequence <400> 301 Glu Val Ser Lys Arg Pro Ser 1 5 <210> 302 <211> 11 <212> PRT <213> Artificial sequence <400> 302 Ser Ser His Ala Gly Ser Asn Asn Phe Tyr Val 1 5 10 <210> 303 <211> 7 <212> PRT <213> Artificial sequence <400> 303 Ser Asn Ser Ala Ala Trp Asn 1 5 <210> 304 <211> 18 <212> PRT <213> Artificial sequence <400> 304 Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala Pro Ser Val 1 5 10 15 Glu Ser <210> 305 <211> 11 <212> PRT <213> Artificial sequence <400> 305 Asp Pro Pro Tyr Val Leu Ser Thr Phe Asp Ile 1 5 10 <210> 306 <211> 13 <212> PRT <213> Artificial sequence <400> 306 Thr Arg Ser Ser Gly Asn Ile Ala Ser Phe Tyr Val Gln 1 5 10 <210> 307 <211> 7 <212> PRT <213> Artificial sequence <400> 307 Glu Asp Asp Gln Arg Pro Ser 1 5 <210> 308 <211> 9 <212> PRT <213> Artificial sequence <400> 308 Gln Ser Tyr Asp Thr Asn Asn Val Ile 1 5 <210> 309 <211> 7 <212> PRT <213> Artificial sequence <400> 309 Ser Asn Ser Ala Ala Trp Asn 1 5 <210> 310 <211> 18 <212> PRT <213> Artificial sequence <400> 310 Arg Thr Tyr Tyr Arg Ser Arg Trp Tyr Ser Asp Tyr Ala Ser Ser Val 1 5 10 15 Glu Ser <210> 311 <211> 11 <212> PRT <213> Artificial sequence <400> 311 Asp Pro Pro Tyr Val Leu Ser Thr Phe Asp Ile 1 5 10 <210> 312 <211> 13 <212> PRT <213> Artificial sequence <400> 312 Thr Arg Ser Ser Gly Asn Ile Ala Ser Phe Tyr Val Gln 1 5 10 <210> 313 <211> 7 <212> PRT <213> Artificial sequence <400> 313 Glu Asp Asp Gln Arg Pro Ser 1 5 <210> 314 <211> 9 <212> PRT <213> Artificial sequence <400> 314 Gln Ser Tyr Asp Thr Asn Asn Val Ile 1 5 <210> 315 <211> 7 <212> PRT <213> Artificial sequence <400> 315 Ser Asp Ser Ala Ala Trp Asn 1 5 <210> 316 <211> 18 <212> PRT <213> Artificial sequence <400> 316 Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala Pro Ser Val 1 5 10 15 Glu Ser <210> 317 <211> 11 <212> PRT <213> Artificial sequence <400> 317 Asp Pro Pro Tyr Val Leu Ser Thr Phe Asp Ile 1 5 10 <210> 318 <211> 13 <212> PRT <213> Artificial sequence <400> 318 Thr Arg Ser Ser Gly Asn Ile Ala Ser Phe Tyr Val Gln 1 5 10 <210> 319 <211> 7 <212> PRT <213> Artificial sequence <400> 319 Glu Asp Asp Gln Arg Pro Ser 1 5 <210> 320 <211> 9 <212> PRT <213> Artificial sequence <400> 320 Gln Ser Tyr Asp Thr Asn Asn Val Ile 1 5 <210> 321 <211> 7 <212> PRT <213> Artificial sequence <400> 321 Ser Asn Ser Ala Ala Trp Asn 1 5 <210> 322 <211> 18 <212> PRT <213> Artificial sequence <400> 322 Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala Pro Ser Val 1 5 10 15 Glu Ser <210> 323 <211> 11 <212> PRT <213> Artificial sequence <400> 323 Asp Pro Pro Tyr Val Leu Ser Thr Phe Asp Ile 1 5 10 <210> 324 <211> 13 <212> PRT <213> Artificial sequence <400> 324 Thr Arg Ser Ser Gly Asn Ile Ala Ser Phe Tyr Val Gln 1 5 10 <210> 325 <211> 7 <212> PRT <213> Artificial sequence <400> 325 Asp Asp Asp Gln Arg Pro Ser 1 5 <210> 326 <211> 9 <212> PRT <213> Artificial sequence <400> 326 Gln Ser Tyr Asp Thr Asn Asn Val Ile 1 5 <210> 327 <211> 7 <212> PRT <213> Artificial sequence <400> 327 Ser Asn Ser Ala Ala Trp Asn 1 5 <210> 328 <211> 18 <212> PRT <213> Artificial sequence <400> 328 Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala Pro Ser Val 1 5 10 15 Glu Ser <210> 329 <211> 11 <212> PRT <213> Artificial sequence <400> 329 Asp Pro Pro Tyr Val Leu Ser Thr Phe Asp Ile 1 5 10 <210> 330 <211> 13 <212> PRT <213> Artificial sequence <400> 330 Thr Arg Ser Ser Gly Asn Ile Ala Ser Phe Tyr Val Gln 1 5 10 <210> 331 <211> 7 <212> PRT <213> Artificial sequence <400> 331 Glu Asp Asp Gln Arg Pro Ser 1 5 <210> 332 <211> 9 <212> PRT <213> Artificial sequence <400> 332 Gln Ser Tyr Asp Thr Asn Lys Val Ile 1 5 <210> 333 <211> 7 <212> PRT <213> Artificial sequence <400> 333 Ser Asn Ser Ala Ala Trp Asn 1 5 <210> 334 <211> 18 <212> PRT <213> Artificial sequence <400> 334 Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala Pro Ser Val 1 5 10 15 Glu Ser <210> 335 <211> 11 <212> PRT <213> Artificial sequence <400> 335 Asp Pro Pro Tyr Val Leu Ser Thr Phe Asp Ile 1 5 10 <210> 336 <211> 13 <212> PRT <213> Artificial sequence <400> 336 Thr Arg Ser Ser Gly Asn Ile Ala Ser Phe Tyr Val Gln 1 5 10 <210> 337 <211> 7 <212> PRT <213> Artificial sequence <400> 337 Glu Asp Asp Gln Arg Pro Ser 1 5 <210> 338 <211> 9 <212> PRT <213> Artificial sequence <400> 338 Gln Ser Tyr Asp Ile Asn Lys Val Ile 1 5 <210> 339 <211> 7 <212> PRT <213> Artificial sequence <400> 339 Ser Asn Ser Ala Ala Trp Asn 1 5 <210> 340 <211> 18 <212> PRT <213> Artificial sequence <400> 340 Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala Pro Ser Val 1 5 10 15 Glu Ser <210> 341 <211> 11 <212> PRT <213> Artificial sequence <400> 341 Asp Pro Pro Tyr Val Leu Ser Thr Phe Asp Ile 1 5 10 <210> 342 <211> 13 <212> PRT <213> Artificial sequence <400> 342 Thr Arg Ser Ser Gly Asn Ile Ala Ser Phe Tyr Val Gln 1 5 10 <210> 343 <211> 7 <212> PRT <213> Artificial sequence <400> 343 Asp Asp Asp Gln Arg Pro Ser 1 5 <210> 344 <211> 9 <212> PRT <213> Artificial sequence <400> 344 Gln Ser Tyr Asp Ile Asn Lys Val Ile 1 5 <210> 345 <211> 8 <212> PRT <213> Artificial sequence <400> 345 Gly Tyr Met Pro Asp Gly Tyr Tyr 1 5 <210> 346 <211> 8 <212> PRT <213> Artificial sequence <400> 346 Ile Asn Pro Arg Thr Gly Gly Thr 1 5 <210> 347 <211> 13 <212> PRT <213> Artificial sequence <400> 347 Ala Arg Glu Gly Ala Ala Phe Arg Leu Glu Leu Asp Ala 1 5 10 <210> 348 <211> 6 <212> PRT <213> Artificial sequence <400> 348 Asn Ile Gly Ser Lys Ser 1 5 <210> 349 <211> 3 <212> PRT <213> Artificial sequence <400> 349 Tyr Asp Ser 1 <210> 350 <211> 9 <212> PRT <213> Artificial sequence <400> 350 Gln Val Trp Asp Ser Ser Ser Val Val 1 5 <210> 351 <211> 8 <212> PRT <213> Artificial sequence <400> 351 Gly Tyr Ser Phe Thr Gly Tyr Tyr 1 5 <210> 352 <211> 8 <212> PRT <213> Artificial sequence <400> 352 Val Asn Pro Lys Ser Gly Gly Thr 1 5 <210> 353 <211> 13 <212> PRT <213> Artificial sequence <400> 353 Ala Arg Glu Gly Trp Ala Arg Arg Ile Asp Leu Asp Glu 1 5 10 <210> 354 <211> 6 <212> PRT <213> Artificial sequence <400> 354 Asn Ile Gly Ser Lys Ser 1 5 <210> 355 <211> 3 <212> PRT <213> Artificial sequence <400> 355 Tyr Asp Ser 1 <210> 356 <211> 9 <212> PRT <213> Artificial sequence <400> 356 Gln Val Trp Asp Ser Ser Ser Val Val 1 5 <210> 357 <211> 8 <212> PRT <213> Artificial sequence <400> 357 Gly Tyr Ser Phe Ser Gly Tyr Tyr 1 5 <210> 358 <211> 8 <212> PRT <213> Artificial sequence <400> 358 Val Asn Pro Met Ser Gly Gly Thr 1 5 <210> 359 <211> 13 <212> PRT <213> Artificial sequence <400> 359 Ala Arg Glu Gly Met Ala Met Arg Leu Glu Leu Asp Lys 1 5 10 <210> 360 <211> 6 <212> PRT <213> Artificial sequence <400> 360 Asn Ile Gly Ser Lys Ser 1 5 <210> 361 <211> 3 <212> PRT <213> Artificial sequence <400> 361 Tyr Asp Ser 1 <210> 362 <211> 9 <212> PRT <213> Artificial sequence <400> 362 Gln Val Trp Asp Ser Ser Ser Val Val 1 5 <210> 363 <211> 8 <212> PRT <213> Artificial sequence <400> 363 Gly Tyr Asn Phe Gly Gly Tyr Tyr 1 5 <210> 364 <211> 8 <212> PRT <213> Artificial sequence <400> 364 Val Asn Pro His Ser Gly Gly Thr 1 5 <210> 365 <211> 13 <212> PRT <213> Artificial sequence <400>...

Claims

1. An antibody or antigen-binding fragment thereof that binds to 4-1BB (TNF receptor superfamily member 9), the antibody or antigen-binding fragment thereof comprising: a heavy chain variable region (VH) comprising complementarity determining regions (CDR) 1, 2 and 3, wherein the amino acid sequence of the VH CDR1 region is a selected VH CDR1 amino acid sequence, the amino acid sequence of the VH CDR2 region is a selected VH CDR2 amino acid sequence, and the amino acid sequence of the VH CDR3 region is a selected VH CDR3 amino acid sequence; and a light chain variable region (VL) comprising CDR 1, 2 and 3, wherein the amino acid sequence of the VL CDR1 region is a selected VL CDR1 amino acid sequence, the amino acid sequence of the VL CDR2 region is a selected VL CDR2 amino acid sequence, and the amino acid sequence of the VL CDR3 region is a selected VL CDR3 amino acid sequence, in: (1) the selected VH CDR 1, 2, 3 amino acid sequences are represented by SEQ ID NOs: 1, 2, 3, respectively, and the selected VL CDR 1, 2, 3 amino acid sequences are represented by SEQ ID NOs: 4, 5, 6, respectively; wherein the CDRs are defined by the Kabat numbering system; or, (2) The selected VH CDR 1, 2, and 3 amino acid sequences are shown by SEQ ID NOs: 109, 110, and 111, respectively, and the selected VL CDR 1, 2, and 3 amino acid sequences are shown by SEQ ID NOs: 112, 113, and 114, respectively; wherein the CDRs are defined by the Chothia numbering system.

2. The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment specifically binds to human 4-1BB.

3. The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof. 4 . The antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody or antigen-binding fragment is a single-chain variable fragment (scFv).

5. A nucleic acid molecule comprising a polynucleotide encoding: (1) an immunoglobulin heavy chain comprising a heavy chain variable region (VH) or a heavy chain fragment comprising said VH, wherein said heavy chain variable region (VH) comprises: (i) complementary determining regions (CDRs) 1, 2 and 3 having amino acid sequences as shown in SEQ ID NOs: 1, 2 and 3, respectively, wherein said CDRs are defined by the Kabat numbering system; or, (ii) complementary determining regions (CDRs) 1, 2 and 3 having amino acid sequences as shown in SEQ ID NOs: 109, 110 and 111, respectively, wherein said CDRs are defined by the Chothia numbering system; and wherein the VH binds 4-1BB when paired with a light chain variable region (VL) comprising an amino acid sequence set forth by SEQ ID NO: 225, 226, 227, 228 or 244; as well as, (2) an immunoglobulin light chain comprising a VL or a light chain fragment comprising the VL, wherein the VL comprises: (i) CDRs 1, 2 and 3 having amino acid sequences as shown in SEQ ID NOs: 4, 5 and 6, respectively, wherein the CDRs are defined by the Kabat numbering system; or, (ii) CDRs 1, 2 and 3 having amino acid sequences as shown in SEQ ID NOs: 112, 113 and 114, respectively, wherein the CDRs are defined by the Chothia numbering system; And wherein the VL binds 4-1BB when paired with a VH comprising the amino acid sequence shown in SEQ ID NO: 221, 222, 223, 224 or 243.

6. The nucleic acid molecule of claim 5, wherein the 4-1BB is human 4-1BB.

7. The nucleic acid molecule of claim 5, wherein the immunoglobulin heavy chain or the heavy chain fragment is a humanized immunoglobulin heavy chain or heavy chain fragment, and the immunoglobulin light chain or the light chain fragment is a humanized immunoglobulin light chain or light chain fragment.

8. The nucleic acid molecule of claim 5, wherein the nucleic acid encodes a single-chain variable fragment (scFv).

9. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule is cDNA.

10. A vector comprising one or more of the nucleic acid molecules according to any one of claims 5 to 9.

11. A vector comprising two of the nucleic acid molecules according to any one of claims 5-9, wherein the vector encodes a VL region and a VH region that together bind to 4-1BB.

12. A vector pair, wherein each vector comprises one of the nucleic acid molecules according to any one of claims 5-9, wherein the vector pair jointly encodes a VL region and a VH region, and the VL region and VH region together bind to 4-1BB.

13. A cell comprising the vector according to claim 10 or 11, or the vector pair according to claim 12.

14. The cell according to claim 13, wherein the cell is a CHO cell.

15. A cell comprising one or more of the nucleic acid molecules according to any one of claims 5-9.

16. A cell comprising two of the nucleic acid molecules according to any one of claims 5-9.

17. The cell of claim 16, wherein the two nucleic acid molecules together encode a VL region and a VH region that together bind to 4-1BB.

18. A method for producing an antibody or an antigen-binding fragment thereof, the method comprising (a) culturing the cell under conditions sufficient for the cell to produce an antibody or antigen-binding fragment according to any one of claims 13 to 17; and (b) collecting the antibodies or antigen-binding fragments produced by the cells.

19. An antibody or antigen-binding fragment thereof that binds to 4-1BB, the antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising a selected VH sequence, and the light chain variable region (VL) comprising a selected VL sequence, wherein: (1) the selected VH sequence is SEQ ID NO: 221, 222, 223 or 224, and the selected VL sequence is SEQ ID NO: 225, 226, 227 or 228; or, (2) the selected VH sequence is SEQ ID NO: 243, and the selected VL sequence is SEQ ID NO:

244.

20. The antibody or antigen-binding fragment thereof of claim 19, wherein the VH comprises the sequence of SEQ ID NO: 221 and the VL comprises the sequence of SEQ ID NO:

225.

21. The antibody or antigen-binding fragment thereof of claim 19, wherein the antibody or antigen-binding fragment specifically binds to human 4-1BB.

22. The antibody or antigen-binding fragment thereof according to claim 19, wherein the antibody or antigen-binding fragment is a humanized antibody or antigen-binding fragment thereof.

23. The antibody or antigen-binding fragment thereof according to claim 19, wherein the antibody or antigen-binding fragment is a single chain variable fragment (scFv).

24. An antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof according to any one of claims 1-4 and 19-23 covalently bound to a therapeutic agent.

25. The antibody drug conjugate of claim 24, wherein the therapeutic agent is a cytotoxic agent or a cytostatic agent.

26. Use of a composition for preparing a medicament for treating cancer in a subject, the composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1-4 and 19-23, or the antibody-drug conjugate according to claim 24 or 25.

27. The use according to claim 26, wherein the subject has a solid tumor.

28. The use according to claim 26, wherein the cancer is breast cancer, oropharyngeal cancer, ovarian cancer, B-cell lymphoma, or non-Hodgkin lymphoma.

29. The use according to claim 26, wherein the cancer is non-small cell lung cancer (NSCLC), melanoma, B-cell non-Hodgkin lymphoma, colorectal cancer, or multiple myeloma.

30. Use of a composition for preparing a medicament for reducing tumor growth rate, the composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1-4 and 19-23, or the antibody-drug conjugate according to claim 24 or 25.

31. Use of a composition for preparing a medicament for killing tumor cells, the composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1-4 and 19-23, or the antibody-drug conjugate according to claim 24 or 25.

32. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1-4 and 19-23, and a pharmaceutically acceptable carrier.

33. A pharmaceutical composition comprising the antibody-drug conjugate according to claim 24 or 25, and a pharmaceutically acceptable carrier.

34. The antibody or antigen-binding fragment thereof according to any one of claims 1-4 and 19-23, or the antibody-drug conjugate according to claim 24 or 25, wherein the antibody is an IgG1 antibody.

35. The antibody or antigen-binding fragment thereof according to any one of claims 1-4 and 19-23, or the antibody-drug conjugate according to claim 24 or 25, wherein the antibody is a human IgG1 antibody.